CA2139517A1 - Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes - Google Patents
Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopesInfo
- Publication number
- CA2139517A1 CA2139517A1 CA002139517A CA2139517A CA2139517A1 CA 2139517 A1 CA2139517 A1 CA 2139517A1 CA 002139517 A CA002139517 A CA 002139517A CA 2139517 A CA2139517 A CA 2139517A CA 2139517 A1 CA2139517 A1 CA 2139517A1
- Authority
- CA
- Canada
- Prior art keywords
- arg
- seq
- gly
- val
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000006386 neutralization reaction Methods 0.000 title claims abstract description 39
- 230000001900 immune effect Effects 0.000 title abstract description 23
- 208000030507 AIDS Diseases 0.000 claims abstract description 58
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 19
- 150000001413 amino acids Chemical group 0.000 claims description 314
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 217
- 238000000034 method Methods 0.000 claims description 72
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 51
- 238000012216 screening Methods 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 239000000872 buffer Substances 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 239000007790 solid phase Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 230000000890 antigenic effect Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 19
- 150000001450 anions Chemical class 0.000 claims description 18
- 239000002981 blocking agent Substances 0.000 claims description 16
- 241000588653 Neisseria Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 230000007935 neutral effect Effects 0.000 claims description 13
- 125000006850 spacer group Chemical group 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 239000003599 detergent Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 9
- 229920000447 polyanionic polymer Polymers 0.000 claims description 9
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 229940124718 AIDS vaccine Drugs 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 238000010187 selection method Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 6
- 239000000568 immunological adjuvant Substances 0.000 claims 6
- 238000002372 labelling Methods 0.000 claims 1
- 238000007747 plating Methods 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 abstract description 19
- 102000015636 Oligopeptides Human genes 0.000 abstract description 19
- 238000002255 vaccination Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 295
- 229940024606 amino acid Drugs 0.000 description 295
- 230000000692 anti-sense effect Effects 0.000 description 140
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 132
- 108010077515 glycylproline Proteins 0.000 description 91
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 90
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 53
- 241000725303 Human immunodeficiency virus Species 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 42
- 206010001513 AIDS related complex Diseases 0.000 description 34
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 239000013615 primer Substances 0.000 description 28
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 239000011324 bead Substances 0.000 description 23
- 239000006180 TBST buffer Substances 0.000 description 22
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 108010025306 histidylleucine Proteins 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 241000880493 Leptailurus serval Species 0.000 description 15
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 15
- 108010037850 glycylvaline Proteins 0.000 description 15
- NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 14
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 14
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 10
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 229940064914 retrovir Drugs 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 8
- GQKSJYINYYWPMR-NGZCFLSTSA-N Ile-Gly-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N GQKSJYINYYWPMR-NGZCFLSTSA-N 0.000 description 8
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- KVRLNEILGGVBJX-IHRRRGAJSA-N Val-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CN=CN1 KVRLNEILGGVBJX-IHRRRGAJSA-N 0.000 description 8
- SSKKGOWRPNIVDW-AVGNSLFASA-N Val-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SSKKGOWRPNIVDW-AVGNSLFASA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 108010013835 arginine glutamate Proteins 0.000 description 8
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 8
- 108010092114 histidylphenylalanine Proteins 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- BSVLMPMIXPQNKC-KBPBESRZSA-N His-Phe-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O BSVLMPMIXPQNKC-KBPBESRZSA-N 0.000 description 7
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- -1 p-methoxycarbobenzoxy, p-nitrocarbobenzoxy, t-butyloxycarbonyl Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000012465 retentate Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 6
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 description 6
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 6
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 6
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 108010015792 glycyllysine Proteins 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003259 recombinant expression Methods 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108020001019 DNA Primers Proteins 0.000 description 5
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 5
- PZUZIHRPOVVHOT-KBPBESRZSA-N His-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CN=CN1 PZUZIHRPOVVHOT-KBPBESRZSA-N 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 229940121357 antivirals Drugs 0.000 description 5
- 108010008355 arginyl-glutamine Proteins 0.000 description 5
- 108010060035 arginylproline Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 108010029020 prolylglycine Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 229960002555 zidovudine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 4
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 4
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 4
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 4
- VRZDJJWOFXMFRO-ZFWWWQNUSA-N Arg-Gly-Trp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O VRZDJJWOFXMFRO-ZFWWWQNUSA-N 0.000 description 4
- JCROZIFVIYMXHM-GUBZILKMSA-N Arg-Met-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N JCROZIFVIYMXHM-GUBZILKMSA-N 0.000 description 4
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 description 4
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 4
- FXGMURPOWCKNAZ-JYJNAYRXSA-N Arg-Val-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FXGMURPOWCKNAZ-JYJNAYRXSA-N 0.000 description 4
- SUMJNGAMIQSNGX-TUAOUCFPSA-N Arg-Val-Pro Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(O)=O SUMJNGAMIQSNGX-TUAOUCFPSA-N 0.000 description 4
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 4
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 4
- YODBPLSWNJMZOJ-BPUTZDHNSA-N Asp-Trp-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N YODBPLSWNJMZOJ-BPUTZDHNSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- PGPJSRSLQNXBDT-YUMQZZPRSA-N Gln-Arg-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O PGPJSRSLQNXBDT-YUMQZZPRSA-N 0.000 description 4
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 4
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 4
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 4
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 4
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 4
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 4
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 4
- GCFNFKNPCMBHNT-IRXDYDNUSA-N Phe-Tyr-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)O)N GCFNFKNPCMBHNT-IRXDYDNUSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 4
- 108010025216 RVF peptide Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 4
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 4
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 4
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 4
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 4
- SYCFMSYTIFXWAJ-DCAQKATOSA-N Ser-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N SYCFMSYTIFXWAJ-DCAQKATOSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 4
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 4
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 4
- YTPLVNUZZOBFFC-SCZZXKLOSA-N Val-Gly-Pro Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N1CCC[C@@H]1C(O)=O YTPLVNUZZOBFFC-SCZZXKLOSA-N 0.000 description 4
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 4
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 4
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 4
- 235000020187 evaporated milk Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 4
- 108010019407 glycyl-arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 108010081551 glycylphenylalanine Proteins 0.000 description 4
- 108010084389 glycyltryptophan Proteins 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 108010084572 phenylalanyl-valine Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 108010048818 seryl-histidine Proteins 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 3
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 3
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 3
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 108010005942 methionylglycine Proteins 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 2
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- WRDANSJTFOHBPI-FXQIFTODSA-N Ala-Arg-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N WRDANSJTFOHBPI-FXQIFTODSA-N 0.000 description 2
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 2
- UCIYCBSJBQGDGM-LPEHRKFASA-N Ala-Arg-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N UCIYCBSJBQGDGM-LPEHRKFASA-N 0.000 description 2
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 2
- ZRGNRZLDMUACOW-HERUPUMHSA-N Ala-Cys-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N ZRGNRZLDMUACOW-HERUPUMHSA-N 0.000 description 2
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 2
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 2
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 2
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 2
- GFEDXKNBZMPEDM-KZVJFYERSA-N Ala-Met-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFEDXKNBZMPEDM-KZVJFYERSA-N 0.000 description 2
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 2
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 2
- JNJHNBXBGNJESC-KKXDTOCCSA-N Ala-Tyr-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JNJHNBXBGNJESC-KKXDTOCCSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 2
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- YFWTXMRJJDNTLM-LSJOCFKGSA-N Arg-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFWTXMRJJDNTLM-LSJOCFKGSA-N 0.000 description 2
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 2
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
- DCGLNNVKIZXQOJ-FXQIFTODSA-N Arg-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N DCGLNNVKIZXQOJ-FXQIFTODSA-N 0.000 description 2
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 2
- ITVINTQUZMQWJR-QXEWZRGKSA-N Arg-Asn-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ITVINTQUZMQWJR-QXEWZRGKSA-N 0.000 description 2
- RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 2
- ZEAYJGRKRUBDOB-GARJFASQSA-N Arg-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZEAYJGRKRUBDOB-GARJFASQSA-N 0.000 description 2
- LMPKCSXZJSXBBL-NHCYSSNCSA-N Arg-Gln-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O LMPKCSXZJSXBBL-NHCYSSNCSA-N 0.000 description 2
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 2
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 2
- GOWZVQXTHUCNSQ-NHCYSSNCSA-N Arg-Glu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GOWZVQXTHUCNSQ-NHCYSSNCSA-N 0.000 description 2
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 2
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 2
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 2
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 2
- ZZZWQALDSQQBEW-STQMWFEESA-N Arg-Gly-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZZZWQALDSQQBEW-STQMWFEESA-N 0.000 description 2
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 2
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 2
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 2
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 description 2
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 2
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 2
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 2
- VEAIMHJZTIDCIH-KKUMJFAQSA-N Arg-Phe-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEAIMHJZTIDCIH-KKUMJFAQSA-N 0.000 description 2
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 2
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 2
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 2
- AUIJUTGLPVHIRT-FXQIFTODSA-N Arg-Ser-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AUIJUTGLPVHIRT-FXQIFTODSA-N 0.000 description 2
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 2
- SYFHFLGAROUHNT-VEVYYDQMSA-N Arg-Thr-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SYFHFLGAROUHNT-VEVYYDQMSA-N 0.000 description 2
- KSHJMDSNSKDJPU-QTKMDUPCSA-N Arg-Thr-His Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KSHJMDSNSKDJPU-QTKMDUPCSA-N 0.000 description 2
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 2
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 2
- QCTOLCVIGRLMQS-HRCADAONSA-N Arg-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O QCTOLCVIGRLMQS-HRCADAONSA-N 0.000 description 2
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 2
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 2
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 2
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 2
- DNYRZPOWBTYFAF-IHRRRGAJSA-N Asn-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)O DNYRZPOWBTYFAF-IHRRRGAJSA-N 0.000 description 2
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 2
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 2
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 2
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 2
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 2
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 2
- PPCORQFLAZWUNO-QWRGUYRKSA-N Asn-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N PPCORQFLAZWUNO-QWRGUYRKSA-N 0.000 description 2
- VLDRQOHCMKCXLY-SRVKXCTJSA-N Asn-Ser-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VLDRQOHCMKCXLY-SRVKXCTJSA-N 0.000 description 2
- QIRJQYQOIKBPBZ-IHRRRGAJSA-N Asn-Tyr-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QIRJQYQOIKBPBZ-IHRRRGAJSA-N 0.000 description 2
- YSYTWUMRHSFODC-QWRGUYRKSA-N Asn-Tyr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O YSYTWUMRHSFODC-QWRGUYRKSA-N 0.000 description 2
- QUCCLIXMVPIVOB-BZSNNMDCSA-N Asn-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N QUCCLIXMVPIVOB-BZSNNMDCSA-N 0.000 description 2
- WQAOZCVOOYUWKG-LSJOCFKGSA-N Asn-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC(=O)N)N WQAOZCVOOYUWKG-LSJOCFKGSA-N 0.000 description 2
- ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 2
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 2
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 2
- ILQCHXURSRRIRY-YUMQZZPRSA-N Asp-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)N ILQCHXURSRRIRY-YUMQZZPRSA-N 0.000 description 2
- SEMWSADZTMJELF-BYULHYEWSA-N Asp-Ile-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O SEMWSADZTMJELF-BYULHYEWSA-N 0.000 description 2
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 description 2
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 2
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 2
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 2
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 2
- QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 2
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 2
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 2
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 2
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 description 2
- CEZSLNCYQUFOSL-BQBZGAKWSA-N Cys-Arg-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O CEZSLNCYQUFOSL-BQBZGAKWSA-N 0.000 description 2
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 2
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 2
- FWYBFUDWUUFLDN-FXQIFTODSA-N Cys-Asp-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N FWYBFUDWUUFLDN-FXQIFTODSA-N 0.000 description 2
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 2
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 2
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 2
- DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 2
- XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 description 2
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 description 2
- IZJLAQMWJHCHTN-BPUTZDHNSA-N Cys-Trp-Arg Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O IZJLAQMWJHCHTN-BPUTZDHNSA-N 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- 108010090461 DFG peptide Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OVQXQLWWJSNYFV-XEGUGMAKSA-N Gln-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(N)=O)C)C(O)=O)=CNC2=C1 OVQXQLWWJSNYFV-XEGUGMAKSA-N 0.000 description 2
- RGXXLQWXBFNXTG-CIUDSAMLSA-N Gln-Arg-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O RGXXLQWXBFNXTG-CIUDSAMLSA-N 0.000 description 2
- JFOKLAPFYCTNHW-SRVKXCTJSA-N Gln-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N JFOKLAPFYCTNHW-SRVKXCTJSA-N 0.000 description 2
- JESJDAAGXULQOP-CIUDSAMLSA-N Gln-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N JESJDAAGXULQOP-CIUDSAMLSA-N 0.000 description 2
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 2
- DWDBJWAXPXXYLP-SRVKXCTJSA-N Gln-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DWDBJWAXPXXYLP-SRVKXCTJSA-N 0.000 description 2
- TYRMVTKPOWPZBC-SXNHZJKMSA-N Gln-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCC(=O)N)N TYRMVTKPOWPZBC-SXNHZJKMSA-N 0.000 description 2
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 2
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 2
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 2
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 2
- LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 description 2
- WRNAXCVRSBBKGS-BQBZGAKWSA-N Glu-Gly-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O WRNAXCVRSBBKGS-BQBZGAKWSA-N 0.000 description 2
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 2
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 2
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 2
- ATVYZJGOZLVXDK-IUCAKERBSA-N Glu-Leu-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O ATVYZJGOZLVXDK-IUCAKERBSA-N 0.000 description 2
- YRMZCZIRHYCNHX-RYUDHWBXSA-N Glu-Phe-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O YRMZCZIRHYCNHX-RYUDHWBXSA-N 0.000 description 2
- DDXZHOHEABQXSE-NKIYYHGXSA-N Glu-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O DDXZHOHEABQXSE-NKIYYHGXSA-N 0.000 description 2
- STDOKNKEXOLSII-SZMVWBNQSA-N Glu-Trp-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)NC(=O)[C@H](CCC(=O)O)N STDOKNKEXOLSII-SZMVWBNQSA-N 0.000 description 2
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 2
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 2
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 2
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 2
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 2
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 2
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 description 2
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 2
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 2
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 2
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 2
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 2
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 2
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 2
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 2
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 2
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 2
- SCJJPCQUJYPHRZ-BQBZGAKWSA-N Gly-Pro-Asn Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O SCJJPCQUJYPHRZ-BQBZGAKWSA-N 0.000 description 2
- ZZJVYSAQQMDIRD-UWVGGRQHSA-N Gly-Pro-His Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ZZJVYSAQQMDIRD-UWVGGRQHSA-N 0.000 description 2
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 2
- YABRDIBSPZONIY-BQBZGAKWSA-N Gly-Ser-Met Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O YABRDIBSPZONIY-BQBZGAKWSA-N 0.000 description 2
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 2
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 2
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 2
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 2
- PDSUIXMZYNURGI-AVGNSLFASA-N His-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 PDSUIXMZYNURGI-AVGNSLFASA-N 0.000 description 2
- SYMSVYVUSPSAAO-IHRRRGAJSA-N His-Arg-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O SYMSVYVUSPSAAO-IHRRRGAJSA-N 0.000 description 2
- ZUPVLBAXUUGKKN-VHSXEESVSA-N His-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CN=CN2)N)C(=O)O ZUPVLBAXUUGKKN-VHSXEESVSA-N 0.000 description 2
- NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 description 2
- YXASFUBDSDAXQD-UWVGGRQHSA-N His-Met-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O YXASFUBDSDAXQD-UWVGGRQHSA-N 0.000 description 2
- PLCAEMGSYOYIPP-GUBZILKMSA-N His-Ser-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 PLCAEMGSYOYIPP-GUBZILKMSA-N 0.000 description 2
- JVEKQAYXFGIISZ-HOCLYGCPSA-N His-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JVEKQAYXFGIISZ-HOCLYGCPSA-N 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 2
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 2
- JHCVYQKVKOLAIU-NAKRPEOUSA-N Ile-Cys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N JHCVYQKVKOLAIU-NAKRPEOUSA-N 0.000 description 2
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 2
- NHJKZMDIMMTVCK-QXEWZRGKSA-N Ile-Gly-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N NHJKZMDIMMTVCK-QXEWZRGKSA-N 0.000 description 2
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 2
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 2
- WYUHAXJAMDTOAU-IAVJCBSLSA-N Ile-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N WYUHAXJAMDTOAU-IAVJCBSLSA-N 0.000 description 2
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 description 2
- DUBAVOVZNZKEQQ-AVGNSLFASA-N Leu-Arg-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCN=C(N)N DUBAVOVZNZKEQQ-AVGNSLFASA-N 0.000 description 2
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 description 2
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 2
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 2
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 2
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 2
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 2
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 2
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 2
- MJTOYIHCKVQICL-ULQDDVLXSA-N Leu-Met-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N MJTOYIHCKVQICL-ULQDDVLXSA-N 0.000 description 2
- NJMXCOOEFLMZSR-AVGNSLFASA-N Leu-Met-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O NJMXCOOEFLMZSR-AVGNSLFASA-N 0.000 description 2
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 2
- QMKFDEUJGYNFMC-AVGNSLFASA-N Leu-Pro-Arg Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QMKFDEUJGYNFMC-AVGNSLFASA-N 0.000 description 2
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 2
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 2
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 2
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 2
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- NTXYXFDMIHXTHE-WDSOQIARSA-N Leu-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 NTXYXFDMIHXTHE-WDSOQIARSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 2
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 2
- LZWNAOIMTLNMDW-NHCYSSNCSA-N Lys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N LZWNAOIMTLNMDW-NHCYSSNCSA-N 0.000 description 2
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 2
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 2
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 2
- MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 2
- IVFUVMSKSFSFBT-NHCYSSNCSA-N Lys-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN IVFUVMSKSFSFBT-NHCYSSNCSA-N 0.000 description 2
- WAIHHELKYSFIQN-XUXIUFHCSA-N Lys-Ile-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O WAIHHELKYSFIQN-XUXIUFHCSA-N 0.000 description 2
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 2
- WLXGMVVHTIUPHE-ULQDDVLXSA-N Lys-Phe-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O WLXGMVVHTIUPHE-ULQDDVLXSA-N 0.000 description 2
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 2
- YCJCEMKOZOYBEF-OEAJRASXSA-N Lys-Thr-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YCJCEMKOZOYBEF-OEAJRASXSA-N 0.000 description 2
- YFQSSOAGMZGXFT-MEYUZBJRSA-N Lys-Thr-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YFQSSOAGMZGXFT-MEYUZBJRSA-N 0.000 description 2
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 description 2
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 2
- PJWDQHNOJIBMRY-JYJNAYRXSA-N Met-Arg-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PJWDQHNOJIBMRY-JYJNAYRXSA-N 0.000 description 2
- FJVJLMZUIGMFFU-BQBZGAKWSA-N Met-Asp-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FJVJLMZUIGMFFU-BQBZGAKWSA-N 0.000 description 2
- KQBJYJXPZBNEIK-DCAQKATOSA-N Met-Glu-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQBJYJXPZBNEIK-DCAQKATOSA-N 0.000 description 2
- MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 2
- GETCJHFFECHWHI-QXEWZRGKSA-N Met-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCSC)N GETCJHFFECHWHI-QXEWZRGKSA-N 0.000 description 2
- CHDYFPCQVUOJEB-ULQDDVLXSA-N Met-Leu-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CHDYFPCQVUOJEB-ULQDDVLXSA-N 0.000 description 2
- ZGVYWHODYWRPLK-GUBZILKMSA-N Met-Pro-Cys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O ZGVYWHODYWRPLK-GUBZILKMSA-N 0.000 description 2
- KPVLLNDCBYXKNV-CYDGBPFRSA-N Met-Val-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KPVLLNDCBYXKNV-CYDGBPFRSA-N 0.000 description 2
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
- DSXPMZMSJHOKKK-HJOGWXRNSA-N Phe-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DSXPMZMSJHOKKK-HJOGWXRNSA-N 0.000 description 2
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 2
- KDIIENQUNVNWHR-JYJNAYRXSA-N Pro-Arg-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KDIIENQUNVNWHR-JYJNAYRXSA-N 0.000 description 2
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 2
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 2
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 2
- BBFRBZYKHIKFBX-GMOBBJLQSA-N Pro-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@@H]1CCCN1 BBFRBZYKHIKFBX-GMOBBJLQSA-N 0.000 description 2
- RYJRPPUATSKNAY-STECZYCISA-N Pro-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@@H]2CCCN2 RYJRPPUATSKNAY-STECZYCISA-N 0.000 description 2
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 2
- JUJCUYWRJMFJJF-AVGNSLFASA-N Pro-Lys-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 JUJCUYWRJMFJJF-AVGNSLFASA-N 0.000 description 2
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 2
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 2
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 2
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 2
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 2
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 2
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 2
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 2
- UCOYFSCEIWQYNL-FXQIFTODSA-N Ser-Cys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O UCOYFSCEIWQYNL-FXQIFTODSA-N 0.000 description 2
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 2
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 2
- SNVIOQXAHVORQM-WDSKDSINSA-N Ser-Gly-Gln Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O SNVIOQXAHVORQM-WDSKDSINSA-N 0.000 description 2
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 2
- IFPBAGJBHSNYPR-ZKWXMUAHSA-N Ser-Ile-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O IFPBAGJBHSNYPR-ZKWXMUAHSA-N 0.000 description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 2
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 2
- STIAINRLUUKYKM-WFBYXXMGSA-N Ser-Trp-Ala Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 STIAINRLUUKYKM-WFBYXXMGSA-N 0.000 description 2
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 2
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 2
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 2
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 2
- NRBUKAHTWRCUEQ-XGEHTFHBSA-N Thr-Cys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O NRBUKAHTWRCUEQ-XGEHTFHBSA-N 0.000 description 2
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 2
- LCCSEJSPBWKBNT-OSUNSFLBSA-N Thr-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N LCCSEJSPBWKBNT-OSUNSFLBSA-N 0.000 description 2
- UYTYTDMCDBPDSC-URLPEUOOSA-N Thr-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N UYTYTDMCDBPDSC-URLPEUOOSA-N 0.000 description 2
- UUSQVWOVUYMLJA-PPCPHDFISA-N Thr-Lys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UUSQVWOVUYMLJA-PPCPHDFISA-N 0.000 description 2
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 2
- PJCYRZVSACOYSN-ZJDVBMNYSA-N Thr-Thr-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O PJCYRZVSACOYSN-ZJDVBMNYSA-N 0.000 description 2
- VEENWOSZGWWKHW-SZZJOZGLSA-N Thr-Trp-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N)O VEENWOSZGWWKHW-SZZJOZGLSA-N 0.000 description 2
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- KZIQDVNORJKTMO-WDSOQIARSA-N Trp-Arg-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N KZIQDVNORJKTMO-WDSOQIARSA-N 0.000 description 2
- PXYJUECTGMGIDT-WDSOQIARSA-N Trp-Arg-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 PXYJUECTGMGIDT-WDSOQIARSA-N 0.000 description 2
- VFURAIPBOIWAKP-SZMVWBNQSA-N Trp-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N VFURAIPBOIWAKP-SZMVWBNQSA-N 0.000 description 2
- AOAMKFFPFOPMLX-BVSLBCMMSA-N Trp-Arg-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 AOAMKFFPFOPMLX-BVSLBCMMSA-N 0.000 description 2
- TWJDQTTXXZDJKV-BPUTZDHNSA-N Trp-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O TWJDQTTXXZDJKV-BPUTZDHNSA-N 0.000 description 2
- GKUROEIXVURAAO-BPUTZDHNSA-N Trp-Asp-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GKUROEIXVURAAO-BPUTZDHNSA-N 0.000 description 2
- LHHDBONOFZDWMW-AAEUAGOBSA-N Trp-Asp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LHHDBONOFZDWMW-AAEUAGOBSA-N 0.000 description 2
- LTLBNCDNXQCOLB-UBHSHLNASA-N Trp-Asp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 LTLBNCDNXQCOLB-UBHSHLNASA-N 0.000 description 2
- NKUIXQOJUAEIET-AQZXSJQPSA-N Trp-Asp-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)=CNC2=C1 NKUIXQOJUAEIET-AQZXSJQPSA-N 0.000 description 2
- QEJHHFFFCUDPDV-WDSOQIARSA-N Trp-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N QEJHHFFFCUDPDV-WDSOQIARSA-N 0.000 description 2
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 2
- WSMVEHPVOYXPAQ-XIRDDKMYSA-N Trp-Ser-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N WSMVEHPVOYXPAQ-XIRDDKMYSA-N 0.000 description 2
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 description 2
- FBHHJGOJWXHGDO-TUSQITKMSA-N Trp-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 FBHHJGOJWXHGDO-TUSQITKMSA-N 0.000 description 2
- RWTFCAMQLFNPTK-UMPQAUOISA-N Trp-Val-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 RWTFCAMQLFNPTK-UMPQAUOISA-N 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 2
- PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 2
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 2
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 2
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 2
- QHLIUFUEUDFAOT-MGHWNKPDSA-N Tyr-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHLIUFUEUDFAOT-MGHWNKPDSA-N 0.000 description 2
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 2
- IVXJODPZRWHCCR-JYJNAYRXSA-N Val-Arg-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IVXJODPZRWHCCR-JYJNAYRXSA-N 0.000 description 2
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- UZDHNIJRRTUKKC-DLOVCJGASA-N Val-Gln-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N UZDHNIJRRTUKKC-DLOVCJGASA-N 0.000 description 2
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 2
- FEFZWCSXEMVSPO-LSJOCFKGSA-N Val-His-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C)C(O)=O FEFZWCSXEMVSPO-LSJOCFKGSA-N 0.000 description 2
- OPGWZDIYEYJVRX-AVGNSLFASA-N Val-His-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N OPGWZDIYEYJVRX-AVGNSLFASA-N 0.000 description 2
- PTFPUAXGIKTVNN-ONGXEEELSA-N Val-His-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N PTFPUAXGIKTVNN-ONGXEEELSA-N 0.000 description 2
- ZTKGDWOUYRRAOQ-ULQDDVLXSA-N Val-His-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N ZTKGDWOUYRRAOQ-ULQDDVLXSA-N 0.000 description 2
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 2
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 2
- KNYHAWKHFQRYOX-PYJNHQTQSA-N Val-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N KNYHAWKHFQRYOX-PYJNHQTQSA-N 0.000 description 2
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 2
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 2
- RSGHLMMKXJGCMK-JYJNAYRXSA-N Val-Met-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N RSGHLMMKXJGCMK-JYJNAYRXSA-N 0.000 description 2
- MHHAWNPHDLCPLF-ULQDDVLXSA-N Val-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=CC=C1 MHHAWNPHDLCPLF-ULQDDVLXSA-N 0.000 description 2
- BCBFMJYTNKDALA-UFYCRDLUSA-N Val-Phe-Phe Chemical compound N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O BCBFMJYTNKDALA-UFYCRDLUSA-N 0.000 description 2
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 2
- JXCOEPXCBVCTRD-JYJNAYRXSA-N Val-Tyr-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JXCOEPXCBVCTRD-JYJNAYRXSA-N 0.000 description 2
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 2
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 2
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 2
- 108010094001 arginyl-tryptophyl-arginine Proteins 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical group NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 229960002759 eflornithine Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 2
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 2
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108010063431 methionyl-aspartyl-glycine Proteins 0.000 description 2
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 2
- 108010085203 methionylmethionine Proteins 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 2
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000006177 thiolation reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 108010058119 tryptophyl-glycyl-glycine Proteins 0.000 description 2
- 108010029384 tryptophyl-histidine Proteins 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- LJXGLQWLORNQQY-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid;3,6-dichloro-2-methoxybenzoic acid;n-methylmethanamine Chemical compound CNC.CNC.COC1=C(Cl)C=CC(Cl)=C1C(O)=O.OC(=O)C(C)OC1=CC=C(Cl)C=C1C LJXGLQWLORNQQY-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 1
- JVMKBJNSRZWDBO-FXQIFTODSA-N Arg-Cys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O JVMKBJNSRZWDBO-FXQIFTODSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- FLYANDHDFRGGTM-PYJNHQTQSA-N Arg-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FLYANDHDFRGGTM-PYJNHQTQSA-N 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 1
- VLIJAPRTSXSGFY-STQMWFEESA-N Arg-Tyr-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 VLIJAPRTSXSGFY-STQMWFEESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- YMBAVNPKBWHDAW-CIUDSAMLSA-N Cys-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N YMBAVNPKBWHDAW-CIUDSAMLSA-N 0.000 description 1
- IWVNIQXKTIQXCT-SRVKXCTJSA-N Cys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N)O IWVNIQXKTIQXCT-SRVKXCTJSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- QYTKAVBFRUGYAU-ACZMJKKPSA-N Gln-Asp-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QYTKAVBFRUGYAU-ACZMJKKPSA-N 0.000 description 1
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 description 1
- QGWXAMDECCKGRU-XVKPBYJWSA-N Gln-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(N)=O)C(=O)NCC(O)=O QGWXAMDECCKGRU-XVKPBYJWSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 1
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 241000191393 Phage fuse 5 Species 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- HWMGTNOVUDIKRE-UWVGGRQHSA-N Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 HWMGTNOVUDIKRE-UWVGGRQHSA-N 0.000 description 1
- CSYVXYQDIVCQNU-QWRGUYRKSA-N Phe-Asp-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O CSYVXYQDIVCQNU-QWRGUYRKSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- PEEAINPHPNDNGE-JQWIXIFHSA-N Trp-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 PEEAINPHPNDNGE-JQWIXIFHSA-N 0.000 description 1
- PXQPYPMSLBQHJJ-WFBYXXMGSA-N Trp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N PXQPYPMSLBQHJJ-WFBYXXMGSA-N 0.000 description 1
- RQKMZXSRILVOQZ-GMVOTWDCSA-N Trp-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N RQKMZXSRILVOQZ-GMVOTWDCSA-N 0.000 description 1
- ZKVANNIVSDOQMG-HKUYNNGSSA-N Trp-Tyr-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NCC(=O)O)N ZKVANNIVSDOQMG-HKUYNNGSSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- BRPKEERLGYNCNC-NHCYSSNCSA-N Val-Glu-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N BRPKEERLGYNCNC-NHCYSSNCSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- VTIAEOKFUJJBTC-YDHLFZDLSA-N Val-Tyr-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VTIAEOKFUJJBTC-YDHLFZDLSA-N 0.000 description 1
- YKZVPMUGEJXEOR-JYJNAYRXSA-N Val-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N YKZVPMUGEJXEOR-JYJNAYRXSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004753 citiolone Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940087451 cytovene Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010032388 glycyl-prolyl-glycyl-arginyl-alanyl-phenylanine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002614 leucines Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002064 post-exposure prophylaxis Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Immunological conjugates of HIV-specific selected principal neutralization epitopes are prepared. These epitopes bind a broadly neutralizing human monoclonal antibody specific for the HIV principal neutralization epitope(s) and are identified from oligopeptide epitope libraries. The conjugates are useful for vaccination against AIDS or ARC, as well as in the production of other HIV-specific broadly neutralizing antibodies for passive immunity against AIDS or ARC.
Description
213g517 ~ ~094/02626 PCT/US93/06751 TITLE OF THE INV~NL10N
IMMUNOLOGICAL CONJUGATES OF OMPC AND HIV-SPECIFIC
SELECTED PRINCIPAL NEUTRALIZATION EPITOPES
BACKGROUND OF THE 1NV~:N110N
This application is related to U.S.
07/684,090, filed April 12, 1991, which iæ a continuation-in-part of U.S. 07/538,451, filed June 15, 1990, which applications are assigned to MedImmune, a Merck licensor. This application is also related to Merck cases 18709, 17858, 17943, 17944, 17945, 18114, 18154, and 18155.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 ~
Acquired Immune Deficiency Syndrome (AIDS) is the clinical manifestation of the apparent infection of CD4 helper T-cells and other cell targets by human immunodeficiency virus (HIV), also previously referred to as human T-lymphotropic virus type III (ETLV-III), Lymphoadenopathy-aæsociated virus (LAV), or AIDS-related virus (ARV) (hereinafter collectively "HIV"). AIDS is a transmissible deficiency of cellular immunity characterized by opportunistic infections and certain malignancies. A
similar disease, AIDS-related complex (ARC), shares many of the epidemiological features and immune abnormalities with AIDS, and often precedes the clinical manifestations of AIDS.
AIDS is a disease of a virus with a unique collection of attributes. HIV itself targets the immune system; it possesses a reverse transcriptase capable of turning out highly mutated progeny; it is sequestered from the immune system and it has a hypervariable sequence in the (env) region. See, e.g., Hilleman, M.R., Vaccine 6, 175 (1988); Barnes, D.M., Science 240, 719 (1988).
One consequence of these attributes is the diversity of HIV serotypes. The principal neutralizing determinant is an epitope residing in a 2s hypervariable region of the (env) region. As a result, neutralizing antibodies directed against this epitope are generally extremely type-specific; that is, they neutralize only the parental virus and not 213g517 _ NO94/02626 PCT/US93/06751 other variants. Appropriate immunological therapies for AIDS require special consideration of this serological diversity. In particular, it is widely believed that a likely AIDS vaccine will be polyvalent and comprise HIV determinants corresponding to each serotype.
Neutralization is now regarded as one of the key features in the successful design of an HIV
immunological therapy. When a virus-specific antibody neutralizes its virus, it blocks continued replication of the virus, but the precise mechanism is not fully characterized and is thought to vary with virus and target cell. See, e.g, Dimmock, N.J., Trends in Biochem. Sci. 12, 70 (1987).
Applicants have now formulated and reduced to practice a unique method to make vaccines suitable for the serological diversity of HIV and the requirements of neutralization. Applicants employ monoclonal antibodies to define a broadly neutralizing response, then identify oligopeptide epitopes bound by these monoclonal antibodies out of a large random or semi random array or library. The identified epitopes do not have to share any protein sequence with the native HIV protein used to generate the monoclonal antibodies in the first place.
2s Recently, a broadly neutralizing monoclonal antibody against HIV has been discovered. This "447 antibody" binds to about 90Z of all known HIV
serotypes and neutralizes HIV. It was isolated from a human patient.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 _ Applicants have used the 447 antibody to screen phage libraries of synthetic random or semi random oligopeptides. Applicants have discovered novel homologous oligopeptides useful as neutralization epitopes specific for HIV, known hereafter as selected principal neutralization epitopes (SPNEs). These oligopeptides are of synthetic origin.
Applicants have conjugated the oligopeptides of interest to an immunological carrier to provide an immunological conjugate useful as an AIDS vaccine.
Alternatively, this immunological conjugate(s) is useful for generating better and improved broadly neutralizing antibodies for HIV, which are in turn useful for passive immunization and like therapies.
The SPNEs as well as their immunological conjugates are also useful as reagents in the assay of virus in a human host, and in screening blood in blood banks.
A method for screening phage epitope libraries with an antibody of desired specificity or screening antibody is also described. For this screening, applicants have developed a novel selection procedure for the selection of phages bearing epitopes that bind antibody of desired specificity. The screening method of the present invention includes such selection, and, optionally, an identification method for identifying phages bearing desired epitopes.
BRIEF DESCRIPTION OF Tn~; lNV~;NllON
Synthetic amino acid sequences of Table A
that bind a broadly neutralizing human monoclonal antibody (447 antibody) specific for the _ W094/02626 2 1 3 9 S 1 ~7 PCT/US93/06751 HIV principal neutralization determinant are selected and identified from oligopeptide epitope libraries, and are useful in immunological conjugates with OMPC
for vaccination against AIDS or ARC, as well as in the production of other HIV-specific broadly neutralizing antibodies for passive immunity against AIDS or ARC. Screening methods for selecting and/or identifying desired oligopeptide epitopes from phage epitope libraries are also described. The SPNES and their conjugates are also useful in the detection of HIV, or antibodies to HIV in blood samples, for the purpose of screening, clinical evaluation and diagnosis.
BRIEF DFSCRIPTION OF THE FIGURES
Figure l shows the consensus peptide 58 and variants thereof, derived from isolated peptides from the Alpha Library. Thus the consensus peptide has an N-terminal sequence beginning Trp Asp Gly..., or, as variants, Trp Tyr Gly... or Trp Tyr Ala... or Trp Asp Ala...
Figure 2 illustrates one embodiment of the method of screening phage epitope libraries.
Selection and identification are included.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751_ ABBREVIATIONS AND DEFINITIONS
AIDS Acquired immune deficiency syndrome ARC AIDS-related complex conjugation The process of covalently attaching 2 (sometimes 3) molecules each containing one or more immunological determinants, e.g., HIV envelope fragments and OMPC
conjugate Result of conjugation, also known as an antigenic conjugate or immunological conjugate.
Coconjugates are a special subgenus of conjugates.
20 GXG Gly-Xaa-Gly, wherein Xaa is any amino acid.
GPXR Gly-Pro-Xaa-Arg, wherein Xaa in this sequence is any amino acid except Gly. SEQ. ID NO:146.
HIV Generic term for the presumed etiological agent of AIDS and/
or ARC, also referred to as strains HTLV-III, LAV, and ARV
~_ W O 94/02626 2 1 3 9 5 1 7 PC~r/US93/06751 Library A collection of DNA or - oligopeptide sequences, of defined length, with or without limited sequence restrictions OMPC Outer membrane proteosome PCR Polymerase chain reaction poly (gly, ser, ala, val) a linear, random polymer of amino acids selected from the group consisting of glycine, serine, alanine or valine.
Recombinant fusion A polypeptide or oligopeptide polypeptide (RFP) expressed as a contiguous translation product from a spliced foreign DNA in a recombinant eukaryotic or procaryotic expression system, wherein the spliced foreign DNA
is derived from 2 or more coding sequences of different origin, and joined together by ligation or PCR.
Recombinant protein A polypeptide or oligopeptide expressed by foreign DNA in a recombinant eukaryotic or procaryotic expression system.
Recombinant expression system A cell containing a foreign DNA
expressing a foreign protein or a foreign oligopeptide.
W094/02626 PCT/US93/06751-_ 21395 1~ _ 8 -SPNE Selected Principal Neutralization Epitope, which is a principal neutralization determinant bound by one or more broadly neutralizing antibodies. SPNE is defined~ as including consensus sequences. SPNE may have~flexible flanking region(s) of poly (gly, ser, ala, val) of l-lO amino acids in length.
Amino Acids Lo Three-letter One-Letter Full Name symbol symbol Alanine Ala A
Arginine Arg R
15 Asparagine Asn N
Aspartic acid Asp D
Asn or Asp Asx B
Cysteine Cys C
Glutamine Gln Q
20 Glutamic acid Glu E
Gln or Glu Glx Z
Glycine Gly G
Histidine His Isoleucine Ile 25 Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
30 Serine Ser S
Threonine Thr T
W094/02626 213 ~ 5 17 PCT/US93/06751 _ 9 _ Amino Acids cont'd.
Three-letter One-Letter Full Name symbol symbol Tryptophan Trp W
5 Tyrosine Tyr Y
Valine Val V
Norlencine Nle Nucleotides Bases in DNA or RNA
Name One-letter symbol Adenine A
Cytosine C
Guanine G
l5 Thymine T
Uracil U
The terms "protein," "peptide," "oligo-peptide," and "polypeptide" and their plurals have been used interchangeably to refer to chemical compounds having amino acid sequences of five or more amino acids. "Amino acid" refers to any of the 20 common amino acids for which codons are naturally available, and are listed in the table of amino acids given above.
When any variable (e.g. SPNE) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
2139517 lo -SPNE oligopeptides may e~ist as peptides, as internal sequences in e.g. phage pIII proteins, in immunological conjugates with outermembrane proteosome, or as a fragment of a fusion protein with an immunoenhancer sequence such as Hepatitis B core. The position of SPNE
in a fusion protein may be N-terminal, internal or C-terminal.
DETAILED DESCRIPTION OF THE INv~NllON
The present invention provides HIV selected lo principal neutralization epitopes of synthetic origin, immunological conjugates of these epitopes with a carrier such as OMPC, and methods of treating or preventing AIDS
or A`RC with these conjugates. Also described is a method of screening these epitopes from phage epitope libraries.
The epitopes of the present invention bind an HIV
broadly neutralizing antibody and were originally identified in the screening of phage epitope libraries having randomly or semi randomly generated epitope polypeptides accessible to the antibody. These screened polypeptides are hereinafter the selected principal neutralization epitope (SPNE) polypeptides. The sequences of these polypeptides were deduced from their corresponding DNA sequence, determined by the polymerase chain reaction. The SPNE polypeptides including consensus sequences thereof are characterized as having the sequences of Table A.
TABLE A
30 SEQ ID NO:2:
Trp Arg Leu Gly Pro Gly Arg Gly Ser Met Pro Cys Arg Leu Gly lû 15 _~vo g4/02626 2 1 3 9 5 1 7 PCr/US93/067~1 SEQ ID NO:3:
Gln Gly Leu Leu Arg Val Leu Tyr Ala Phe Gly Pro Gly Arg Val SEQ ID NO:6:
His Ser Gln Ala Val Lys Phe Gly Pro Gly Arg Thr Leu Val Pro SEQ ID NO:8:
Asp Leu Gln Ala Arg Ser Lys Thr Tyr Phe Tyr Gly Pro Gly Arg lû 15 SEQ ID NO:13:
Leu Leu Leu Ile Gly Pro Gly Arg Glu Leu Arg Pro Ile Asn Leu lû 15 SEQ ID NO:15:
Phe Phe Tyr Gly Pro Gly Arg Tyr Pro Pro Arg Phe Lys Leu Gly SEQ ID NO:18:
Cys Ala Thr Ser Ile Gly Gly Val Leu Phe Gly Pro Gly Arg Gly WO 94/02626 ` PCI/US93/06751-213~517 SEQ ID NO: 19:
Trp Arg Met Met Leu Gly Pro Gly Arg Asp Tyr Ala Gly Pro Ala SEQ ID NO:21:
Arg Ile Arg Leu Pro Arg Gly Pro Gly Arg Pro Gln Thr Thr Met 1 5 lû 15 SEQ ID NO:23:
Leu Leu Arg Thr Ile Met Ile Gly Pro Gly Arg Leu Leu H;s Ser SEQ ID NO:25:
Gly Gln Ile Ile Phe Ile Gly Pro Gly Arg Leu Gly Asn Gly Glu SEQ ID NO:26:
Leu Gln Leu Leu Ile Gly Pro Gly Arg Thr Val Gly Lys Ile Arg SEQ I D NO:28:
Thr Lys Ile Gly Pro Gly Arg Val Phe Asp Gly Arg Trp Arg Phe _ 13 -SEQ ID NO:30:
Ile Leu Phe Gly Pro Gly Arg Cy5 Ser Val Asp Ala Val Ser Gly SEQ ID NO:31:
Tyr Leu Ala Met Arg Gly Ala Gly Tyr Met Ile Gly Pro Ala Arg SEQ ID NO:32:
Asn Cys Ser Val His Val Gly Ala Gly Arg Asn Ser Ala Trp Cys SEQ ID NO:33:
Asn Arg Tyr Gly Pro Gly Arg Val Gly Phe Val Arg Ser Gln Pro SEQ ID NO:34:
Ala Arg Gly Trp Gly Gly Val Phe Tyr Gly Pro Gly Arg Gly Glu SEQ ID NO:35:
Tyr Gly Arg Phe Ser Phe Gly Pro Gly Arg Gly Tyr Met Val Ile WO 94/02626 PCI/US93/0675I _ 21 ~q~ l~
- 14 _ SEQ ID N0:36:
Tyr Tyr Tyr Arg Asn Val Leu Val Gly Pro Gly Arg Trp Trp Leu SEQ ID N0:38:
Arg Phe Gln Glu Gly Gln Lys Val Leu Val Gly Pro Gly Arg Arg lû 15 1'0 SEQ ID N0:39:
Ser Cys Met Thr Ser Val Leu Val Gly Pro Gly Arg Gln Asp Asn SEQ ID N0:40:
Gly Ile Leu Arg Gln Pro Leu Leu Ile Gly Pro Gly Arg Ala Pro SEQ ID N0:41:
Trp Asp Thr Leu Gly Trp Val Val Ser Asn Phe Gly Pro Gly Arg SEQ ID NO: 43:
Gln Ile Trp Tyr Phe Gly Pro Gly Arg Ser Gln Ser Gly Ser Met 2139~17 _ WO 94/02626 PCI /US93/06751 SEQ ID NO:47:
Pro Tyr Ser Asp Leu Leu Leu Ser Lys Tyr Phe Gly Pro Gly Arg 1 5 lû 15 S
SEQ ID NO:48:
Leu Asp Gln Tyr Arg Val Leu Leu Trp Gly Pro Gly Arg Thr Thr '0 SEQ ID NO: 49:
Val Leu Lys Ile Leu Arg His Ala Tyr Phe Gly Pro Gly Arg Trp SEQ ID N0:50:
Val Arg His Met Gly Pro Gly Arg Gly Met Val Leu Gly Ile Thr 1 5 lû 15 SEQ ID N0:51:
Asn Tyr Phe Gly Pro Gly Arg Gly Gly Val Val Val Thr Gly His SEQ ID N0:52:
Gln Val Phe Gly Pro Gly Arg Thr Asn Pro Arg 5er Asn Leu Leu WO 94/02626 213g5 17 PCI/US93/06751 _ SEQ ID N0:55:
Phe Asp Gl y Gl n Ser Lys Val Val Leu Arg Gl y Pro Gl y Arg Gl y SEQ ID N0:58:
Trp Asp Gl y Leu Gl y Trp Gl n Ile Val Hi s Phe Gl y Pro Gl y Arg Gly Gly Asn Gly Ile Asn Leu Gly Ala ZO
SEQ ID N0:61:
Gl y Al a Gl y Hi s Val Gl y Pro Gl y Arg Tyr Gl y Al a Leu Ser
IMMUNOLOGICAL CONJUGATES OF OMPC AND HIV-SPECIFIC
SELECTED PRINCIPAL NEUTRALIZATION EPITOPES
BACKGROUND OF THE 1NV~:N110N
This application is related to U.S.
07/684,090, filed April 12, 1991, which iæ a continuation-in-part of U.S. 07/538,451, filed June 15, 1990, which applications are assigned to MedImmune, a Merck licensor. This application is also related to Merck cases 18709, 17858, 17943, 17944, 17945, 18114, 18154, and 18155.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 ~
Acquired Immune Deficiency Syndrome (AIDS) is the clinical manifestation of the apparent infection of CD4 helper T-cells and other cell targets by human immunodeficiency virus (HIV), also previously referred to as human T-lymphotropic virus type III (ETLV-III), Lymphoadenopathy-aæsociated virus (LAV), or AIDS-related virus (ARV) (hereinafter collectively "HIV"). AIDS is a transmissible deficiency of cellular immunity characterized by opportunistic infections and certain malignancies. A
similar disease, AIDS-related complex (ARC), shares many of the epidemiological features and immune abnormalities with AIDS, and often precedes the clinical manifestations of AIDS.
AIDS is a disease of a virus with a unique collection of attributes. HIV itself targets the immune system; it possesses a reverse transcriptase capable of turning out highly mutated progeny; it is sequestered from the immune system and it has a hypervariable sequence in the (env) region. See, e.g., Hilleman, M.R., Vaccine 6, 175 (1988); Barnes, D.M., Science 240, 719 (1988).
One consequence of these attributes is the diversity of HIV serotypes. The principal neutralizing determinant is an epitope residing in a 2s hypervariable region of the (env) region. As a result, neutralizing antibodies directed against this epitope are generally extremely type-specific; that is, they neutralize only the parental virus and not 213g517 _ NO94/02626 PCT/US93/06751 other variants. Appropriate immunological therapies for AIDS require special consideration of this serological diversity. In particular, it is widely believed that a likely AIDS vaccine will be polyvalent and comprise HIV determinants corresponding to each serotype.
Neutralization is now regarded as one of the key features in the successful design of an HIV
immunological therapy. When a virus-specific antibody neutralizes its virus, it blocks continued replication of the virus, but the precise mechanism is not fully characterized and is thought to vary with virus and target cell. See, e.g, Dimmock, N.J., Trends in Biochem. Sci. 12, 70 (1987).
Applicants have now formulated and reduced to practice a unique method to make vaccines suitable for the serological diversity of HIV and the requirements of neutralization. Applicants employ monoclonal antibodies to define a broadly neutralizing response, then identify oligopeptide epitopes bound by these monoclonal antibodies out of a large random or semi random array or library. The identified epitopes do not have to share any protein sequence with the native HIV protein used to generate the monoclonal antibodies in the first place.
2s Recently, a broadly neutralizing monoclonal antibody against HIV has been discovered. This "447 antibody" binds to about 90Z of all known HIV
serotypes and neutralizes HIV. It was isolated from a human patient.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 _ Applicants have used the 447 antibody to screen phage libraries of synthetic random or semi random oligopeptides. Applicants have discovered novel homologous oligopeptides useful as neutralization epitopes specific for HIV, known hereafter as selected principal neutralization epitopes (SPNEs). These oligopeptides are of synthetic origin.
Applicants have conjugated the oligopeptides of interest to an immunological carrier to provide an immunological conjugate useful as an AIDS vaccine.
Alternatively, this immunological conjugate(s) is useful for generating better and improved broadly neutralizing antibodies for HIV, which are in turn useful for passive immunization and like therapies.
The SPNEs as well as their immunological conjugates are also useful as reagents in the assay of virus in a human host, and in screening blood in blood banks.
A method for screening phage epitope libraries with an antibody of desired specificity or screening antibody is also described. For this screening, applicants have developed a novel selection procedure for the selection of phages bearing epitopes that bind antibody of desired specificity. The screening method of the present invention includes such selection, and, optionally, an identification method for identifying phages bearing desired epitopes.
BRIEF DESCRIPTION OF Tn~; lNV~;NllON
Synthetic amino acid sequences of Table A
that bind a broadly neutralizing human monoclonal antibody (447 antibody) specific for the _ W094/02626 2 1 3 9 S 1 ~7 PCT/US93/06751 HIV principal neutralization determinant are selected and identified from oligopeptide epitope libraries, and are useful in immunological conjugates with OMPC
for vaccination against AIDS or ARC, as well as in the production of other HIV-specific broadly neutralizing antibodies for passive immunity against AIDS or ARC. Screening methods for selecting and/or identifying desired oligopeptide epitopes from phage epitope libraries are also described. The SPNES and their conjugates are also useful in the detection of HIV, or antibodies to HIV in blood samples, for the purpose of screening, clinical evaluation and diagnosis.
BRIEF DFSCRIPTION OF THE FIGURES
Figure l shows the consensus peptide 58 and variants thereof, derived from isolated peptides from the Alpha Library. Thus the consensus peptide has an N-terminal sequence beginning Trp Asp Gly..., or, as variants, Trp Tyr Gly... or Trp Tyr Ala... or Trp Asp Ala...
Figure 2 illustrates one embodiment of the method of screening phage epitope libraries.
Selection and identification are included.
W094/02626 2 1 3 9 5 1 7 PCT/US93/06751_ ABBREVIATIONS AND DEFINITIONS
AIDS Acquired immune deficiency syndrome ARC AIDS-related complex conjugation The process of covalently attaching 2 (sometimes 3) molecules each containing one or more immunological determinants, e.g., HIV envelope fragments and OMPC
conjugate Result of conjugation, also known as an antigenic conjugate or immunological conjugate.
Coconjugates are a special subgenus of conjugates.
20 GXG Gly-Xaa-Gly, wherein Xaa is any amino acid.
GPXR Gly-Pro-Xaa-Arg, wherein Xaa in this sequence is any amino acid except Gly. SEQ. ID NO:146.
HIV Generic term for the presumed etiological agent of AIDS and/
or ARC, also referred to as strains HTLV-III, LAV, and ARV
~_ W O 94/02626 2 1 3 9 5 1 7 PC~r/US93/06751 Library A collection of DNA or - oligopeptide sequences, of defined length, with or without limited sequence restrictions OMPC Outer membrane proteosome PCR Polymerase chain reaction poly (gly, ser, ala, val) a linear, random polymer of amino acids selected from the group consisting of glycine, serine, alanine or valine.
Recombinant fusion A polypeptide or oligopeptide polypeptide (RFP) expressed as a contiguous translation product from a spliced foreign DNA in a recombinant eukaryotic or procaryotic expression system, wherein the spliced foreign DNA
is derived from 2 or more coding sequences of different origin, and joined together by ligation or PCR.
Recombinant protein A polypeptide or oligopeptide expressed by foreign DNA in a recombinant eukaryotic or procaryotic expression system.
Recombinant expression system A cell containing a foreign DNA
expressing a foreign protein or a foreign oligopeptide.
W094/02626 PCT/US93/06751-_ 21395 1~ _ 8 -SPNE Selected Principal Neutralization Epitope, which is a principal neutralization determinant bound by one or more broadly neutralizing antibodies. SPNE is defined~ as including consensus sequences. SPNE may have~flexible flanking region(s) of poly (gly, ser, ala, val) of l-lO amino acids in length.
Amino Acids Lo Three-letter One-Letter Full Name symbol symbol Alanine Ala A
Arginine Arg R
15 Asparagine Asn N
Aspartic acid Asp D
Asn or Asp Asx B
Cysteine Cys C
Glutamine Gln Q
20 Glutamic acid Glu E
Gln or Glu Glx Z
Glycine Gly G
Histidine His Isoleucine Ile 25 Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
30 Serine Ser S
Threonine Thr T
W094/02626 213 ~ 5 17 PCT/US93/06751 _ 9 _ Amino Acids cont'd.
Three-letter One-Letter Full Name symbol symbol Tryptophan Trp W
5 Tyrosine Tyr Y
Valine Val V
Norlencine Nle Nucleotides Bases in DNA or RNA
Name One-letter symbol Adenine A
Cytosine C
Guanine G
l5 Thymine T
Uracil U
The terms "protein," "peptide," "oligo-peptide," and "polypeptide" and their plurals have been used interchangeably to refer to chemical compounds having amino acid sequences of five or more amino acids. "Amino acid" refers to any of the 20 common amino acids for which codons are naturally available, and are listed in the table of amino acids given above.
When any variable (e.g. SPNE) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
2139517 lo -SPNE oligopeptides may e~ist as peptides, as internal sequences in e.g. phage pIII proteins, in immunological conjugates with outermembrane proteosome, or as a fragment of a fusion protein with an immunoenhancer sequence such as Hepatitis B core. The position of SPNE
in a fusion protein may be N-terminal, internal or C-terminal.
DETAILED DESCRIPTION OF THE INv~NllON
The present invention provides HIV selected lo principal neutralization epitopes of synthetic origin, immunological conjugates of these epitopes with a carrier such as OMPC, and methods of treating or preventing AIDS
or A`RC with these conjugates. Also described is a method of screening these epitopes from phage epitope libraries.
The epitopes of the present invention bind an HIV
broadly neutralizing antibody and were originally identified in the screening of phage epitope libraries having randomly or semi randomly generated epitope polypeptides accessible to the antibody. These screened polypeptides are hereinafter the selected principal neutralization epitope (SPNE) polypeptides. The sequences of these polypeptides were deduced from their corresponding DNA sequence, determined by the polymerase chain reaction. The SPNE polypeptides including consensus sequences thereof are characterized as having the sequences of Table A.
TABLE A
30 SEQ ID NO:2:
Trp Arg Leu Gly Pro Gly Arg Gly Ser Met Pro Cys Arg Leu Gly lû 15 _~vo g4/02626 2 1 3 9 5 1 7 PCr/US93/067~1 SEQ ID NO:3:
Gln Gly Leu Leu Arg Val Leu Tyr Ala Phe Gly Pro Gly Arg Val SEQ ID NO:6:
His Ser Gln Ala Val Lys Phe Gly Pro Gly Arg Thr Leu Val Pro SEQ ID NO:8:
Asp Leu Gln Ala Arg Ser Lys Thr Tyr Phe Tyr Gly Pro Gly Arg lû 15 SEQ ID NO:13:
Leu Leu Leu Ile Gly Pro Gly Arg Glu Leu Arg Pro Ile Asn Leu lû 15 SEQ ID NO:15:
Phe Phe Tyr Gly Pro Gly Arg Tyr Pro Pro Arg Phe Lys Leu Gly SEQ ID NO:18:
Cys Ala Thr Ser Ile Gly Gly Val Leu Phe Gly Pro Gly Arg Gly WO 94/02626 ` PCI/US93/06751-213~517 SEQ ID NO: 19:
Trp Arg Met Met Leu Gly Pro Gly Arg Asp Tyr Ala Gly Pro Ala SEQ ID NO:21:
Arg Ile Arg Leu Pro Arg Gly Pro Gly Arg Pro Gln Thr Thr Met 1 5 lû 15 SEQ ID NO:23:
Leu Leu Arg Thr Ile Met Ile Gly Pro Gly Arg Leu Leu H;s Ser SEQ ID NO:25:
Gly Gln Ile Ile Phe Ile Gly Pro Gly Arg Leu Gly Asn Gly Glu SEQ ID NO:26:
Leu Gln Leu Leu Ile Gly Pro Gly Arg Thr Val Gly Lys Ile Arg SEQ I D NO:28:
Thr Lys Ile Gly Pro Gly Arg Val Phe Asp Gly Arg Trp Arg Phe _ 13 -SEQ ID NO:30:
Ile Leu Phe Gly Pro Gly Arg Cy5 Ser Val Asp Ala Val Ser Gly SEQ ID NO:31:
Tyr Leu Ala Met Arg Gly Ala Gly Tyr Met Ile Gly Pro Ala Arg SEQ ID NO:32:
Asn Cys Ser Val His Val Gly Ala Gly Arg Asn Ser Ala Trp Cys SEQ ID NO:33:
Asn Arg Tyr Gly Pro Gly Arg Val Gly Phe Val Arg Ser Gln Pro SEQ ID NO:34:
Ala Arg Gly Trp Gly Gly Val Phe Tyr Gly Pro Gly Arg Gly Glu SEQ ID NO:35:
Tyr Gly Arg Phe Ser Phe Gly Pro Gly Arg Gly Tyr Met Val Ile WO 94/02626 PCI/US93/0675I _ 21 ~q~ l~
- 14 _ SEQ ID N0:36:
Tyr Tyr Tyr Arg Asn Val Leu Val Gly Pro Gly Arg Trp Trp Leu SEQ ID N0:38:
Arg Phe Gln Glu Gly Gln Lys Val Leu Val Gly Pro Gly Arg Arg lû 15 1'0 SEQ ID N0:39:
Ser Cys Met Thr Ser Val Leu Val Gly Pro Gly Arg Gln Asp Asn SEQ ID N0:40:
Gly Ile Leu Arg Gln Pro Leu Leu Ile Gly Pro Gly Arg Ala Pro SEQ ID N0:41:
Trp Asp Thr Leu Gly Trp Val Val Ser Asn Phe Gly Pro Gly Arg SEQ ID NO: 43:
Gln Ile Trp Tyr Phe Gly Pro Gly Arg Ser Gln Ser Gly Ser Met 2139~17 _ WO 94/02626 PCI /US93/06751 SEQ ID NO:47:
Pro Tyr Ser Asp Leu Leu Leu Ser Lys Tyr Phe Gly Pro Gly Arg 1 5 lû 15 S
SEQ ID NO:48:
Leu Asp Gln Tyr Arg Val Leu Leu Trp Gly Pro Gly Arg Thr Thr '0 SEQ ID NO: 49:
Val Leu Lys Ile Leu Arg His Ala Tyr Phe Gly Pro Gly Arg Trp SEQ ID N0:50:
Val Arg His Met Gly Pro Gly Arg Gly Met Val Leu Gly Ile Thr 1 5 lû 15 SEQ ID N0:51:
Asn Tyr Phe Gly Pro Gly Arg Gly Gly Val Val Val Thr Gly His SEQ ID N0:52:
Gln Val Phe Gly Pro Gly Arg Thr Asn Pro Arg 5er Asn Leu Leu WO 94/02626 213g5 17 PCI/US93/06751 _ SEQ ID N0:55:
Phe Asp Gl y Gl n Ser Lys Val Val Leu Arg Gl y Pro Gl y Arg Gl y SEQ ID N0:58:
Trp Asp Gl y Leu Gl y Trp Gl n Ile Val Hi s Phe Gl y Pro Gl y Arg Gly Gly Asn Gly Ile Asn Leu Gly Ala ZO
SEQ ID N0:61:
Gl y Al a Gl y Hi s Val Gl y Pro Gl y Arg Tyr Gl y Al a Leu Ser
2 0 SEQ ID N0:63:
Ser Thr Arg His Leu Gly Pro Gly Arg Val Glu Gly Val Leu SEQ ID N0:64:
Gly Val His Arg Phe Gly Pro Gly Arg Gly Glu Gly Met Val
Ser Thr Arg His Leu Gly Pro Gly Arg Val Glu Gly Val Leu SEQ ID N0:64:
Gly Val His Arg Phe Gly Pro Gly Arg Gly Glu Gly Met Val
3 0 _ WO 94/02626 PCl/US93/06751 SEQ ID NO:65:
Gly Gly Tyr His Trp Gly Pro Gly Arg Gly Ser Val Glu Ala SEQ ID NO:66:
Gln Ala Trp His Phe Gly Pro Gly Arg Asp His Gly Glu SEQ ID NO:67:
Lys Ala Asn His Tyr Gly Pro Ser Arg Gly Pro Gly Ser Arg SEQ ID NO:68:
Leu Leu Gly Pro Gly Arg Gly Ser Ser Ser Val Arg Gly Glu Leu SEQ ID N0:69:
Ser Gly Trp Trp Gly Gly Val His Val Gly Pro Gly Arg Gly Thr 1 5 lû 15 SEQ ID N0:70:
Trp Ser Lys Arg Glu Ser Val Met Phe Gly Pro Gly Arg Gly Thr W094/02626 2 1 3q5 ~ PCI/US93/06751 _ 18 --SEQ ID NO:71:
Trp Asp Ser Arg Ala Thr Leu Arg Leu Gly Pro Gly Arg Ser Ser SEQ ID NO:72:
Gly Lys Val Phe Tyr Gly Pro Gly Arg Glu Trp His Ala lû
1'0 SEQ ID NO:73:
Ala Arg Val Phe Leu Gly Pro Gly Arg Gly Val Val Tyr Asp lû
SEQ ID NO:74:
Arg Val Gln Lys Leu Gly Pro Gly Arg Gln Thr Ala Ser Gly SEQ ID NO:75:
Lys Leu Gl y Pro Gl y Arg Gl y Gl y Tyr Phe Gl y Al a Gl n Val SEQ ID NO:76:
Arg Lys Val Asn Ile Gly Pro Gly Arg Val His Gly Asn Ser 213g517 _ WO 94/02626 PCI/US93/06751 SEQ ID N0:77:
Arg Gly Val Lys Ile Gly Pro Gly Arg Ile Ala Ser Gly Tyr SEQ ID N0:78:
Lys Asp Leu His Ile Gly Pro Gly Arg Met Asp Gly Leu Arg SEQ ID N0:79:
Ala Gln Arg Ser His Leu ~le Gly Pro Gly Arg Ala Glu Thr Gly 1 5 lû 15 SEQ ID N0:81:
Arg Gln Val Met Leu Gly Pro Gly Arg Gly Asp Arg Leu Glu SEQ ID N0:83:
Lys Phe Val Glu Leu Gly Pro Gly Arg Lys Gly Gl n Gl y SEQ ID N0:84:
Asp Arg Gly Ser Arg Phe Val Leu Leu Gly Pro Gly Arg Met Gly 1 5 10 lS
W O 94/02626 2 1 3 9 ~ I ~ PC~r/US93/06751 _ 20 -SEQ ID NO:85:
Glu Gln Leu His Arg Leu Val Ala Phe Gly Pro Gly Arg Ala Ala SEQ ID NO:86:
Leu Pro Ser Val Asn Leu Gly Pro Gly Arg Asn Ala Arg Lys Gly 5 lO l5 SEQ ID NO:9û:
Arg Glu Leu His Met Gly Pro Gly Arg Ala Arg Pro Gly Phe SEQ ID NO:91:
Cys Arg Val Asp Phe Gly Pro Gly Arg Leu Gly Ser Arg Thr SEQ ID NO:92:
Asn Val Val Ala Ile Gly Pro Gly Arg Ser Asn Val Val Thr SEQ ID NO:93:
Lys Glu Val His Phe Gly Pro Gly Arg Gly Gly Gln Arg Ser _ ~0 94/02626 2 1 3 9 ~ 1 7 PCI`/US93/067~1 SEQ ID N0:94:
Xaa Xaa Tyr Leu Ile Gly Pro Gly Arg Gly Trp Glu Arg Glu l 5 lO
SEQ ID NO:95:
Ala Gl y Cys Gl n Val Gl y Pro Gl y Arg Pro Xaa Cys Gly Lys l 5 lO
SEQ ID NO:97:
Ile Gly Arg Asn Leu Gly Pro Gly Arg Val Val Ser Asn Val l 5 lO
SEQ ID NO:98:
Lys Asn Val His Val Gl y Pro Gl y Arg Gl y Gl n Arg Thr Val l 5 lO
SEQ ID N0: lOû:
Ser Lys Val Glu Ile Gly Pro Gly Arg Gly Pro Leu Met Arg l 5 lO
SEQ ID N0: 102:
Gly Arg Ile Asn Tyr Gly Pro Gly Ala Pro Gly Leu Met l 5 lO
W O 94/02626 2139S 17 PC~r/US93/06751 __ _ ZZ _ SEQ ID N0: 103:
Glu Val His Tyr Tyr Gly Pro Gly Arg Arg Ala Pro Ala Ser SEQ ID N0: lû4:
Val Gl u Arg Hi s Leu Gl y Pro Gl y Arg Gl y Leu Gl n Met Gl y 1'0 SEQ ID NO: lOS:
Asn Ser Phe His Leu Gly Pro Gly Arg Ser Arg Thr Tyr Ser SEQ ID N0: 106:
Gly Val Val Lys Leu Gly Pro Gly Arg Thr Ala Gly Lys Leu SEQ ID N0: lû7:
Leu Ile 61y Pro Gly Arg Ser Ser Val Ala Met Thr Ile Arg Glu SEQ ID N0: 108:
Leu Val Arg Met Leu Gly Pro Gly Arg Gly Asn Asp Arg Thr His ~0 94/02626 2 1395 ~7 PC~r/US93/06751 SEQ ID NO :109:
Gln Arg Gly Lys Thr Phe Tyr Gly Pro Gly Arg Gly Ser Gly Gln SEQ ID NO:llO:
Asp Arg Gly Lys Ile Val Tyr Gly Pro Gly Arg Thr Gln Ser SEQ ID NO:112:
Gly Phe Ser Ser Ser Arg Val Leu Val Gly Pro Gly Arg Gly Val SEQ ID NO:113:
Val Lys Arg Arg Asp Ala Val His Ala Gly Pro Gly SEQ ID NO: 114:
Asp Ser Glu Arg Val Gly Val Leu Leu Gly Pro Gly Arg Gly Val SEQ ID NO: 115:
Asp Leu Gly Arg Pro Ala Val Arg Phe Gly Pro Gly Arg Ile Ile WO 94/02626 ~, \3q5 ~ ~ ` PCI'/US93/06751 -- 24 _ SEQ ID NO:116:
Leu Ser Arg Phe Arg Glu Trp His Val Gly Pro Gly Arg Val Pro 1 5 lo 15 SEQ ID NO:118:
Ile Gly Val Thr Arg Ala Leu Phe Phe Gly Pro Gly Arg Gly Thr 1 5 lo 15 SEQ ID NO: 119:
Ser Leu Ser Arg Ala His Val His Arg Gly Pro Gly Arg Val Ser 1 5 lo 15 SEQ ID NO:12û:
Leu Val Tyr Arg Ala Ala His Tyr Gly Pro Gly Arg Gly Val 1 5 lo SEQ ID NO: 121:
Arg Gly Trp Arg Pro Val Leu Ala Val Gly Pro Gly Arg Trp Glu 1 5 lo 15 ` _ WO 94/02626 PCI`/US93/06751 _ 25 -SEQ ID NO:134:
Cys Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly 1 5 lû 15 Cys SEQ ID NO:135:
Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly SEQ ID NO:136:
Asp Gly Ser Arg Arg Ala Val His Leu Gly Pro Gly Arg Gly Val SEQ ID NO:137:
Leu Leu Lys Glu Val His Phe Gly Pro Gly Arg Gly Arg Gly Gly Arg Leu Leu W O 94/02626 2 1 3 9 5 1 7 PC~r/US93/06751 __ SEQ ID N0:138:
Cys Arg Gly Val His Leu Gly Pro Gly Arg Gly Ala Arg Met Ser lû 15 Cys SEQ ID N0:139:
Cys Asp Arg Gly Ser Val Leu Ile Gly Pro Gly Arg Gly Ser Ser Xaa Gl y Cys SEQ ID N0:140:
Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser SEQ ID N0:141:
Cys Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser Cys _ WO 94/02626 2 1 3 9 ~ 1 7 PCI`/US93/06751 SEQ ID NO:142:
Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu Gly Leu Ser SEQ ID NO:143:
1'0 Cys Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu 1 5 lû 15 Gly Leu Ser Cys SEQ ID NO:144:
Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser SEQ ID NO:145:
Cys Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser Cys 21395~7 WO 94/02626 PCI`/US93/06751 _ SEQ ID NO:l:
Pro Arg Leu Glu Thr His Phe Gly Pro Lys Arg Ser His Val Gly 1 5 lû 15 SEQ ID NO:4:
Val Leu Val Trp Gln Arg Lys Val Phe Phe Gly Pro His Arg Ser SEQ ID NO:5:
Arg Ser Ser Ser Trp Ala Trp Arg His Leu Tyr Gly Pro Ala Arg 1 5 lû 15 SEQ ID NO:7:
Trp Asp Arg Gly Asn Ser Ser Gly Arg His Leu Gly Pro Ala Arg SEQ ID NO:9:
Thr Trp His Leu Arg Val Arg Gly Ala His Phe Gly Pro Ala Arg SEQ ID NO:10:
Trp Leu Arg Val Leu Leu Gly Pro Ala Arg Pro Ile Tyr Trp Arg _ WO 94/02626 21 3 9 ~17 PCI/US93/06751 _ 29 --SEQ ID NO:ll:
Leu Leu Leu Gly Pro Ala Arg Ala Pro Val Arg Val Asn Leu Ala l 5 10 15 SEQ ID N0: 12:
Cys Lys Pro Arg Ala Pro Met Leu Phe Gly Pro Ala Arg Gly Leu SEQ ID N0:14:
Val Phe Lys Val Ile Asn Arg Ile Leu His Tyr Gly Pro Asn Arg l 5 10 15 SEQ ID N0:16:
Asp Val Gly Trp Val Thr Gly Thr Gln H;s Tyr Gly Pro Arg Arg SEQ ID N0:17:
Gly Leu Tyr Thr Cys Met Tyr Gly Pro Ser Arg His Ile Cys Val l 5 10 15 SEQ ID N0: 20:
Thr Glu Leu Gly Arg Gly Tyr Ile Ser His Gly Pro Ala Arg Gly l 5 10 15 WO 94/02626 ~395 PCr/US93/06751 _ .
SEQ ID NO:22:
His Leu Gly Pro Ser Arg Gly Ala Asn Leu Gly Lys Ile Gly Ala SEQ ID NO:24:
Leu His Val Gly Pro Asn Arg Gly Lys Ser Glu Asp Asn Tyr Arg SEQ ID NO:27:
Phe Tyr Thr Ser Gly Lys Thr Ile Phe Tyr Tyr Gly Pro Arg Arg SEQ ID NO: 29:
Ala Cys Trp Ser Arg Glu Tyr Gly Pro Ala Arg Met Ser Cys Thr SEQ ID NO:37:
Trp Ser Trp Val Arg Leu Lys Ala Val Leu Leu Gly Pro Ser Arg SEQ ID NO:42:
Val Leu Arg Cys Phe Gly Pro Leu Arg Asp Ala Arg Cys Ser Val _ WO 94/02626 2 1 3 9 5 1 7 PCI/US93/06751 SEQ ID NO:44:
Leu Met Val Val Gln Val Gly Pro Ala Arg Thr Phe Leu Gln Gly SEQ ID NO:45:
Gl y Pro Ser Leu Phe Asn Ser Gl y Val Arg Tyr Gl y Pro Lys Arg 1'0 SEQ ID NO:46:
Val His Phe Ile Gly Pro Gln Arg Gly Gly Asn Ser Ser His Leu SEQ ID NO:53:
Met Glu Arg Asp Leu Val Arg Phe Gly Pro Asn Arg Asp Trp Arg SEQ ID NO:54:
Asn Gly Leu Lys Leu Cys Arg Val Gly Pro Ser Arg Glu Gly Cys SEQ ID NO:56:
Pro Val Lys Phe Gly Pro Gln Arg Ser Gly Gly Ala Thr Arg Pro WO 94/02626 2 1 3 9 ~ 1~ ; PCI`/US93/06751 _ SEQ ID N0:57:
Ile Thr Pro Arg Leu Tyr Gly Pro Ser Arg Met Arg Tyr Asn Gln SEQ ID N0:59:
Asn Lys Arg Glu Phe Gly Pro Ala Arg Ala Ala Arg Asn Arg SEQ ID N0:6û:
His Arg Arg Asp Ile Gly Pro Ala Arg Thr Arg Glu Ile Gly SEQ ID N0:62:
Ser Ala Val His Leu Gly Pro Gln Arg Gln Arg Ala Thr Asp 1 5 lo SEQ ID N0:80:
Lys Gln Val Arg Leu Gly Pro Ala Arg Gly Asp Ile Ile Gly 2S 1 5 lo SEQ ID N0:8Z:
Arg Ser Val Leu Met Gly Pro Ala Arg Ser Thr Arg Val Val 1 5 lû
~_ W O 94/02626 2 ~ 3 9 5 1 7 PC~r/US93/06751 SEQ ID NO:87:
Gln His Arg Ala Ala Ser Val His Leu Gly Pro Ser Arg Ala Gly SEQ ID NO:88:
Leu Met Phe Val Arg Val Val Lys Leu Gly Pro Ala Arg Val Pro SEQ ID NO: 89:
Tyr Gly Leu Val Ile Arg Cys Glu Val Gly Pro Ser Arg Ser Cys 5 lû 15 SEQ ID NO:96:
Arg Glu Val His Phe Gly Pro Arg Arg Asp Glu Pro Gly Arg SEQ ID NO: 99:
Arg Leu His Leu Val Gly Pro Ala Arg Val Ser Pro Leu Ser SEQ ID NO: 101:
Ala Val Ile His Val Gly Pro Ser Arg Leu Lys Ser Gln Tyr WO 94/02626 ~ ~39S~ PCI/US93/06751 -- 34 _ SEQ ID N0:111:
Asp Trp Arg Ser Val His Ile Gly Pro Ala Arg Arg Glu Val Leu lû 15 SEQ ID N0:117:
Ala Ala Leu Arg Lys Val Arg Xaa Tyr Gly Pro Ala Arg Gln Ser ~139517 _ W O 94/02626 PC~r/US93/06751 The new SPNE amino acid sequences of this invention include any fragment thereof in the sequence listing, provided said fragment is at least five amino acids in length, and includes the GPXR
(SEQ. ID N0:123) loop region or homolog.
Each SPNE amino acid sequence can be determined by DNA sequencing of phage clones amplified by the polymerase chain reaction.
The present invention also provides an effective immunogen against AIDS or ARC, and comprises an antigenic conjugate of the formula (SPNE)n~(OMPC) I, wherein:
SPNE is the selected principal neutralization epitope of ~IV, which is a polypeptide of one or more amino acid sequences, each sequence having any of sequences of Table A, or fragments thereof, said fragment having at least 5 amino acids in length and including the GPXR loop region or homolog thereof;
n = 1-50, wherein n is the number of polypeptides of SPNE covalently linked to OMPC;
~ indicates covalent linkage;
OMPC is outer membrane proteosome of the micro-organism Neisseria, said conjugate optionally substituted with an anion or polyanion to render it soluble such as polyproprioniC acid, or substituted with a- which is an anion or polyanion at physiological p~, said a- consisting of one to five residues of W094/02626 2 l395 ll` .; PCT/US93/06751 ~
anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid, or pharmaceutically acceptable salts.
Each conjugate molecule of formula I may have different peptides conjugated thereto, or, alternatively, multiples of a single peptide species conjugated thereto, or a combination.
The antigenic conjugates of this invention are prepared by isolating, synthesizing and purifying their component parts SPNE and OMPC, then conjugating SPNE and OMPC together. Subsequent purification of conjugate mixtures may be performed as desired.
Applicants also have developed a method for identifying new SPNE by the screening of phage libraries bearing randomly or semi randomly generated oligopeptide epitopes. The library is screened with any antibody, and is specifically illustrated by screening with a broadly neutralizing monoclonal antibody.
Polymerase Chain Reaction Amplification Large amounts of DNA coding for SPNE protein may be obtained using polymerase chain reaction (PCR) amplification techniques as described in Mullins et al., U.S. Patent No. 4,800,159 and other published sources. See also, for example, Innis, M.A. et al.
PCR Protocols Academic Press 1990. The extension product of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule.
The primer template complexes act as substrate for DNA polymerase which, in performing its replication function, extends the primers. The region in common with both primer extensions, upon denaturation, serves as template for a repeated primer extension.
Taq DNA Polymerase catalyzes primer extension in the amplification process. The enzyme is a thermostable DNA polymerase isolated from Thermus aquaticus. Because it stays active through 0 repeated elevations to high denaturation temperatures, it needs to be added only once.
Deoxynucleotide triphosphates provide the building blocks for primer extension.
The nucleic acid sequence strands are heated until they separate, in the presence of oligonucleo-tide primers that bind to their complementary strand at a particular site on the template. This process is continued with a series of heating and cooling cycles, heating to separate strands, and cooling to reanneal and extend the sequences. More and more copies of the strands are generated as the cycle is repeated. Through amplification, the coding domain and any additional primer-encoded information such as restriction sites or translation signals (signal sequences, start codons and/or stop codons) is obtained. PCR protocols are often performed at the lO0 ~L scale in 0.5 ml microcentrifuge tubes. The PCR sample may be single- or double-stranded DNA or RNA. If the starting material is RNA, reverse tran-scriptase is used to prepare first strand cDNA prior W O 94/02626 PC~r/US93/067S1 ~l395~
to PCR. Typically, nanogram amounts of clonedtemplate, up to microgram amounts of genomic DNA, or 20,000 target copies are chosen to start optimization trials.
PCR primers are oligonucleotides, typically 15 to 50 bases long, and are complementary to sequences defining the 5' ends of the complementary template strands. Non-template complementary 5' extensions may be added to primers to allow a variety of useful post amplification operations on the PCR
product without significant perturbation of the amplification itself. It is important that the two PCR primers not contain more than two bases complementary with each other, eæpecially at their 3' ends. Internal secondary structure should be avoided in primers Because Taq DNA Polymerase has activity in the 37-55C range, primer extension will occur during the annealing step and the hybrid will be stabilized. The concentrations of the primers are preferably equal in conventional PCR and, typically, are in vast excess of the template to be reproduced.
In one typical PCR protocol, each deoxy-nucleotide triphosphate concentration is preferably about 200 ~M. The four dNTP concentrations are preferably above the estimated Km of each dNTP (10-15 ~) Preferably PCR buffer is composed of about 50 mM potassium chloride, 10.0 mM Tris-HCl (pH 8.3 at room temperature), 1.5 mM magnesium chloride, and 0.001% w/v gelatin. In the presence of 0.8 mM total dNTP concentration, a titration series in small ~13~517 _ W094/02626 PCT/US93/06751 increments over the l.5-to 4-mM range will locate the magnesium concentration producing the highest yield of a specific product. Too little free magnesium will result in no PCR product and too much free magnesium may produce a variety of unwanted products.
Preferably, in a lO0-~L reaction volume, 2.0 to 2.5 units of Ia~ DNA Polymerase are recom-mended. The enzyme can be added conveniently to a fresh master mix prepared for a number of reactions, thereby avoiding accuracy problems associated with adding individual 0.5-~L enzyme aliquots to each tube. A typical PCR protocol for amplification of the DNA template includes an initial 8 minute 94C
denaturation step, followed by 30 cycles of 30 seconds at 94C (denaturation), l minute at 55C
lS (primer annealing), and 2 minutes at 72C (polymeriza-tion). At the end of the last cycle, all strands are completed by a 5 minute incubation at 72C.
During DNA denaturation, sufficient time must be allowed for thermal equilibration of the sample. The practical range of effective denaturation temperatures for most samples is 92-95C, with 94C being the standard choice.
Primer annealing is usually performed first at 55C, and the specificity of the product is evaluated. If unwanted bands are observed, the annealing temperature should be raised in subsequent optimization runs. While the primer annealing temperature range is often 37-55C, it may be raised as high as the extension temperature in some cases.
Merging of the primer annealing and primer extension steps results in a two-step PCR process.
W O 94/02626 PC~r/US93/06751 __ _ 40 -Primer extension, in most applications, occurs effectively at a temperature of 72C and seldom needs optimization. In the two-temperature PCR process the temperature range may be 65-70C. In situations where enzyme concentration limits amplification in late cycles, the extension is preferably increased linearly with cyclic number.
Usually, 25 to 45 cycles are required for extensive amplification (i.e., 1,000,000 fold) of a specific target.
Once the DNA sequence is determined, through conventional and well-known techniques, its amino acid sequence can be deduced by "translating~' the DNA
sequence. The resulting amino acid sequence having the selected principal neutralizing epitope of the envelope gene is then employed to synthesize large quantities of SPNE protein or fragment thereof.
Synthesis is performed by organic synthesis or by recombinant expression systems, or both.
Preparation of Selected Principal Neutralization Epitope A. Or anic Synthesis of SPNE:
Standard and conventional methods exist for rapid and accurate synthesis of long peptides on solid-phase supports. Solution-phase synthesis is usually feasible only for selected smaller peptides.
Synthesis on solid-phase supports, or solid-phase synthesis, is most conveniently performed on an automated peptide synthesizer according to .~ W O 94/02626 2 1 3 9 5 1 ~ PC~r/US93/06751 e.g., Kent, S. et al., "Modern Methods for the Chemical Synthesis of Biologically Active Peptides,"
in Alitalo, K. et al., (eds.). Synthetic Peptides in Biology and Medicine, Elsevier 1985, pp. 29-57.
Manual solid-phase synthesis may be employed instead, by following the classical Merrifield techniques, as described, for example, in Merrifield, R.B. J. Am.
Chem. Soc. 85, 2149 (1963), or known improvements thereof. Solid-phase peptide synthesis may also be performed by the Fmoc method, which employs very lo dilute base to remove the Fmoc protecting group.
Segment synthesis-condensation is a further variant of organic synthesis of peptides as within the scope of the techniques of the present invention.
In organic synthesis of peptides, protected amino acids are condensed to form amide or peptide bonds with the N-terminus of a growing peptide.
Condensation is usually performed with the carbo-diimide method by reagents such as dicyclohexyl-carbodiimide, or N-ethyl, Nl-(~-dimethylamino-propyl) carbodiimide. Other methods of forming theamide or peptide bond include, but are not limited to, synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Common solid-phase supports include polystyrene or polyamide 2s resins.
The selection of protecting groups of amino acid side chains is, in part, dictated by particular coupling conditions, in part by the amino acid and peptide components involved in the reaction. Such amino-protecting groups ordinarily employed include those which are well known in the art, for example, ~139517 urethane protecting substituents such as benzyloxy-carbonyl (carbobenzoxy), p-methoxycarbobenzoxy, p-nitrocarbobenzoxy, t-butyloxycarbonyl, and the like. It is preferred to utilize t-butoxycarbonyl (BOC) for protecting the E-amino group, in part because the BOC protecting group is readily removed by relatively mild acids such as trifluoroacetic acid (TFA), or hydrogen chloride in ethyl acetate.
The OH group of Thr and Ser may be protected by the Bzl (benzyl) group and the E-amino group of Lys may be protected by the isopropoxycarbonyl (IPOC) group or the 2-chlorobenzyloxycarbonyl (2-Cl-CBZ) group. Treatment with hydrogen fluoride or catalytic hydrogenation are typically employed for removal of IPOC or 2-Cl-CBZ.
For preparing cocktails of closely related peptides, see, e.g., Houghton, R.A., Proc. Natl.
Acad. Sci. USA 82, 5131 (1985).
B. Expression of SPNE in a Recombinant Expression System It is now a relatively straightforward technology to prepare cells expressing a foreign gene. Such cells act as hosts and include E. coli, B. subtilis, yeasts, fungi, plant cells or animal 2s cells. Expression vectors for many of these host cells have been isolated and characterized, and are used as starting materials in the construction, through conventional recombinant DNA techniques, of vectors having a foreign DNA insert of interest. Any DNA is foreign if it does not naturally derive from the host cells used to express the DNA insert. The 21~9517 W O 94/02626 PC~r/US93/06751 -foreign DNA insert may be expressed on extra-chromosomal plasmids or after integration in whole or in part in the host cell chromosome(s), or may actually exist in the host cell as a combination of more than one molecular form. The choice of host cell and expression vector for the expression of a desired foreign DNA largely depends on availability of the host cell and how fastidious it is, whether the host cell will support the replication of the expression vector, and other factors readily appreciated by those of ordinary skill in the art.
The technology for recombinant procaryotic expression systems is now old and conventional. The typical host cell is E. coli. The technology is illustrated by treatises such as Wu, R (ed) Meth.
Enzymol. 68 (1979) and Maniatis, T. et. al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor 1982.
The foreign DNA insert of interest comprises any DNA sequence coding for a SPNE (or fragment thereof of at least 5 amino acids in length) of the present invention, including any synthetic sequence with this coding capacity or any such cloned sequence or combination thereof. For example, SPNE peptides coded and expressed by an entirely recombinant DNA
sequence is encompassed by this invention.
Vectors useful for constructing eukaryotic expression systems for the production of recombinant SPNE comprise the DNA sequence for SPNE, fragment or variant thereof, operatively linked thereto with appropriate transcriptional activation DNA sequences, such as a promoter and/or operator. Other typical W O 94/02626 P~r/US93/06751 2 1 3 9 5 1 7 _ 44 _ features may include appropriate ribosome binding sites, termination codons, enhancers, terminators, or replicon elements. These additional features can be inserted into the vector at the appropriate site or sites by conventional splicing techniques such as restriction endonuclease digestion and ligation.
Yeast expression systems, which are one variety of recombinant eukaryotic expression systems, generally employ Saccharomyces cerevisiae as the species of choice for expressing recombinant proteins. S. cerevisiae and similar yeasts possess well known promoters useful in the construction of yeast expression systems, including but not limited to GAP491, GAL10, ADH2, and alpha mating factor.
Yeast vectors useful for constructing recombinant yeast expression systems for expressing SPNE include, but are not limited to, shuttle vectors, cosmids, chimeric plasmids, and those having sequences derived from 2-micron circle plasmids.
Insertion of the appropriate DNA sequence coding for SPNE, fragment or variant thereof, into these vectors will, in principle, result in a useful recombinant yeast expression system for SPNE where the modified vector is inserted into the appropriate host cell, by transformation or other means.
Recombinant mammalian expression systems are another means of producing the recombinant SPNE for the conjugates of this invention. In general, a host mammalian cell can be any cell that has been efficiently cloned in cell culture. Host mammalian cells useful for the purposes of constructing a recombinant r~mm~lian expression system include, but _ W O 94/02626 2 1 3 9 ~ 1 7 PC~r/US93/06751 are not limited to, Vero cells, NIH3T3, GH3, COS, murine C127 or mouse L cells. Mammalian expression vectors can be based on virus vectors, plasmid vectors which may have SV40, BPV or other viral replicons, or vectors without a replicon for animal cells. Detailed discussions on mammalian expression vectors can be found in the treatises of Glover, D.M.
(ed.) "DNA Cloning: A Practical Approach," IRL 1985, Vols. I and II.
Recombinant SPNE may possess additional and desirable structural modifications not shared with the same organically synthesized peptide, such as adenylation, carboxylation, glycosylation, hydroxylation, methylation, phosphorylation or myristoylation. These added features may be chosen or preferred as the case may be, by the appropriate choice of recombinant expression system. On the other hand, recombinant SPNE may have its sequence extended by the principles and practice of organic synthesis of section A above.
Conjugation of SPNE and OMPC to Form a Covalent Link~e(s) Yieldin~ Conjugate or Coconju~ate Antigenic conjugates of SPNE and OMPC are useful for vaccination against AIDS or ARC. Such conjugates have at least one covalent linkage between the antigen SPNE and OMPC, and typically have more than one SPNE molecule covalently bound to each OMPC
molecule .
SPNE and OMPC are prepared separately, then linked by non-specific cross-linking agents, W094/02626 ~39S~ PCT/US93/06751 monogeneric spacers or bigeneric spacers. Methods for non-specific cross-linking include, but are not limited to, reaction with glutaraldehyde; reaction with N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide, with or without admixture of a succinylated carrier;
periodate oxidation of glycosylated substituents followed by coupling to free amino groups of a protein carrier in the presence of sodium borohydride or sodium cyanoborohydride; diazotization of aromatic amino groups followed by coupling on tyrosine side chain residues of the protein; reaction with isocyanates; or reaction of mixed anhydrides. See, generally, Briand, J.P. et al. J. Imm. Meth. 78, 59 (1985). These methods of non-specifically cross-linking are conventional and well-known in the typical practice of preparing conjugates for immunological purposes.
In another embodiment of the invention, conjugates formed with a monogeneric spacer are prepared. These spacers are bifunctional and require functionalization of only one of the partners of the reaction pair to be conjugated before conjugation takes place.
By way of illustration rather than limitation, an example of a monogeneric spacer involves coupling the polypeptide SPNE to one end of the bifunctional molecule adipic acid dihydrazide in the presence of carbodiimide. A diacylated hydrazine presumably forms with pendant glutamic or aspartic carboxyl groups of SPNE. Conjugation then is performed by a second coupling reaction with carrier protein in the presence of carbodiimide. For similar _ W094/02626 2 1 3 9 5 i 7 PCT/US93/06751 procedures, see for example, Schneerson, R. et al., J. Exp. Med. 152, 361 (1980). Another example of a monogeneric spacer is described in Fujii, N. et al.
Int. J. Peptide Protein Res. 26, 121 (1985).
In another embodiment of the invention, conjugates of SPNE and OMPC are formed with a bigeneric spacer. These spacers are formed after each partner of the reaction pair to be conjugated, e.g., SPNE and OMPC, is functionalized with a bifunctional spacer. Conjugation occurs when each functionalized partner is reacted with its opposite partner to form a stable covalent bond or bonds.
See, for example, Marburg, S. et al., J. Am. Chem.
Soc. 108, 5282-5287 (1986) and Marburg, S. et al., U.S. Patent 4,695,624, issued 22 September 1987.
lS Bigeneric spacers are preferred for preparing conjugates in human vaccines since the conjugation reaction is well characterized and easily controlled.
In another embodiment of this invention, coconjugates are formed of SPNE and OMPC, comprising conjugates of SPNE and OMPC wherein OMPC is also covalently modified with a low molecular weight moiety (hereinafte-r a-) having an anionic or polyanionic character at physiological pH. The term a- is typically one to five residues of an anionic form of carboxylic, sulfonic, proprionic or phosphonic acid. Such coconjugates are suitable for raising an anti-SPNE response, since the anions enhance solubility of conjugates in aqueous solutions. Their synthesis, detailed description and other advantages are described in EPO467700 of Leanza, W.J. et al.
W094/02626 21395~11 ; PCT/US93/06751 _ Typical and conventional immunological practice provides for the ready and easy synthesis of antigenic conjugates within the scope of the present invention, including the conjugation of OMPC with virtually any desired degree of substitution of virtually any peptide of the Sequence Listing.
Heterogeneous products of the conjugation reaction are easily separable if needed by a variety of suitable column chromatography techniques.
Recombinant Fusion Polypeptides (RFPs) For ease in evaluating SPNE as immunogens, applicants have contructed recombinent shuttle vectors coding for RFPs of novel SPNE and selected peptides or fragments thereof, such as pIII (with or without a polyhistidine tail), Hep B core, Hep B
surface antigen or protein A. The methods for contruction of fusion peptides are well known in the art. Coding sequences are prepared by ligation of other sequences, cloning, PCR, mutagenesis, organic synthesis, or combination thereof, in accordance with the principles and practice of constructing DNA
sequences.
For the particular RFPs of this invention, DNA sequences coding for a selected SPNE are ligated in frame to DNA sequences coding for pIII, Hep B core or protein A. The resulting DNA fragment is expressed in any one of a wide variety of readily available recombinant expression systems, e.g. E.
coli BL21 (DE3), as also discussed in the Examples and in the section on expression of SPNE in a recombinant expression system, above.
_ ~094/02626 2 1 3 9 S 1 7 - ` PCT/US93/067~1 In the alternative, the fusion peptides can be made by synthetic organic means, although this method is limited by feasibility and by practicality to smaller fusion peptides. See also the section on organic synthesis of SPNE, above.
Vaccine Formulation The form of the immunogen within the vaccine takes various molecular configurations. A single molecular species of the antigenic conjugate (SPNE)n-OMPC will often suffice as a useful and suitable antigen for the prevention or treatment of AIDS or ARC. Other antigens in the form of cocktails are also advantageous, and consist of a mixture of conjugates that differ by, for example, the degree of substitution (n) or the amino acid sequence of SPNE
or both.
An immunological vector or adjuvant may be added as an immunological vehicle according to conventional immunological testing or practice.
The conjugates of this invention when used as a vaccine, are to be administered in immuno-logically effective amounts. Dosages of between l ~g and 500 ~g of conjugate, and preferably between 50 ~g and 300 ~g of conjugate are to be administered to a mammal to induce anti-peptide, anti-HIV, or HIV-neutralizing immune responses.
About two weeks after the initial administration, a booster dose may be administered, and then again whenever serum antibody titers diminish. The conjugate should be given intramuscularly at a concentration of between lO ~g/ml and l mg/ml, and W O 94/02626 ~39~1 P(~r/US93/06751 preferably between 50 and 500 ~g/ml, in a volume sufficient to make up the total required for immunological efficacy.
Adjuvants may or may not be added during the preparation of the vaccines of this invention. Alum is the typical and preferred adjuvant in human vaccines, especially in the form of a thixotropic, viscous, and homogeneous aluminum hydroæide gel. For example, one embodiment of the present invention is the prophylactic vaccination of patients with a suspension of alum adjuvant as vehicle and a cocktail of (SPNE)n-OMPC as the selected set of immunogens or antigens.
Other Utilitites The SPNEs and their immunological conjugates in this invention are also useful in screening blood products for the presence of HIV antigen or HIV-specific antibody. Thus, (SPNE)n~OMPC or SPNE
can be readily employed in a variety of immunological assays of the type well known to the skilled artisan, e.g., radioimmunoassay, competitive radioimmunoassay, enzyme-linked immunoassay, and the like. For an extensive discussion of these types of utilities, see, e.g. U.S. 5, 075,211.
Method for Screenin~ Phage Epitope Libraries Phage epitope libraries are unusually versatile vehicles for identifying new antigens or ligands. Typically, the phage has inserted into its genome a small, randomly generated DNA sequence, e.g.
45 base pairs, which will generate exposed oligo-peptide surfaces in the mature phage. Mixing a 21~9517 _ W094/02626 PCT/US93/06751 library of such mature phage with a screening antibody of desired specificity, followed by separation of bound from unbound phage, allows the opportunity to clone and sequence the bound phage. A
conventional example of a phage epitope library is the filamentous phage fd and its gene III coding for minor coat protein pIII. See, e.g., Parmley, S. F.
et al. Gene 73, 305 (1988) and Scott, J. K. et al.
Science 249, 386 (1990), which set forth extensive discussion and detail on construction of these libraries.
Applicants have developed a new method for screening phage epitope libraries. The screening method involves selection of epitopes by binding to a solid-phase supported antibody, optionally followed by identification of desired clones with antibody lifts. The screening method is useful for virtually any antibody, i.e. polyclonal or monoclonal or collection of monoclonals thereto. Any antigen can be screened. The screening method is illustrated by HIV antigens screened with an HIV-specific broadly neutralizing antibody (hereinafter 447 antibody).
The present screening method avoids the typical prior art problem of biotin-avidin complexes. Although, biotin-avidin complex formation has an unusually high binding constant, it produces false positives, is time-consuming, and requires tampering with the antibody by covalent conjugation.
Applicants avoid all of these problems by adsorbing the antibody onto a solid-phase support. With a particular series of mixing and washing steps, applicants demonstrate a practical method of screening phage libraries.
W094/02626 ; PCT/US93/06751 _ 2.13951~
Screening in the present invention is broken down into two separate methods. The first method involves selection of desired phage epitopes with a solid-phase supported antibody of any desired specificity. The second method, which is optional, relates to identification of desired phage epitopes by antibody lifts.
A. Selection Selection of desired phage epitopes in a phage epitope library is performed as follows. An essentially pure preparation of monospecific antibody is adsorbed or otherwise attached to a solid-phase support, hereinafter also referred to as solid-phase supported Ab. The most preferred embodiment is monoclonal antibody adsorbed to polystyrene beads large enough to be picked up with tweezers, e.g., with a diameter of 0.25 inch. Such large beads contribute to the ease of subsequent washing steps.
Other embodiments include any solid-phase adsorbent for antibody, or any plastic, or glass bead or polysaccharide gel, e.g. Sepharose. Polysaccharide gels are typically covalently conjugated to the purified antibody by, e.g., cyanogen bromide activation.
Incubation of the solid-phase supported Ab with BSA, milk solids or other reagent for blocking non-specific interactions iæ preferable before selection. The presence of low levels of a mild or nonionic detergent is desirable, e.g., 0.5%(v/v) of ~094/02626 2~9 5.1~ PCT/US93/06751 , one or more in the polyoxyethylene (20) sorbitan monoleate series (TWEEN), or octylglucopyranoside or Nonidet NP-40. It is apparent to the skilled how to adjust the conditions for coating with such blocking agents.
An appropriate density of antibody should be determined by titration. Applicants have successfully performed selection with a density of about 0.1 ~g447/cm on polystyrene beads (d = 0.25 inch). This falls within a preferred density range lo of between about l~g Ab/cm2 and about lng Ab/cm . Densities in the lower range select high affinity epitopes because of the reduced incidence of multivalent binding by the antibody to the multiple copies of the epitope on the phage tip. It is apparent to the skilled artisan how to determine the most suitable density for an antibody preparation, by monitoring the bound phage population. As a general rule, a manageable complexity of bound and eluted phage ranges from about 5x103 to about 105 phage.
Throughout the selection method described below, a wide variation in incubation times, washing times, temperature and pH is covered. It is apparent to the skilled artisan that, given a particular incubation or washing step, a suitable set of variant reaction conditions can be readily ascertained.
Applicants have discovered that temperature and pH
are critical in the stringent selection of high affinity epitopes, e.g., temperatures exceeding about 70OC at neutral pH, or exceeding about 38C at pH
W O 94/02626 ~ 1 3 9 5 1 7 - PC~r/US93/06751 _
Gly Gly Tyr His Trp Gly Pro Gly Arg Gly Ser Val Glu Ala SEQ ID NO:66:
Gln Ala Trp His Phe Gly Pro Gly Arg Asp His Gly Glu SEQ ID NO:67:
Lys Ala Asn His Tyr Gly Pro Ser Arg Gly Pro Gly Ser Arg SEQ ID NO:68:
Leu Leu Gly Pro Gly Arg Gly Ser Ser Ser Val Arg Gly Glu Leu SEQ ID N0:69:
Ser Gly Trp Trp Gly Gly Val His Val Gly Pro Gly Arg Gly Thr 1 5 lû 15 SEQ ID N0:70:
Trp Ser Lys Arg Glu Ser Val Met Phe Gly Pro Gly Arg Gly Thr W094/02626 2 1 3q5 ~ PCI/US93/06751 _ 18 --SEQ ID NO:71:
Trp Asp Ser Arg Ala Thr Leu Arg Leu Gly Pro Gly Arg Ser Ser SEQ ID NO:72:
Gly Lys Val Phe Tyr Gly Pro Gly Arg Glu Trp His Ala lû
1'0 SEQ ID NO:73:
Ala Arg Val Phe Leu Gly Pro Gly Arg Gly Val Val Tyr Asp lû
SEQ ID NO:74:
Arg Val Gln Lys Leu Gly Pro Gly Arg Gln Thr Ala Ser Gly SEQ ID NO:75:
Lys Leu Gl y Pro Gl y Arg Gl y Gl y Tyr Phe Gl y Al a Gl n Val SEQ ID NO:76:
Arg Lys Val Asn Ile Gly Pro Gly Arg Val His Gly Asn Ser 213g517 _ WO 94/02626 PCI/US93/06751 SEQ ID N0:77:
Arg Gly Val Lys Ile Gly Pro Gly Arg Ile Ala Ser Gly Tyr SEQ ID N0:78:
Lys Asp Leu His Ile Gly Pro Gly Arg Met Asp Gly Leu Arg SEQ ID N0:79:
Ala Gln Arg Ser His Leu ~le Gly Pro Gly Arg Ala Glu Thr Gly 1 5 lû 15 SEQ ID N0:81:
Arg Gln Val Met Leu Gly Pro Gly Arg Gly Asp Arg Leu Glu SEQ ID N0:83:
Lys Phe Val Glu Leu Gly Pro Gly Arg Lys Gly Gl n Gl y SEQ ID N0:84:
Asp Arg Gly Ser Arg Phe Val Leu Leu Gly Pro Gly Arg Met Gly 1 5 10 lS
W O 94/02626 2 1 3 9 ~ I ~ PC~r/US93/06751 _ 20 -SEQ ID NO:85:
Glu Gln Leu His Arg Leu Val Ala Phe Gly Pro Gly Arg Ala Ala SEQ ID NO:86:
Leu Pro Ser Val Asn Leu Gly Pro Gly Arg Asn Ala Arg Lys Gly 5 lO l5 SEQ ID NO:9û:
Arg Glu Leu His Met Gly Pro Gly Arg Ala Arg Pro Gly Phe SEQ ID NO:91:
Cys Arg Val Asp Phe Gly Pro Gly Arg Leu Gly Ser Arg Thr SEQ ID NO:92:
Asn Val Val Ala Ile Gly Pro Gly Arg Ser Asn Val Val Thr SEQ ID NO:93:
Lys Glu Val His Phe Gly Pro Gly Arg Gly Gly Gln Arg Ser _ ~0 94/02626 2 1 3 9 ~ 1 7 PCI`/US93/067~1 SEQ ID N0:94:
Xaa Xaa Tyr Leu Ile Gly Pro Gly Arg Gly Trp Glu Arg Glu l 5 lO
SEQ ID NO:95:
Ala Gl y Cys Gl n Val Gl y Pro Gl y Arg Pro Xaa Cys Gly Lys l 5 lO
SEQ ID NO:97:
Ile Gly Arg Asn Leu Gly Pro Gly Arg Val Val Ser Asn Val l 5 lO
SEQ ID NO:98:
Lys Asn Val His Val Gl y Pro Gl y Arg Gl y Gl n Arg Thr Val l 5 lO
SEQ ID N0: lOû:
Ser Lys Val Glu Ile Gly Pro Gly Arg Gly Pro Leu Met Arg l 5 lO
SEQ ID N0: 102:
Gly Arg Ile Asn Tyr Gly Pro Gly Ala Pro Gly Leu Met l 5 lO
W O 94/02626 2139S 17 PC~r/US93/06751 __ _ ZZ _ SEQ ID N0: 103:
Glu Val His Tyr Tyr Gly Pro Gly Arg Arg Ala Pro Ala Ser SEQ ID N0: lû4:
Val Gl u Arg Hi s Leu Gl y Pro Gl y Arg Gl y Leu Gl n Met Gl y 1'0 SEQ ID NO: lOS:
Asn Ser Phe His Leu Gly Pro Gly Arg Ser Arg Thr Tyr Ser SEQ ID N0: 106:
Gly Val Val Lys Leu Gly Pro Gly Arg Thr Ala Gly Lys Leu SEQ ID N0: lû7:
Leu Ile 61y Pro Gly Arg Ser Ser Val Ala Met Thr Ile Arg Glu SEQ ID N0: 108:
Leu Val Arg Met Leu Gly Pro Gly Arg Gly Asn Asp Arg Thr His ~0 94/02626 2 1395 ~7 PC~r/US93/06751 SEQ ID NO :109:
Gln Arg Gly Lys Thr Phe Tyr Gly Pro Gly Arg Gly Ser Gly Gln SEQ ID NO:llO:
Asp Arg Gly Lys Ile Val Tyr Gly Pro Gly Arg Thr Gln Ser SEQ ID NO:112:
Gly Phe Ser Ser Ser Arg Val Leu Val Gly Pro Gly Arg Gly Val SEQ ID NO:113:
Val Lys Arg Arg Asp Ala Val His Ala Gly Pro Gly SEQ ID NO: 114:
Asp Ser Glu Arg Val Gly Val Leu Leu Gly Pro Gly Arg Gly Val SEQ ID NO: 115:
Asp Leu Gly Arg Pro Ala Val Arg Phe Gly Pro Gly Arg Ile Ile WO 94/02626 ~, \3q5 ~ ~ ` PCI'/US93/06751 -- 24 _ SEQ ID NO:116:
Leu Ser Arg Phe Arg Glu Trp His Val Gly Pro Gly Arg Val Pro 1 5 lo 15 SEQ ID NO:118:
Ile Gly Val Thr Arg Ala Leu Phe Phe Gly Pro Gly Arg Gly Thr 1 5 lo 15 SEQ ID NO: 119:
Ser Leu Ser Arg Ala His Val His Arg Gly Pro Gly Arg Val Ser 1 5 lo 15 SEQ ID NO:12û:
Leu Val Tyr Arg Ala Ala His Tyr Gly Pro Gly Arg Gly Val 1 5 lo SEQ ID NO: 121:
Arg Gly Trp Arg Pro Val Leu Ala Val Gly Pro Gly Arg Trp Glu 1 5 lo 15 ` _ WO 94/02626 PCI`/US93/06751 _ 25 -SEQ ID NO:134:
Cys Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly 1 5 lû 15 Cys SEQ ID NO:135:
Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly SEQ ID NO:136:
Asp Gly Ser Arg Arg Ala Val His Leu Gly Pro Gly Arg Gly Val SEQ ID NO:137:
Leu Leu Lys Glu Val His Phe Gly Pro Gly Arg Gly Arg Gly Gly Arg Leu Leu W O 94/02626 2 1 3 9 5 1 7 PC~r/US93/06751 __ SEQ ID N0:138:
Cys Arg Gly Val His Leu Gly Pro Gly Arg Gly Ala Arg Met Ser lû 15 Cys SEQ ID N0:139:
Cys Asp Arg Gly Ser Val Leu Ile Gly Pro Gly Arg Gly Ser Ser Xaa Gl y Cys SEQ ID N0:140:
Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser SEQ ID N0:141:
Cys Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser Cys _ WO 94/02626 2 1 3 9 ~ 1 7 PCI`/US93/06751 SEQ ID NO:142:
Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu Gly Leu Ser SEQ ID NO:143:
1'0 Cys Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu 1 5 lû 15 Gly Leu Ser Cys SEQ ID NO:144:
Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser SEQ ID NO:145:
Cys Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser Cys 21395~7 WO 94/02626 PCI`/US93/06751 _ SEQ ID NO:l:
Pro Arg Leu Glu Thr His Phe Gly Pro Lys Arg Ser His Val Gly 1 5 lû 15 SEQ ID NO:4:
Val Leu Val Trp Gln Arg Lys Val Phe Phe Gly Pro His Arg Ser SEQ ID NO:5:
Arg Ser Ser Ser Trp Ala Trp Arg His Leu Tyr Gly Pro Ala Arg 1 5 lû 15 SEQ ID NO:7:
Trp Asp Arg Gly Asn Ser Ser Gly Arg His Leu Gly Pro Ala Arg SEQ ID NO:9:
Thr Trp His Leu Arg Val Arg Gly Ala His Phe Gly Pro Ala Arg SEQ ID NO:10:
Trp Leu Arg Val Leu Leu Gly Pro Ala Arg Pro Ile Tyr Trp Arg _ WO 94/02626 21 3 9 ~17 PCI/US93/06751 _ 29 --SEQ ID NO:ll:
Leu Leu Leu Gly Pro Ala Arg Ala Pro Val Arg Val Asn Leu Ala l 5 10 15 SEQ ID N0: 12:
Cys Lys Pro Arg Ala Pro Met Leu Phe Gly Pro Ala Arg Gly Leu SEQ ID N0:14:
Val Phe Lys Val Ile Asn Arg Ile Leu His Tyr Gly Pro Asn Arg l 5 10 15 SEQ ID N0:16:
Asp Val Gly Trp Val Thr Gly Thr Gln H;s Tyr Gly Pro Arg Arg SEQ ID N0:17:
Gly Leu Tyr Thr Cys Met Tyr Gly Pro Ser Arg His Ile Cys Val l 5 10 15 SEQ ID N0: 20:
Thr Glu Leu Gly Arg Gly Tyr Ile Ser His Gly Pro Ala Arg Gly l 5 10 15 WO 94/02626 ~395 PCr/US93/06751 _ .
SEQ ID NO:22:
His Leu Gly Pro Ser Arg Gly Ala Asn Leu Gly Lys Ile Gly Ala SEQ ID NO:24:
Leu His Val Gly Pro Asn Arg Gly Lys Ser Glu Asp Asn Tyr Arg SEQ ID NO:27:
Phe Tyr Thr Ser Gly Lys Thr Ile Phe Tyr Tyr Gly Pro Arg Arg SEQ ID NO: 29:
Ala Cys Trp Ser Arg Glu Tyr Gly Pro Ala Arg Met Ser Cys Thr SEQ ID NO:37:
Trp Ser Trp Val Arg Leu Lys Ala Val Leu Leu Gly Pro Ser Arg SEQ ID NO:42:
Val Leu Arg Cys Phe Gly Pro Leu Arg Asp Ala Arg Cys Ser Val _ WO 94/02626 2 1 3 9 5 1 7 PCI/US93/06751 SEQ ID NO:44:
Leu Met Val Val Gln Val Gly Pro Ala Arg Thr Phe Leu Gln Gly SEQ ID NO:45:
Gl y Pro Ser Leu Phe Asn Ser Gl y Val Arg Tyr Gl y Pro Lys Arg 1'0 SEQ ID NO:46:
Val His Phe Ile Gly Pro Gln Arg Gly Gly Asn Ser Ser His Leu SEQ ID NO:53:
Met Glu Arg Asp Leu Val Arg Phe Gly Pro Asn Arg Asp Trp Arg SEQ ID NO:54:
Asn Gly Leu Lys Leu Cys Arg Val Gly Pro Ser Arg Glu Gly Cys SEQ ID NO:56:
Pro Val Lys Phe Gly Pro Gln Arg Ser Gly Gly Ala Thr Arg Pro WO 94/02626 2 1 3 9 ~ 1~ ; PCI`/US93/06751 _ SEQ ID N0:57:
Ile Thr Pro Arg Leu Tyr Gly Pro Ser Arg Met Arg Tyr Asn Gln SEQ ID N0:59:
Asn Lys Arg Glu Phe Gly Pro Ala Arg Ala Ala Arg Asn Arg SEQ ID N0:6û:
His Arg Arg Asp Ile Gly Pro Ala Arg Thr Arg Glu Ile Gly SEQ ID N0:62:
Ser Ala Val His Leu Gly Pro Gln Arg Gln Arg Ala Thr Asp 1 5 lo SEQ ID N0:80:
Lys Gln Val Arg Leu Gly Pro Ala Arg Gly Asp Ile Ile Gly 2S 1 5 lo SEQ ID N0:8Z:
Arg Ser Val Leu Met Gly Pro Ala Arg Ser Thr Arg Val Val 1 5 lû
~_ W O 94/02626 2 ~ 3 9 5 1 7 PC~r/US93/06751 SEQ ID NO:87:
Gln His Arg Ala Ala Ser Val His Leu Gly Pro Ser Arg Ala Gly SEQ ID NO:88:
Leu Met Phe Val Arg Val Val Lys Leu Gly Pro Ala Arg Val Pro SEQ ID NO: 89:
Tyr Gly Leu Val Ile Arg Cys Glu Val Gly Pro Ser Arg Ser Cys 5 lû 15 SEQ ID NO:96:
Arg Glu Val His Phe Gly Pro Arg Arg Asp Glu Pro Gly Arg SEQ ID NO: 99:
Arg Leu His Leu Val Gly Pro Ala Arg Val Ser Pro Leu Ser SEQ ID NO: 101:
Ala Val Ile His Val Gly Pro Ser Arg Leu Lys Ser Gln Tyr WO 94/02626 ~ ~39S~ PCI/US93/06751 -- 34 _ SEQ ID N0:111:
Asp Trp Arg Ser Val His Ile Gly Pro Ala Arg Arg Glu Val Leu lû 15 SEQ ID N0:117:
Ala Ala Leu Arg Lys Val Arg Xaa Tyr Gly Pro Ala Arg Gln Ser ~139517 _ W O 94/02626 PC~r/US93/06751 The new SPNE amino acid sequences of this invention include any fragment thereof in the sequence listing, provided said fragment is at least five amino acids in length, and includes the GPXR
(SEQ. ID N0:123) loop region or homolog.
Each SPNE amino acid sequence can be determined by DNA sequencing of phage clones amplified by the polymerase chain reaction.
The present invention also provides an effective immunogen against AIDS or ARC, and comprises an antigenic conjugate of the formula (SPNE)n~(OMPC) I, wherein:
SPNE is the selected principal neutralization epitope of ~IV, which is a polypeptide of one or more amino acid sequences, each sequence having any of sequences of Table A, or fragments thereof, said fragment having at least 5 amino acids in length and including the GPXR loop region or homolog thereof;
n = 1-50, wherein n is the number of polypeptides of SPNE covalently linked to OMPC;
~ indicates covalent linkage;
OMPC is outer membrane proteosome of the micro-organism Neisseria, said conjugate optionally substituted with an anion or polyanion to render it soluble such as polyproprioniC acid, or substituted with a- which is an anion or polyanion at physiological p~, said a- consisting of one to five residues of W094/02626 2 l395 ll` .; PCT/US93/06751 ~
anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid, or pharmaceutically acceptable salts.
Each conjugate molecule of formula I may have different peptides conjugated thereto, or, alternatively, multiples of a single peptide species conjugated thereto, or a combination.
The antigenic conjugates of this invention are prepared by isolating, synthesizing and purifying their component parts SPNE and OMPC, then conjugating SPNE and OMPC together. Subsequent purification of conjugate mixtures may be performed as desired.
Applicants also have developed a method for identifying new SPNE by the screening of phage libraries bearing randomly or semi randomly generated oligopeptide epitopes. The library is screened with any antibody, and is specifically illustrated by screening with a broadly neutralizing monoclonal antibody.
Polymerase Chain Reaction Amplification Large amounts of DNA coding for SPNE protein may be obtained using polymerase chain reaction (PCR) amplification techniques as described in Mullins et al., U.S. Patent No. 4,800,159 and other published sources. See also, for example, Innis, M.A. et al.
PCR Protocols Academic Press 1990. The extension product of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule.
The primer template complexes act as substrate for DNA polymerase which, in performing its replication function, extends the primers. The region in common with both primer extensions, upon denaturation, serves as template for a repeated primer extension.
Taq DNA Polymerase catalyzes primer extension in the amplification process. The enzyme is a thermostable DNA polymerase isolated from Thermus aquaticus. Because it stays active through 0 repeated elevations to high denaturation temperatures, it needs to be added only once.
Deoxynucleotide triphosphates provide the building blocks for primer extension.
The nucleic acid sequence strands are heated until they separate, in the presence of oligonucleo-tide primers that bind to their complementary strand at a particular site on the template. This process is continued with a series of heating and cooling cycles, heating to separate strands, and cooling to reanneal and extend the sequences. More and more copies of the strands are generated as the cycle is repeated. Through amplification, the coding domain and any additional primer-encoded information such as restriction sites or translation signals (signal sequences, start codons and/or stop codons) is obtained. PCR protocols are often performed at the lO0 ~L scale in 0.5 ml microcentrifuge tubes. The PCR sample may be single- or double-stranded DNA or RNA. If the starting material is RNA, reverse tran-scriptase is used to prepare first strand cDNA prior W O 94/02626 PC~r/US93/067S1 ~l395~
to PCR. Typically, nanogram amounts of clonedtemplate, up to microgram amounts of genomic DNA, or 20,000 target copies are chosen to start optimization trials.
PCR primers are oligonucleotides, typically 15 to 50 bases long, and are complementary to sequences defining the 5' ends of the complementary template strands. Non-template complementary 5' extensions may be added to primers to allow a variety of useful post amplification operations on the PCR
product without significant perturbation of the amplification itself. It is important that the two PCR primers not contain more than two bases complementary with each other, eæpecially at their 3' ends. Internal secondary structure should be avoided in primers Because Taq DNA Polymerase has activity in the 37-55C range, primer extension will occur during the annealing step and the hybrid will be stabilized. The concentrations of the primers are preferably equal in conventional PCR and, typically, are in vast excess of the template to be reproduced.
In one typical PCR protocol, each deoxy-nucleotide triphosphate concentration is preferably about 200 ~M. The four dNTP concentrations are preferably above the estimated Km of each dNTP (10-15 ~) Preferably PCR buffer is composed of about 50 mM potassium chloride, 10.0 mM Tris-HCl (pH 8.3 at room temperature), 1.5 mM magnesium chloride, and 0.001% w/v gelatin. In the presence of 0.8 mM total dNTP concentration, a titration series in small ~13~517 _ W094/02626 PCT/US93/06751 increments over the l.5-to 4-mM range will locate the magnesium concentration producing the highest yield of a specific product. Too little free magnesium will result in no PCR product and too much free magnesium may produce a variety of unwanted products.
Preferably, in a lO0-~L reaction volume, 2.0 to 2.5 units of Ia~ DNA Polymerase are recom-mended. The enzyme can be added conveniently to a fresh master mix prepared for a number of reactions, thereby avoiding accuracy problems associated with adding individual 0.5-~L enzyme aliquots to each tube. A typical PCR protocol for amplification of the DNA template includes an initial 8 minute 94C
denaturation step, followed by 30 cycles of 30 seconds at 94C (denaturation), l minute at 55C
lS (primer annealing), and 2 minutes at 72C (polymeriza-tion). At the end of the last cycle, all strands are completed by a 5 minute incubation at 72C.
During DNA denaturation, sufficient time must be allowed for thermal equilibration of the sample. The practical range of effective denaturation temperatures for most samples is 92-95C, with 94C being the standard choice.
Primer annealing is usually performed first at 55C, and the specificity of the product is evaluated. If unwanted bands are observed, the annealing temperature should be raised in subsequent optimization runs. While the primer annealing temperature range is often 37-55C, it may be raised as high as the extension temperature in some cases.
Merging of the primer annealing and primer extension steps results in a two-step PCR process.
W O 94/02626 PC~r/US93/06751 __ _ 40 -Primer extension, in most applications, occurs effectively at a temperature of 72C and seldom needs optimization. In the two-temperature PCR process the temperature range may be 65-70C. In situations where enzyme concentration limits amplification in late cycles, the extension is preferably increased linearly with cyclic number.
Usually, 25 to 45 cycles are required for extensive amplification (i.e., 1,000,000 fold) of a specific target.
Once the DNA sequence is determined, through conventional and well-known techniques, its amino acid sequence can be deduced by "translating~' the DNA
sequence. The resulting amino acid sequence having the selected principal neutralizing epitope of the envelope gene is then employed to synthesize large quantities of SPNE protein or fragment thereof.
Synthesis is performed by organic synthesis or by recombinant expression systems, or both.
Preparation of Selected Principal Neutralization Epitope A. Or anic Synthesis of SPNE:
Standard and conventional methods exist for rapid and accurate synthesis of long peptides on solid-phase supports. Solution-phase synthesis is usually feasible only for selected smaller peptides.
Synthesis on solid-phase supports, or solid-phase synthesis, is most conveniently performed on an automated peptide synthesizer according to .~ W O 94/02626 2 1 3 9 5 1 ~ PC~r/US93/06751 e.g., Kent, S. et al., "Modern Methods for the Chemical Synthesis of Biologically Active Peptides,"
in Alitalo, K. et al., (eds.). Synthetic Peptides in Biology and Medicine, Elsevier 1985, pp. 29-57.
Manual solid-phase synthesis may be employed instead, by following the classical Merrifield techniques, as described, for example, in Merrifield, R.B. J. Am.
Chem. Soc. 85, 2149 (1963), or known improvements thereof. Solid-phase peptide synthesis may also be performed by the Fmoc method, which employs very lo dilute base to remove the Fmoc protecting group.
Segment synthesis-condensation is a further variant of organic synthesis of peptides as within the scope of the techniques of the present invention.
In organic synthesis of peptides, protected amino acids are condensed to form amide or peptide bonds with the N-terminus of a growing peptide.
Condensation is usually performed with the carbo-diimide method by reagents such as dicyclohexyl-carbodiimide, or N-ethyl, Nl-(~-dimethylamino-propyl) carbodiimide. Other methods of forming theamide or peptide bond include, but are not limited to, synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Common solid-phase supports include polystyrene or polyamide 2s resins.
The selection of protecting groups of amino acid side chains is, in part, dictated by particular coupling conditions, in part by the amino acid and peptide components involved in the reaction. Such amino-protecting groups ordinarily employed include those which are well known in the art, for example, ~139517 urethane protecting substituents such as benzyloxy-carbonyl (carbobenzoxy), p-methoxycarbobenzoxy, p-nitrocarbobenzoxy, t-butyloxycarbonyl, and the like. It is preferred to utilize t-butoxycarbonyl (BOC) for protecting the E-amino group, in part because the BOC protecting group is readily removed by relatively mild acids such as trifluoroacetic acid (TFA), or hydrogen chloride in ethyl acetate.
The OH group of Thr and Ser may be protected by the Bzl (benzyl) group and the E-amino group of Lys may be protected by the isopropoxycarbonyl (IPOC) group or the 2-chlorobenzyloxycarbonyl (2-Cl-CBZ) group. Treatment with hydrogen fluoride or catalytic hydrogenation are typically employed for removal of IPOC or 2-Cl-CBZ.
For preparing cocktails of closely related peptides, see, e.g., Houghton, R.A., Proc. Natl.
Acad. Sci. USA 82, 5131 (1985).
B. Expression of SPNE in a Recombinant Expression System It is now a relatively straightforward technology to prepare cells expressing a foreign gene. Such cells act as hosts and include E. coli, B. subtilis, yeasts, fungi, plant cells or animal 2s cells. Expression vectors for many of these host cells have been isolated and characterized, and are used as starting materials in the construction, through conventional recombinant DNA techniques, of vectors having a foreign DNA insert of interest. Any DNA is foreign if it does not naturally derive from the host cells used to express the DNA insert. The 21~9517 W O 94/02626 PC~r/US93/06751 -foreign DNA insert may be expressed on extra-chromosomal plasmids or after integration in whole or in part in the host cell chromosome(s), or may actually exist in the host cell as a combination of more than one molecular form. The choice of host cell and expression vector for the expression of a desired foreign DNA largely depends on availability of the host cell and how fastidious it is, whether the host cell will support the replication of the expression vector, and other factors readily appreciated by those of ordinary skill in the art.
The technology for recombinant procaryotic expression systems is now old and conventional. The typical host cell is E. coli. The technology is illustrated by treatises such as Wu, R (ed) Meth.
Enzymol. 68 (1979) and Maniatis, T. et. al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor 1982.
The foreign DNA insert of interest comprises any DNA sequence coding for a SPNE (or fragment thereof of at least 5 amino acids in length) of the present invention, including any synthetic sequence with this coding capacity or any such cloned sequence or combination thereof. For example, SPNE peptides coded and expressed by an entirely recombinant DNA
sequence is encompassed by this invention.
Vectors useful for constructing eukaryotic expression systems for the production of recombinant SPNE comprise the DNA sequence for SPNE, fragment or variant thereof, operatively linked thereto with appropriate transcriptional activation DNA sequences, such as a promoter and/or operator. Other typical W O 94/02626 P~r/US93/06751 2 1 3 9 5 1 7 _ 44 _ features may include appropriate ribosome binding sites, termination codons, enhancers, terminators, or replicon elements. These additional features can be inserted into the vector at the appropriate site or sites by conventional splicing techniques such as restriction endonuclease digestion and ligation.
Yeast expression systems, which are one variety of recombinant eukaryotic expression systems, generally employ Saccharomyces cerevisiae as the species of choice for expressing recombinant proteins. S. cerevisiae and similar yeasts possess well known promoters useful in the construction of yeast expression systems, including but not limited to GAP491, GAL10, ADH2, and alpha mating factor.
Yeast vectors useful for constructing recombinant yeast expression systems for expressing SPNE include, but are not limited to, shuttle vectors, cosmids, chimeric plasmids, and those having sequences derived from 2-micron circle plasmids.
Insertion of the appropriate DNA sequence coding for SPNE, fragment or variant thereof, into these vectors will, in principle, result in a useful recombinant yeast expression system for SPNE where the modified vector is inserted into the appropriate host cell, by transformation or other means.
Recombinant mammalian expression systems are another means of producing the recombinant SPNE for the conjugates of this invention. In general, a host mammalian cell can be any cell that has been efficiently cloned in cell culture. Host mammalian cells useful for the purposes of constructing a recombinant r~mm~lian expression system include, but _ W O 94/02626 2 1 3 9 ~ 1 7 PC~r/US93/06751 are not limited to, Vero cells, NIH3T3, GH3, COS, murine C127 or mouse L cells. Mammalian expression vectors can be based on virus vectors, plasmid vectors which may have SV40, BPV or other viral replicons, or vectors without a replicon for animal cells. Detailed discussions on mammalian expression vectors can be found in the treatises of Glover, D.M.
(ed.) "DNA Cloning: A Practical Approach," IRL 1985, Vols. I and II.
Recombinant SPNE may possess additional and desirable structural modifications not shared with the same organically synthesized peptide, such as adenylation, carboxylation, glycosylation, hydroxylation, methylation, phosphorylation or myristoylation. These added features may be chosen or preferred as the case may be, by the appropriate choice of recombinant expression system. On the other hand, recombinant SPNE may have its sequence extended by the principles and practice of organic synthesis of section A above.
Conjugation of SPNE and OMPC to Form a Covalent Link~e(s) Yieldin~ Conjugate or Coconju~ate Antigenic conjugates of SPNE and OMPC are useful for vaccination against AIDS or ARC. Such conjugates have at least one covalent linkage between the antigen SPNE and OMPC, and typically have more than one SPNE molecule covalently bound to each OMPC
molecule .
SPNE and OMPC are prepared separately, then linked by non-specific cross-linking agents, W094/02626 ~39S~ PCT/US93/06751 monogeneric spacers or bigeneric spacers. Methods for non-specific cross-linking include, but are not limited to, reaction with glutaraldehyde; reaction with N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide, with or without admixture of a succinylated carrier;
periodate oxidation of glycosylated substituents followed by coupling to free amino groups of a protein carrier in the presence of sodium borohydride or sodium cyanoborohydride; diazotization of aromatic amino groups followed by coupling on tyrosine side chain residues of the protein; reaction with isocyanates; or reaction of mixed anhydrides. See, generally, Briand, J.P. et al. J. Imm. Meth. 78, 59 (1985). These methods of non-specifically cross-linking are conventional and well-known in the typical practice of preparing conjugates for immunological purposes.
In another embodiment of the invention, conjugates formed with a monogeneric spacer are prepared. These spacers are bifunctional and require functionalization of only one of the partners of the reaction pair to be conjugated before conjugation takes place.
By way of illustration rather than limitation, an example of a monogeneric spacer involves coupling the polypeptide SPNE to one end of the bifunctional molecule adipic acid dihydrazide in the presence of carbodiimide. A diacylated hydrazine presumably forms with pendant glutamic or aspartic carboxyl groups of SPNE. Conjugation then is performed by a second coupling reaction with carrier protein in the presence of carbodiimide. For similar _ W094/02626 2 1 3 9 5 i 7 PCT/US93/06751 procedures, see for example, Schneerson, R. et al., J. Exp. Med. 152, 361 (1980). Another example of a monogeneric spacer is described in Fujii, N. et al.
Int. J. Peptide Protein Res. 26, 121 (1985).
In another embodiment of the invention, conjugates of SPNE and OMPC are formed with a bigeneric spacer. These spacers are formed after each partner of the reaction pair to be conjugated, e.g., SPNE and OMPC, is functionalized with a bifunctional spacer. Conjugation occurs when each functionalized partner is reacted with its opposite partner to form a stable covalent bond or bonds.
See, for example, Marburg, S. et al., J. Am. Chem.
Soc. 108, 5282-5287 (1986) and Marburg, S. et al., U.S. Patent 4,695,624, issued 22 September 1987.
lS Bigeneric spacers are preferred for preparing conjugates in human vaccines since the conjugation reaction is well characterized and easily controlled.
In another embodiment of this invention, coconjugates are formed of SPNE and OMPC, comprising conjugates of SPNE and OMPC wherein OMPC is also covalently modified with a low molecular weight moiety (hereinafte-r a-) having an anionic or polyanionic character at physiological pH. The term a- is typically one to five residues of an anionic form of carboxylic, sulfonic, proprionic or phosphonic acid. Such coconjugates are suitable for raising an anti-SPNE response, since the anions enhance solubility of conjugates in aqueous solutions. Their synthesis, detailed description and other advantages are described in EPO467700 of Leanza, W.J. et al.
W094/02626 21395~11 ; PCT/US93/06751 _ Typical and conventional immunological practice provides for the ready and easy synthesis of antigenic conjugates within the scope of the present invention, including the conjugation of OMPC with virtually any desired degree of substitution of virtually any peptide of the Sequence Listing.
Heterogeneous products of the conjugation reaction are easily separable if needed by a variety of suitable column chromatography techniques.
Recombinant Fusion Polypeptides (RFPs) For ease in evaluating SPNE as immunogens, applicants have contructed recombinent shuttle vectors coding for RFPs of novel SPNE and selected peptides or fragments thereof, such as pIII (with or without a polyhistidine tail), Hep B core, Hep B
surface antigen or protein A. The methods for contruction of fusion peptides are well known in the art. Coding sequences are prepared by ligation of other sequences, cloning, PCR, mutagenesis, organic synthesis, or combination thereof, in accordance with the principles and practice of constructing DNA
sequences.
For the particular RFPs of this invention, DNA sequences coding for a selected SPNE are ligated in frame to DNA sequences coding for pIII, Hep B core or protein A. The resulting DNA fragment is expressed in any one of a wide variety of readily available recombinant expression systems, e.g. E.
coli BL21 (DE3), as also discussed in the Examples and in the section on expression of SPNE in a recombinant expression system, above.
_ ~094/02626 2 1 3 9 S 1 7 - ` PCT/US93/067~1 In the alternative, the fusion peptides can be made by synthetic organic means, although this method is limited by feasibility and by practicality to smaller fusion peptides. See also the section on organic synthesis of SPNE, above.
Vaccine Formulation The form of the immunogen within the vaccine takes various molecular configurations. A single molecular species of the antigenic conjugate (SPNE)n-OMPC will often suffice as a useful and suitable antigen for the prevention or treatment of AIDS or ARC. Other antigens in the form of cocktails are also advantageous, and consist of a mixture of conjugates that differ by, for example, the degree of substitution (n) or the amino acid sequence of SPNE
or both.
An immunological vector or adjuvant may be added as an immunological vehicle according to conventional immunological testing or practice.
The conjugates of this invention when used as a vaccine, are to be administered in immuno-logically effective amounts. Dosages of between l ~g and 500 ~g of conjugate, and preferably between 50 ~g and 300 ~g of conjugate are to be administered to a mammal to induce anti-peptide, anti-HIV, or HIV-neutralizing immune responses.
About two weeks after the initial administration, a booster dose may be administered, and then again whenever serum antibody titers diminish. The conjugate should be given intramuscularly at a concentration of between lO ~g/ml and l mg/ml, and W O 94/02626 ~39~1 P(~r/US93/06751 preferably between 50 and 500 ~g/ml, in a volume sufficient to make up the total required for immunological efficacy.
Adjuvants may or may not be added during the preparation of the vaccines of this invention. Alum is the typical and preferred adjuvant in human vaccines, especially in the form of a thixotropic, viscous, and homogeneous aluminum hydroæide gel. For example, one embodiment of the present invention is the prophylactic vaccination of patients with a suspension of alum adjuvant as vehicle and a cocktail of (SPNE)n-OMPC as the selected set of immunogens or antigens.
Other Utilitites The SPNEs and their immunological conjugates in this invention are also useful in screening blood products for the presence of HIV antigen or HIV-specific antibody. Thus, (SPNE)n~OMPC or SPNE
can be readily employed in a variety of immunological assays of the type well known to the skilled artisan, e.g., radioimmunoassay, competitive radioimmunoassay, enzyme-linked immunoassay, and the like. For an extensive discussion of these types of utilities, see, e.g. U.S. 5, 075,211.
Method for Screenin~ Phage Epitope Libraries Phage epitope libraries are unusually versatile vehicles for identifying new antigens or ligands. Typically, the phage has inserted into its genome a small, randomly generated DNA sequence, e.g.
45 base pairs, which will generate exposed oligo-peptide surfaces in the mature phage. Mixing a 21~9517 _ W094/02626 PCT/US93/06751 library of such mature phage with a screening antibody of desired specificity, followed by separation of bound from unbound phage, allows the opportunity to clone and sequence the bound phage. A
conventional example of a phage epitope library is the filamentous phage fd and its gene III coding for minor coat protein pIII. See, e.g., Parmley, S. F.
et al. Gene 73, 305 (1988) and Scott, J. K. et al.
Science 249, 386 (1990), which set forth extensive discussion and detail on construction of these libraries.
Applicants have developed a new method for screening phage epitope libraries. The screening method involves selection of epitopes by binding to a solid-phase supported antibody, optionally followed by identification of desired clones with antibody lifts. The screening method is useful for virtually any antibody, i.e. polyclonal or monoclonal or collection of monoclonals thereto. Any antigen can be screened. The screening method is illustrated by HIV antigens screened with an HIV-specific broadly neutralizing antibody (hereinafter 447 antibody).
The present screening method avoids the typical prior art problem of biotin-avidin complexes. Although, biotin-avidin complex formation has an unusually high binding constant, it produces false positives, is time-consuming, and requires tampering with the antibody by covalent conjugation.
Applicants avoid all of these problems by adsorbing the antibody onto a solid-phase support. With a particular series of mixing and washing steps, applicants demonstrate a practical method of screening phage libraries.
W094/02626 ; PCT/US93/06751 _ 2.13951~
Screening in the present invention is broken down into two separate methods. The first method involves selection of desired phage epitopes with a solid-phase supported antibody of any desired specificity. The second method, which is optional, relates to identification of desired phage epitopes by antibody lifts.
A. Selection Selection of desired phage epitopes in a phage epitope library is performed as follows. An essentially pure preparation of monospecific antibody is adsorbed or otherwise attached to a solid-phase support, hereinafter also referred to as solid-phase supported Ab. The most preferred embodiment is monoclonal antibody adsorbed to polystyrene beads large enough to be picked up with tweezers, e.g., with a diameter of 0.25 inch. Such large beads contribute to the ease of subsequent washing steps.
Other embodiments include any solid-phase adsorbent for antibody, or any plastic, or glass bead or polysaccharide gel, e.g. Sepharose. Polysaccharide gels are typically covalently conjugated to the purified antibody by, e.g., cyanogen bromide activation.
Incubation of the solid-phase supported Ab with BSA, milk solids or other reagent for blocking non-specific interactions iæ preferable before selection. The presence of low levels of a mild or nonionic detergent is desirable, e.g., 0.5%(v/v) of ~094/02626 2~9 5.1~ PCT/US93/06751 , one or more in the polyoxyethylene (20) sorbitan monoleate series (TWEEN), or octylglucopyranoside or Nonidet NP-40. It is apparent to the skilled how to adjust the conditions for coating with such blocking agents.
An appropriate density of antibody should be determined by titration. Applicants have successfully performed selection with a density of about 0.1 ~g447/cm on polystyrene beads (d = 0.25 inch). This falls within a preferred density range lo of between about l~g Ab/cm2 and about lng Ab/cm . Densities in the lower range select high affinity epitopes because of the reduced incidence of multivalent binding by the antibody to the multiple copies of the epitope on the phage tip. It is apparent to the skilled artisan how to determine the most suitable density for an antibody preparation, by monitoring the bound phage population. As a general rule, a manageable complexity of bound and eluted phage ranges from about 5x103 to about 105 phage.
Throughout the selection method described below, a wide variation in incubation times, washing times, temperature and pH is covered. It is apparent to the skilled artisan that, given a particular incubation or washing step, a suitable set of variant reaction conditions can be readily ascertained.
Applicants have discovered that temperature and pH
are critical in the stringent selection of high affinity epitopes, e.g., temperatures exceeding about 70OC at neutral pH, or exceeding about 38C at pH
W O 94/02626 ~ 1 3 9 5 1 7 - PC~r/US93/06751 _
4.0, are lethal to the phage. Aside from the critical parameters of temperature and pH, the typical buffer is isotonic to saline, and may contain a non-specific blocking agent such as bovine serum albumin (BSA) or milk solids, as well as low levels of a nonionic detergent. For example, TTBS (50mM
Tris pH 7.5, 150 mM NaCl, 0.5% (v/v) TWEEN-20) in lmg/ml BSA is typical.
Solid-phase supported antibody is first incubated with the epitope phage library to effect binding of the phage epitopes to the antibody. It is preferred to use enough phage to vastly exceed the library complexity, e.g., 1011 phage which is 1000 fold more than its complexity of 108. Incubation between about 4C and about 65C, for at least 10 minutes is performed. Applicants typically incubate overnight at 4C. Alternatively, a one hour incubation at 37C will select epitopes binding at a fast "on" or forward rate. Incubation conditions are subject to a wide range of variations, as also discussed above, but a neutral buffer containing a non-specific blocking agent is preferred, e.g., TTBS, 1 mg/ml BSA.
Washing of the mixture of phage epitope library and solid-phase supported antibody to remove unbound phage is carried out in a variety of conditions, depending on the desired stringency. The higher the desired stringency, the higher the temperature conditions of washing, up to 70C in some conditions.
_,W O 94/02626 ~ 1 ~ g 5 1 7 PC~r/US93/06751 For high stringency selection, washing of the mixture is carried out by washing 3 to 20 times in buffer at neutral pH at 65C without blocking agent (hereinafter the 65C wash). Low-affinity phage epitopes are then eluted by washing one or more times by brief (2-5 minutes) immersion in a mildly acidic buffer without blocking agent (about pH 4.0, between
Tris pH 7.5, 150 mM NaCl, 0.5% (v/v) TWEEN-20) in lmg/ml BSA is typical.
Solid-phase supported antibody is first incubated with the epitope phage library to effect binding of the phage epitopes to the antibody. It is preferred to use enough phage to vastly exceed the library complexity, e.g., 1011 phage which is 1000 fold more than its complexity of 108. Incubation between about 4C and about 65C, for at least 10 minutes is performed. Applicants typically incubate overnight at 4C. Alternatively, a one hour incubation at 37C will select epitopes binding at a fast "on" or forward rate. Incubation conditions are subject to a wide range of variations, as also discussed above, but a neutral buffer containing a non-specific blocking agent is preferred, e.g., TTBS, 1 mg/ml BSA.
Washing of the mixture of phage epitope library and solid-phase supported antibody to remove unbound phage is carried out in a variety of conditions, depending on the desired stringency. The higher the desired stringency, the higher the temperature conditions of washing, up to 70C in some conditions.
_,W O 94/02626 ~ 1 ~ g 5 1 7 PC~r/US93/06751 For high stringency selection, washing of the mixture is carried out by washing 3 to 20 times in buffer at neutral pH at 65C without blocking agent (hereinafter the 65C wash). Low-affinity phage epitopes are then eluted by washing one or more times by brief (2-5 minutes) immersion in a mildly acidic buffer without blocking agent (about pH 4.0, between
5.0 and 3.0) at ambient temperature or between about 4C and 37C (the pH 4.0 wash). The pH 4.0 wash is optional in high stringency selection, but it cannot L0 be completely combined with the 65C wash. For example, the phage die in pH 4.0 buffer at 65OC.
High stringency selection may be enhanced by lowering the antibody density on the bead or other solid-phase support. In this case, lowering the probability that a given phage will bind more than one antibody molecule selects for higher affinity epitopes. It will be apparent to those skilled in the art how to test density ~ariations within the aforementioned ranges.
Lower stringency selection is performed instead by washing 3 to 20 times at neutral pH at about room temperature. A pH 4.0 wash may optionally follow.
Elution of high affinity epitopes is the next required step (hereinafter the pH 2.0 elution) for both high and low stringency selection. Phage bound to solid-phase supported antibody are incubated briefly (1-15 minutes) in a low pH buffer in about 0.1-10 mg/ml BSA or other non-specific binder. The buffer pH can vary from about 2.3 to about 1.0, but 2.2 is preferred. Temperature conditions range from 2~39~ 56 -about 37C to 4C, room temperature being desirable.
Preferred buffered conditions are O.lN glycine-HCl pH
2.2, l mg/ml BSA at room temperature.
After the pH 2.0 elution, the eluted solution containing phage is neutralized by standard and well-known techniques. The eluted phage are grown in infectable E. coli, e.g. tet+ phage are grown in tet E.coli on media containing tetracycline.
Thus concludes one cycle of selection, lo either at high stringency or low stringency.
Repetition of the cycle is often found advantageous, as it lowers the complexity of eluted phage to manageable quantities (less than about 105).
Repeating the cycle 2-lO times, preferably 3-5 times, is found most practical. It will be apparent to those skilled in the art that indicated variations are readily performed and evaluated, such as switching from high stringency to low stringency on the second cycle of selection, or changing the buffer or its pH.
B. Identification With Antibody Lifts After selection of epitopes bound to phage, it is advantageous to identify with antibody lifts those clones with desired epitopes. The principle is to overlay culture plates of cells infected with selected phage epitopes, remove the overlay, block the overlay, incubate the blocked overlay with desired antibody, label the bound antibody, and locate on the original culture plate those colonies that bind the antibody. Versions of this overlay technique that differ from the present method exist W094/02626 2 1 3 9 ~ 1 7 PCT/US93/06751 in the literature. Methods known in the art are typically adopted for use with plaque formers, unlike the present invention. See, e.g., Young, R.A. et al., Proc Natl. Acad Sci 80, 1194 (1983); Ausubel, F.M. et al. (eds.), "Screening Recombinant DNA
Libraries," in Current Protocols in Molecular Biology, Chapter 6, Greene 1989; and Davis, L.G. et al., Basic Methods in Molecular Biology, pp. 214-215, Elsevier 1986.
Plates having epitope phage-infected lo colonies are grown to the extent that the colonies are sufficiently large, i.e., between about lmm and about 4mm in diameter, yielding mature plates.
Mature plates are overlaid with a disk that binds proteins. The disc is typically nitrocellulose, but it may also be IMMOBILON P, cellulose acetate and the like. The disk is immediately removed and subjected to further treatment.
Blocking the overlay or disk is first performed to eliminate or substantially reduce the background of non-specific interactions. Useful blocking agents include BSA, milk solids and similar proteinaceous preparations. The disks are soaked for at least 2 hours in buffer, containing between about 0.1% (v/v) and about 1.0% (v/v) neutral detergent and at least 1% blocking agent. One preferred embodiment for this blocking step is soaking for 4 hours each disk in TTBS, 10% evaporated milk, at room temperature. A preferred range is incubation for at least 2 hours, in a buffer near neutrality (5.0-8.0) containing 0.1% (v/v) - 1.0% (v/v) neutral detergent, 21~ 7 in about 1% to about 20% blocking agent, within a temperature range of about 4C to about 80C.
Washing the blocked disks to remove excess blocking agent follows, and is carried out in a buffer lacking the blocking agent. One preferred embodiment for this washing step is soaking each disk two or three times in TTBS, pH 7.3-7.5, at room temperature. A preferred range of conditions is soaking for at least 10 minutes, in a buffer with a pH that does not destroy antibody (5.0-8.0), containing 0.1% (v/v) to 1.0% (v/v) neutral detergent, within a temperature range of about 4C to about 80C.
Contacting the disk with screening antibody follows. One preferred embodiment is incubating the washed disks overnight at 4C with gentle rocking, in TTBS, 1% evaporated milk, 0.5 to 1.0 ~g/ml antibody. A preferred range of conditions is incubating the disks for at least 4 hours, within a temperature range of between about 4C and about 65C, in buffer near neutrality containing about 0.1%
(v/v) to about 1.0~/o (v/v) neutral detergent, in 0.1%
to 5% blocking agent, and 0.1 to 5 ~g/ul antibody.
A second series of washes are performed, here to remove excess or unbound antibody. One preferred embodiment is soaking each disk four times in TTBS for 20 minutes at room temperature.
Preferred ranges of conditions are at least 2 soaks in buffer without blocking agents at a pH near neutrality (6.0-8.0), for 5 minutes to 1 hour, between about 10C and 45C.
_ W094/02626 ; PCT/US93/06751 The resulting washed disks having bound antibody are treated with a labeled second-stage ~ reagent to determine the location of the bound antibody and the corresponding epitope clone. Any labeled or tagged second-stage reagent useful for binding the bound antibody can in principle be incorporated into the procedure for the purposes of identifying the clones having epitopes bound by antibody. One preferred embodiment is soaking the washed disks having bound antibody in TTBS, 1% milk, l25I-protein A (0.5 to l~ curie/ml) for l.5 to 3 hours. Preferred ranges of conditions are incubating the disks for at least l hour, within a temperature range of between about 4C to about 65C, in buffer near neutrality containing about 0.1% (v/v) to about l.O% (v/v) neutral detergent, in about 0.1% to about 5% blocking agent and detectable quantities of labeled protein A. Another preferred second-stage reagent is labeled protein G, e.g., l25I-protein G. Other appropriate second-stage reagents include, but are not limited to, double antibody, such as l25I-labeled mouse anti-human IgG, or mouse anti-human IgG tagged with beta-galactosidase or peroxidase. Substantial purity of labeled second-stage reagent is desirable.
The disks having bound labeled antibody are now soaked or washed to remove unbound label. One preferred embodiment is soaking 20 minutes four times in TTBS. The location of the labeled, bound antibody on the disks is determined by conventional procedures appropriate for the labeled second-stage reagent.
W094/02626 2~395-1~ PCT/US93/0675,~
X-ray film is used for 125I. Chromogenic substrates are useful in a variety of enzyme-antibody detection kits.
Once the location of the bound antibody is determined, e.g., a pattern of dark spots on developed X-ray film, one identifies the appropriate colonies on the original mature plate, since regrown as needed. Subsequent replating, growth, and sequencing gives a particular selected principal neutralizing epitope (SPNE).
COMBINATION THERAPY
The vaccines of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immuno-modulators, anti-infectives, or vaccines of the following Table.
_ ~094/02626 21 3951 7 PCT/US93/067~1 TABLE I
ANTI-VIRALS
Drl-g Name Manufacturer Indication AL-721 Ethigen ARC, PGL
(Los Angeles, CA) HIV positive, AIDS
Recombinant Human Triton Biosciences AIDS, Kaposi's Interferon Beta (Almeda, CA) sarcoma, ARC
Acem~nn~n Carrington Labs ARC
(Irving, TX) (See also immuno-modulators) Cytovene Syntex sight Ganciclovir threateining CMV
(Palo Alto, CA) peripheral CMV
retinitis d4T Bristol-Myers AIDS, ARC
Didehydrodeoxy- (New York, NY) 15 thymidine ddI Bristol-Myers AIDS, ARC
Dideoxyinosine (New York, NY) EL10 Elan Corp, PLC HIV infection (Gainesville, GA) (See also immuno-modulators) Foscarnet Astra Pharm. CMV retinitis, HIV
Trisodium Products, Inc. infection, other Phosphonoformate (Westborough, MA) CMV infections W O 94/02626 PC~r/US93/06751 . _ 2~39~ 62 -Drug Name Manufacturer Indication L-697,661 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV RT
L-696,229 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV RT
L-735,524 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV Protease, not HIV RT
Dideoxycytidine; Hoffman-La Roche AIDS, ARC
ddC (Nutley, NJ) 20 Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Diapren, Inc.
(Roseville, MN, marketer) W094/02626 2 1 ~ 9 5 1 7 PCT/US93/06751 Drug Name Manufacturer Indication Peptide T Peninsula Labs AIDS
- Octapeptide (Belmont, CA) Sequence Retrovir Burroughs Wellcome AIDS, adv, ARC
Zidovudine; AZT (Rsch. Triangle Park, pediatric AIDS, NC) Kaposi's sarcoma, asymptomatic EIV
infection, less severe EIV
disease, neu~ological involvement, in combination w/
other therapies, post-exposure pro-phylaxis in health care workers Rifabutin Adria Laboratories ARC
Ansamycin LM 427 (Dublin, OH) Erbamont (Stamford, CT) Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV
Ind. Ltd. positive asymptomatic (Osaka, Japan) Viratek/ICN
Virazole (Costa Mesa, CA) asymptomatic HIV
Ribavirin positive, LAS, ARC
Alpha Interferon Burroughs Wellcome Kaposi's sarcoma, (Rsch. Triangle HIV in combination Park, NC) w/Retrovir 2139~
- 64 _ Immuno-modulators Dru~ Name Manufacturer Indication Antibody which Advanced Biotherapy AIDS, ARC
neutralizes pH Concepts labile alpha aber- (Rockville, MD) rant Interferon in an immuno-adsorption column AS-101 Wyeth-Ayerst Labs. AIDS
(Philadelphia, PA) . Bropirimine Upjohn advanced AIDS
(Kalamazoo, MI) Acemannan Carrington Labs, Inc. AIDS, ARC
(Irving, TX) (See also anti-virals) CL246,738 American Cyanamid AIDS, Kaposi's (Pearl River, NY) sarcoma Lederle Labs (Wayne, NJ) EL10 Elan Corp, PLC HIV infection (Gainesville, GA) (See also anti-virals) 20 Gamma Interferon Genentech ARC, in combination (S. San Francisco, w/TNF (tumor necrosis CA) factor) _ W094/02626 2 1 3 9 5 ~ 7 PCT/US93/06751 Dru~ Name Manufacturer Indication Granulocyte Genetics Institute AIDS
- Macrophage Colony (Cambridge, MA) Stimulating Sandoz Factor (East Hanover, NJ) Granulocyte Hoeschst-Roussel AIDS
5 Macrophage Colony (Somerville, NJ) Stimulating Immunex Factor (Seattle, WA) Granulocyte Schering-Plough AIDS
Macrophage Colony (Madison, NJ) Stimulating Factor AIDS, in combination w/Retrovir HIV Core Particle Rorer seropositive HIV
Immunostimulant (Ft. Washington, PA) IL-2 Cetus AIDS, in combaintion Interleukin-2 (Emerycille, CA) w/Retrovir l5 IL-2 Hoffman-La Roche AIDS, ARC, HIV, in Interleukin-2 (Nutley, NJ) combination w/Retrovir Immune Globulin Cutter Biological pediatric AIDS, in Intravenous (Berkeley, CA) combination (human) w/Retrovir W094/02626 ` ` PCT/US93/06751 2139~17 Drug Name Manufacturer Indication IMREG-l Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL
IMREG-2 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL
Imuthiol Diethyl Merieux Institute AIDS, ARC
Dithio Carbamate (Miami, FL) INTRON A Schering Plough Kaposi's sarcoma Alpha-2 (Madison, NJ) w/Retrovir: AIDS
Interferon Methionine- TNI Pharmaceutical AIDS, ARC
Enkephalin (Chicago, IL) MTP-PE Ciba-Geigy Corp. Kaposi's sarcoma Muramyl- (Summit, NJ) Tripeptide Granulocyte Amgen AIDS, in combination Colony (Thousand Oaks, CA) w/Retrovir 15 Stimulating Factor rCD4 Genentech AIDS, ARC
Recombinant (S. San Francisco, Soluble Human CD4 CA) 20 Recombinant Biogen AIDS, ARC
Soluble Human CD4 (Cambridge, MA) _ W094/02626 2 1 ~`9 5 1 7 PCT/US93/06751 Drug Name Manufacturer Indication Roferon-A Hoffman-La Roche Kaposi's sarcoma Interferon (Nutley, NJ) AIDS, ARC, in Alfa 2a combination wlRetrovir SK&Fl06528 Smith, Kline & French HIV infection Soluble T4 Laboratories (Philadelphia, PA) Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ) Tumor Necrosis Genentech ARC, in combina-l~ Factor; TNF (S. San Francisco, tion w/gamma CA) Interferon Anti-Infectives Clindamycin with Upjohn PCP
Primaquine (Kalamazoo, MI) Diflucan Pfizer cryptococcal Fluconazole (New York, NY) meningitis, candidiasis Pastille Squibb Corp. prevention of Nystatin Pastille (Princeton, NJ) oral candidiasis 20 Ornidyl Merrell Dow PCP
Eflornithine (Cincinnati, OH) W094/02626 2 1 3 ~ 5 1 7 PCT/US93/06751 Dru~ Name Manufacturer Indication Pentamidine LyphoMed PCP treatment Isethionate (IM (Rosemont, IL) & IV) Piritrexim Burroughs Wellcome PCP treatment (Rsch. Triangle Park, NC) Pentamidine Fisons Corporation PCP prophylaxis isethionate for (Bedford, MA) inhalation Spiramycin Phone-Poulenc cryptosporidial Pharmaceuticals diarrhea (Princeton, NJ) Intraconazole- Janssen Pharm. histoplasmosis;
R51211 (Piscataway, NJ) cryptococcal meningitis Trimetrexate Warner-Lambert PCP
Other Recombinant ~uman Ortho Pharm. Corp. severe anemia Erythropoietin (Raritan, NJ) assoc. and Retrovir therapy 20 Megestrol Acetate Bristol-Myers treatment of (New York, NY) anorexia assoc.
w/AIDS
It will be understood that the scope of combinations of the antigenic conjugates of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS. The antigenic conjugates as AIDS or HIV vaccines of this invention include vaccines to be used pre- or post-exposure to prevent or treat HIV infection or disease, and are I0 capable of producing an immune response specific for the immunogen.
The compound L-697,661 is 3-([4,7-dichloro-1,3-benzoxazol-2-yl)methyl]amino)-5-ethyl-6-methyl-pyridin-2(1H)-one or pharmaceutically acceptable salt thereof. The compound L-696,229 is 3-t2-(1,3-benz-oxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one or pharmaceutically acceptable salt thereof. The compound L-735,524 is N-(2(R)-hydroxy-l(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide, or pharmaceutically acceptable salt thereof.
Biolo~ical Deposits The cell line producing "447 antibody", also known as 447-52D, is a Human x Human x Mouse Heterohybridoma cell line, which was deposited on or before 12 April 1991 at the American Type Culture Collection, Rockville, Maryland, under the requirement of a U.S. Patent Deposit.
W 0 94/02626 2~9517 PC~r/US93/06751 Library Construction A. Random Library A phage library containing random 15 amino acid epitopes was constructed by the methods of Scott, J.K. et al. Science 249, 386 (1990). In this protocol, synthetic 110 bp BglI fragments were prepared containing the degenerate coding æequence (NNK)15, wherein N stands for an equal mixture of lo G, A, T and C, and K stands for an equal mixture of G
and T. The library was constructed by ligating the synthetic 110 bp BglI fragments in phage fUSE5 and transfecting E. coli cells with the ligation product by electroporation.
The resulting phage oligopeptide epitope library (also known as Library ALPHA) had a complexity of approximately 40 x 106 different epitopes.
B. Semi Random Libraries In order to determine the influence of sequence which flanks GPXR (SEQ. ID N0: 123) on binding and ultimately on the induction of a 447 like antibody response, and to determine the influence of potential loop formation, the following libraries were constructed in the same manner as Example lA:
__W094/02626 2 ~ 3 9 S 1 7 PCT/US93/06751 LIBRARY Peptide Sequence Complexity SEQ. ID.
BETA xxxxxxxxxGPXRXX 92X106 124 GAMMA T.T.xxxxxGP~Rxxxxxl.T. 66X10 125 DELTA ~xxxxxGPXR~C 45X106 126 EPSILON ~xxxxxxxxxxxxxxC 200X106 127 X is any amino acid Library BETA consists of random polypeptide sequences around GP~R (SEQ. ID NO: 123); library GAMMA adds terminal leucines for potential loop formation;
library DELTA instead adds a terminal cysteine on each end for potential loop formation; library EPSILON is a control of any sequence with a cysteine loop.
Bead Coatin~ Procedure Polystyrene beads (d = 0.25 inch) were coated with between 1 and 10 ~g of 447 antibody per ml in 50 mM Na2 C03, pH 9.6, 0.02% sodium azide.
(Note that any solid phase adsorbent should work).
Beads were incubated in the antibody solution at 4C
overnight. The next day the coated beads were washed 3x with phosphate buffered saline and lx with water.
After washing, the antibody-coated beads were air dried and stored frozen at -20OC until needed.
Before use, the antibody-coated beads were coated with 10 mg/ml BSA (to block free sites on the plastic) in TTBS (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% (v/v) Tween 20) for 4 or more hours. Each batch of beads was checked for antibody activity by its ability to bind l25I protein A, before being used in a phage selection screen.
Stringent PhaPe Selection with Antibody-Coated Beads A. First Method-Low Strin~ency The random epitope phage library ALPHA was incubated at 4C overnight with gentle rocking, with antibody-coated beads in TTBS, l mg/ml BSA.
Typically, a total volume of lcc containing about lOll total phage was used. The next day the bead, containing bound phage, was washed lO to 12 times in TTBS, in a volume of lOcc per wash, at room temperature, with a gentle rocking motion, for lO
minutes per wash. The liquid was carefully drained off the bead between each wash. After the last wash the bound phage were eluted off the bead by incubating for 5 minutes at room temperature in a minimal volume (typically 200 ~l) of O.lN HCl, adjusted to pH 2.2 with glycine, lmg/ml BSA. The solution with the eluted phage was neutralized by adding 12 ~l of 2M Tris, pH unadjusted, per 200 ~l phage solution. The eluted phage were then used to infect E. coli K9lK cells. Infected cells were plated onto LB agar plates containing 40 ~g/ml tetracycline. Since the phage carry a tetracycline resistance marker, only infected cells grow on the plates. Typically, one bead selected between 5000 and lO0,000 independent phage.
_ ~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 B. Second Method-HiEh Strin~ency The random epitope library or semi-random library was incubated at 4C overnight with gentle rocking, with antibody-coated beads in TTBS, l mg/ml BSA. Typicallyi a total volume of lcc containing on 5 the order of lO total phage was used, corresponding to the complexity of the library 2 lO00. The next day the bead containing the bound phage was washed lO times in TTBS, in a volume of lOcc per wash, at 65C, with gentle rocking, for lO
minutes per wash. Note that 65C in TTBS does not destroy phage. There followed one wash at room temperature in TTBS pH 4Ø The liquid was carefully drained off the bead between each wash. Next, the bound phage were eluted off the bead by incubating for 5 minutes at room temperature in 200 ~l of O.lN
HCl, adjusted to pH 2.2 with glycine, l mg/ml BSA.
The phage solution was neutralized by adding 12 ~l of 2M Tris, pH unadjusted. The eluted phage were then used to infect E. coli K9lK cells. Infected cells were grown in l x Luria broth containing 40 ~g/ml tetracycline (250 cc) and incubated with shaking for 48 hours at 37C. Phage were harvested and precipitated twice with PEG (polyethylene glycol). The precipitated phage were then titered 2s and approximately lOlO of the first round selected phage were again incubated with a 447-antibody coated bead, washed as described above, regrown and harvested. Three cycles of selection and growth were performed. E. coli infected with phage were plated as clonal isolates.
2139517 ` ~ 74 Screening of Selected Phage with Antibody Lifts After l or more rounds of selection according to Example 3, the infected E.coli colonies were screened for the ability to bind 447 antibody (using the same antibody as used to select the phage). This was done by growing the plates until the colonies reached a diameter of one to four mm, placing nitrocellulose disks onto the plates, lifting the disks and placing them in a solution of 10%
evaporated milk, TTBS for 4 or more hours. After lifting, the plate containing the infected colonies were regrown for several hours at 37C and placed at 4C until needed. The nitrocellulose disks, at the end of 4 or more hours in the solution of 10%
evaporated milk and TTBS, were washed 2-3x in TTBS
and placed in TTBS and 1% milk and 0.5 to l ~glml antibody solution. They were then incubated at 4C
overnight with gentle rocking. After incubation in the antibody solution, the disks were washed 4x in lOOcc TTBS for 20 minutes with gentle rocking. They were then incubated in TTBS and 1% milk and Il25 protein A (.5 to l ~ curie/ml) for l-l/2 to 3 hours. The disks were again washed 4x in lO0 cc TTBS
for 20 minutes. They were placed on X-ray film for 12 to 72 hours. The film was developed and colonies corresponding to dark spots were picked. If the plates were too dense to pick isolated colonies, the picked colony(ies) was replated at a lower density and the screen repeated to get clonal isolates.
_ W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 PCR Sequencin~
Phage infected E. coli K9lK cells were grown overnight at 37C in lx Luria broth, 40 ~g/ml tetra-cycline on a rollerdrum. The cells were pelleted and 1 ~1 of æupernatant was used as the template in PCR
reactions. The template was amplified using a 100-fold excess of one primer over the other.
Template and oligonucleotide primers (Primer 1008:
5'-TCG AAA GCA AGC TGA TAA ACC G-3' SEQ ID N0:129, located 106 nucleotides upstream of random insert and Primer 1009: 5'-ACA GAC AGC CCT CAT AGT TAG CG-3' SEQ
ID N0 130, located 87 nucleotides downstream from random insert) were reacted in a volume of 100 ~1 containing 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM
MgC12, O.01% (w/v) gelatin, 200 ~M each dNTP, and 2.5 units Taq polymerase. Reactions were overlaid with mineral oil and amplified in a thermal cycler for an initial 8 minute 94C incubation, then 30 cycles of 30 seconds at 94C, 1 minute at 55C and 2 minutes at 72C followed by a 5 minute incubation at 72C. The mineral oil was removed, 2 ml of water added to the reactions, and the sample centrifuged in a microconcentrator for 30 minutes at 1000 x g. The retentate volume was brought to 2 ml with water and centrifuged as above. The retentate was then collected by centrifugation for 2 minutes at 500 x g. Retentate concentrations were determined by electrophoresis on a 1% agarose gel containing 0.5 ~g/ml Ethidium bromide and visualization under W094/02626 2 1 3g 5 17 PCT/US93/067~1 _ ultraviolet light. The retentate was dried along with enough limiting primer from PCR reaction (or internal primer 1059-5'GTA AAT GAA TTT TCT GTA TGA GG
3' SEQ. ID N0:128 located 27 nucleotides downstream from insert) to give a 5:1 primer:template molar ratio. The DNA/primer mixture was resuspended in 8~1 water and 2~1 Tris-Buffer (200 mM Tris HCl, pH 7.5, 100 mM MgC12, 250 mM NaCl) Kit). The primer and template were annealed, and chain-termination sequencing reactions were set up. A 6% sequencing gel was run at 60 watts for approximately 1 hour and 30 minutes. The gel was dried and exposed to X-ray film overnight, and the sequence determined.
SPNE-pIII-(His~6Fusions The HIV/pIII fusion was expressed in E. Coli using the T7 polymerase system from Rosenberg, A.H.
et. al., Gene 56, 125 (1987). The plasmid pET-3a (commercially available from Novagen, Madison, WI) was digested with Xba I and BamHI and the 5 kb vector fragment isolated. The isolated vector fragment was ligated with the Xba I,BgI II-digested HIV/pIII
fusion prepared by polymerase chain reaction (PCR) of the candidate HIV fuse phage clones.
Two synthetic DNA oligomers were used to amplify a portion of the phage pIII gene (including the HIV sequences) and append sequences which permit _~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 efficient expression and purification of the pIII
product. The first synthetic DNA oligomers, 5' CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCCGACG
GGGCT 3' (Seq ID No: 131), has homology with the fuse phage pIII gene with sequences encoding the mature amino terminus of Ala-Asp-Gly-Ala. PCR amplification from this site incorporates sequences encoding the mature pIII protein, and rebuilds the pET-3a vector from the Xba I site to the initiating methionine.
The second synthetic DNA oligomer, sequence 5' CTCAGATCTATTAATGGTGATGGTGATGATGTATTTTGTCACAATCAA-TAGAAAATTC 3' (Seq ID No.: 132) encodes the reverse strand of the carboxyl-terminal portion of pIII
ending with residues Cys-Asp-Lys-Ile (Seq ID No:
133). PCR with this oligo rebuilds the fuse phage lS pIII gene up to the transmembrane domain and appends six histidine residues to the carboxyl-terminal isoleucine. The presence of the histidine residues facilitates purification of the pIII fusion protein by metal chelation chromotography tHochuli, E. et al., J. Chromat. 411, 177 (1987)] using nitrilotriacetic acid (NTA) resin (available from Qiagen, Chatsworth, CA).
Expression of the pIII fusion is obtained by transforming the expression plasmid into E. coli strain ~L21 (DE3) [Rosenberg, A.H. et al., supra;
U.S. Patent 4,952,496; Steen, et al., EMB0 J 5, 1099 (1986).] This strain contains the T7 phage RNA
polymerase gene under control of the lac operator/promoter. Addition of isopropylthiogalactoside (IPTG) at culture OD6oo=0.6-0.8 induces T7 RNA polymerase expression 2`3q~\~
W 094/02626- ` PC~r/US93/067~1 _ which transcribes pIII mRNA to high levels. This RNA
is translated yielding pIII fusion protein which is harvested 3-4 hours post-induction and chromatographed on NTA resin.
E} ~ LE 7 Synthesis of Selected Oli~opeptide The oligopeptide LLRTIMIGPGRLLHS (SEQUENCE
lo ID. NO. 23, hereinafter 473) was selected for immunological characterization. It was synthesized by the solid-phase method.
Extraction and Purification of OMPC
A. First Method All materials, reagents and equipment were sterilized by filtration, steam autoclave or ethylene oxide, as appropriate; asceptic technique was used throughout.
A 300 gm (wet weight) aliquot of 0.5% phenol inactivated cell paste of Meningococcal group Bll was suspended in 1200 mls of distilled water then suspended by stirring magnetically for 20 minutes at room temperature. The suspended cells were pelleted at 20,000 xg for 45 minutes at 5C.
For extraction, the washed cells were suspended in 1500 mls 0.1 M Tris, 0.01 M EDTA Buffer pH 8.5 with 0.5V/o sodium deoxycholate (TED Buffer) and homogenized with a 500 ml Sorvall omnimixer at _ W094/02626 2 ~ 3 9 517 PCT/US93/06751 setting 3 for 60 seconds. The resulting suspension was transferred to ten Erlenmeyer flasks (500 ml) for extraction in a shaking water bath for 15 minutes at 56C. The extract was centrifuged at 20,000 x g for 90 minutes at 5C and the viscous supernatant fluid was decanted (volume = 1500 mls). The decanted fluid was very turbid and was recentrifuged to clarify further at 20,000 x g for 90 minutes at 5C. The twice spun supernatant fluid was stored at 5C. The extracted cell pellets were resuspended in 1500 mls TED Buffer. The suspension was extracted for 15 minutes at 56C and recentrifuged at 20,000 x g for 90 minutes. The supernatant fluids which contained purified OMPC were decanted (volume = 1500 mls) and stored at 5C.
B. Second Method All material, reagents, equipment and filters were sterilized by heat, filtration or ethylene oxide. One e~ception was the K-2 ultracentrifuge which was sanitized with a 0.5%
formalin solution. Laminar flow canopies provided sterility protection during equipment connections.
Aseptic techniques were followed throughout the entire operations. Overnight storage of the protein was at 2-8C between steps. A 0.2 micron sterile filtration was conducted just before the final diafiltration to ensure product sterility.
Two 600-liter batches of Neisseria meningitidis were fermented and killed with 0.5%
phenol, then concentrated to roughly 25 liters using two 10 ft2 0.2 micron polypropylene cross-flow W094/02626 PCT/US93/06751 _ 2~395~
filtration membranes. The concentrated broth then was diafiltered with 125 liters of cell wash buffer (0.11 M Sodium Chloride, 17.6 mM Sodium Phosphate Diabasic, 23.3 mM Ammonium Chloride, 1.34 mM
Potassium Chloride, adjusted to pH 7 with 85%
Phosphoric Acid followed by 2.03 mM Magnesium Sulfate Heptahydrate).
For extraction, an equal volume of 2X-TED
buffer (0.2M Tris, 0.02M EDTA adjusted to pH 8.5 with concentrated HCl followed by the addition of 1.0%
sodium deoxycholate) was added to the cell slurry.
The resulting slurry was heated to 56% 3C and maintained at this temperature for 30 minutes to complete the extraction of OMPC from the cells.
For further purification, the extracted cell slurry was centrifuged at 30,000 x g (18,000 rpm) in a "one-pass" flow mode in a K-ultracentrifuge, and the supernatant stream was collected. The low-speed supernatant was concentrated to 10 liters on two 0.1-micron polysulfone autoclavable hollow-fiber membranes and collected in an 18 liter sterile bottle. The filtration equipment was given two 4-liter rinses with TED buffer (O.lM Tris, 0.01M
EDTA, adjusted to pH 8.5 with concentrated HCl, followed by the addition of sodium deoxycholate to 0.5%) which was combined with the retentate. The retentate was subdivided into two or three equal parts. Each part was centrifuged at 80,000 x g (35,000 rpm) for 30 minutes. The OMPC protein was pelleted, and the majority of soluble proteins, nucleic acids and endotoxins remained in the supernatant. The supernatant was discarded. The _ W094/02626 2~ 3 95 1 7 PCT/US93/06751 pelleted protein was resuspended by recirculating 55% 5C TED buffer through the rotor. The first high-speed resuspensions were combined and subjected to a second low-speed spin. The second low-speed spin ensured that residual cell debris was removed from the product stream. The second low speed supernatant was subdivided into two or three equal parts. Each fraction was given two consecutive high-speed spins. All high-speed spins were operated under the same conditions and each further purified io the OMPC protein.
For sterile filtration and final diafiltration, the third high-speed resuspensions were diluted with an equal volume of TED buffer and filtered through a 0.2 micron cellulose acetate filter. When all fractions were permeated, an 8 L
TED buffer rinse was used to flush the filtration system. The permeate and rinse were combined and concentrated to 3 liters on a 0.1 micron polysulfone autoclavable hollow fiber membrane. The material then was diafiltered with 15 liters of sterile pyrogen free water. The retentate was collected in a 4-liter bottle along with a l-L rinse to give the final product. The final aqueous suæpension was stored at 2-8C, as purified OMPC.
C. Third Method OMPC is purified from 0.2 M LiCl-O.lM Na Acetate, pH 5.8, extracts by ultracentrifugation, by the method of C.E. Frasch et al. J. Exp. Med. 140, 87-104 (1974).
wog4~o2626 ~395~ PCT/US93/06751_ Oligopeptide 473 was conjugated to OMPC by the co-conjugation method of EPO467700 of Leanza, W.J. et al., to give 473-OMPC conjugate, as follows:
A. Thiolation of OMPC:
OMPC (43.4 mg, 10 mL) was pelleted by ultracentrifugation (43K rpm, 2h, 4C). The pellet was resuspended in a sterile filtered (0.22~m) solution which consisted of: pH 11, 0.1 M borate buffer (4 mL), N-Acetyl homocysteine thiolactone (45 mg), DTT (15 mg), and EDTA (85 mg). The resulting solution was degassed and purged with nitrogen (process repeated 3x) and stored under N2 overnight at room temperature (17 h). The thiolation mixture was transferred to a centrifuge tube and topped with pH 8.0, 0.1 M phosphate buffer (approximately 4.5 mL). The protein was pelleted via ultracentrifugation, resuspended (after homogeniz-ation) in pH 8.0, 0.1 M phosphate buffer, and repelleted by ultracentrifugation. This pellet was resuspended in lX TED buffer, wtih a total resuspension volume of 7.0 mL. An Ellman's analysis on this solution (100 ~L) revealed that it contained 0.961 ~mol SH/mL solution (6.72 ~mol SH total, 0.15S ~mol SH/mg OMPC used).
B. Conjugation:
The beta-maleimidopropionyl peptide (5.8 ~mol) was dissolved in acetonitrile (1.0 mL) giving Solution P. A solution of beta-maleimidopropionic _ ~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 acid (5.5 ~mol) in water (l.o mL) was prepared, which is Solution M.
Thiolated OMPC (6.0 mL, 5.77 ~mol), which was prepared in step A, was transferred to a sterile 15 mL centrifuge tube. This solution was vortexed and solution M (420 ~L, 2.31 ~mol) added. The mixture was stirred briefly and allowed to age at room temperature (10 min). Negt, the reaction mixture was vortexed and solution P (596 ~L, 3.46 ~mol) added. The reaction migture was vortexed briefly and allowed to age at room temperature for 2 h.
The conjugate was spun in a clinical centrifuge to remove any precipitated material. The supernatant was removed and the conjugate was pelleted by ultracentrifugation (43K rpm, 2 h, 4C).
The pellet was resuspended in TED buffer (total volume 6.5 mL), affording 473-OMPC conjugate.
Lowry Protein Assay: 3.04 mg/mL
Amino Acid Analysis:
Lys: 835 nmol/mL
Beta-Ala: 157 nmol/mL
Nle: 175 nmol/mL
Loading (Based on Nle): 58 nmol peptide/mg OMPC
Loading % (w/w%; Based on Nle): 11%
~l395l7 W O 94/02626 - . P(~r/US93/06751 Immunization Protocol for 473-OMPC conjugate Four New Zealand white rabbits (2 to 2.5 kg) were immunized with the peptide 473-OMPC conjugate vaccine (the vaccine) in the following manner: For time zero inoculations the vaccine was formulated into complete Freund's adjuvant (CFA) tl:l(v/v) of CFA and 600~g/ml of conjugate in saline]. Each dose (1.0 ml) consisted of a total of 300 ~g of vaccine.
Each rabbit was inoculated with the vaccine preparation at two sites, by intra-muscular (im) injection, in the upper hind leg. Two booster inoculations were given to each rabbit at week 4 and week 8 post initial injection. The vaccine for these booster injections was formulated into incomplete Freund's adjuvant. Each dose also consisted of a total of 300 ~g of vaccine.
Each rabbit was bled and sera was prepared by standard methods for anti-peptide ELISA tests (Example 10) and anti-HIV neutralization tests (Example 11). Sera collected represent time zero and biweekly intervals through week 14.
Measurement of Antibody Responses in Rabbits Immunized with 473-OMPC Conjugate Vaccine (ELISA).
Elicited anti-peptide antibody responses in vaccinated rabbits were determined by the use of an _ ~094/02626 2 1 ~ 9 5 1 ~ PCT/US93/06751 enzyme-linked immunoadæorbent assay (ELISA). In this assay, microtiter plates were coated with about 0.5 ~g peptide 473 per well using an overnight incubation of peptide solution at 36C in a humidified atmosphere.
Elicited anti-HIV isolate MN specific antibody responses were measured by the use of an anti-peptide 402 ELISA assay. In this assay the 402 peptide (primary sequence = NleCYNKRKRIHIGPGRA~YllKNlIGC, SEQ. ID. NO. 122, with disulfide bonding between the two C residues) was the coating peptide. Peptide 402 is a cyclic representation of the ~IV isolate MN
gpl20 V3 loop sequence.
For 473 ELISA tests, titers were determined with 0 time and weeks 2, 4, 6, 8, 10, 12 and 14 sera.
See Table I. For 402 ELISA tests, titers were determined for weeks 10, 12 and 14 sera. See Table II, in which the ELISA antigen is 402 instead of 473.
Test sera were diluted 5-fold serially, were reacted for 1 hr with the peptide adsorbed wells, and were washed extensively. Positive results were identified after reactions of phosphatase-conjugated goat anti-rabbit sera with each well for 1 hr at 36C, washing and the addition of a solution of 1.0 mg/mL
p-nitrophenyl phosphate (pNPP) in 10% diethanolamine, 0.5 mM MgC12 (pH 9.8) to each well. This last 2S reaction proceeded for 30 minutes at room temperature and was stopped by addition of 3.0 _ NaOH. Absorbance at 405 nm was determined by using a plate reader.
-W 0 94/02626 ~ 13~ 5 17 PC~r/US93/06751 Measurement of Virus Neutralizin~ Antibody Responses Elicited in Rabbits Immunized with 473-OMPC ConjuPates.
Neutralization of Infectivity in MT-4 Cells in vitro: For neutralization tests 2-fold serial dilutions of sera were made and 100 ~L volumes were used in each test well in 96 well culture plates.
All sera were heat inactivated before use. Generally 1:10 was the starting dilution of sera. An aliquot of 100 ~L virus stock dilution was added to each test well. The HIV isolates used to determine virus neutralization by anti-473 rabbit sera were IIIB, MN, SF-2, AL-l and WMW-2. The virus-antisera mixtures were incubated at 37C for 1 hr after which 1 x 104 MT-4 cells in 50 ~L of culture medium were added to each well and the cultures were incubated for 7 days. The level of neutralization was determined by using the MTT dye reduction readout. MTT was added to each well to 500 ~g/mL, incubated at 37C for 2 hr, and solubilized after addition of acid-isopro-panol (0.04N HCl in isopropanol) to approximately 50%
of the volume of each well. A clearly distinguishable bluish-purple color develops in wells containing viable cells that are protected from infection due to virus neutralization by anti-473 antibody whereas wells containing MT-4 cells killed by the infection remain yellow. The neutralization endpoints were determined as the last dilution of antisera preparation that prevents cell killing. Uninfected _ NO94/02626 21~ g ~1 7 PCT/US93/06751 MT-4 cells were cultured with each test and a virus retitration was performed with each analysis.
For results, see Tables IIIA and IIIB.
Table IIIA contains the neutralization data obtained in experiments using isolates MN, AL-l (Alabama) and SF-2. Table IIIB contains that for WMJ-2 and lO week only for isolate IIIB. Values given represent the reciprocal of the endpoint dilution.
1'0
High stringency selection may be enhanced by lowering the antibody density on the bead or other solid-phase support. In this case, lowering the probability that a given phage will bind more than one antibody molecule selects for higher affinity epitopes. It will be apparent to those skilled in the art how to test density ~ariations within the aforementioned ranges.
Lower stringency selection is performed instead by washing 3 to 20 times at neutral pH at about room temperature. A pH 4.0 wash may optionally follow.
Elution of high affinity epitopes is the next required step (hereinafter the pH 2.0 elution) for both high and low stringency selection. Phage bound to solid-phase supported antibody are incubated briefly (1-15 minutes) in a low pH buffer in about 0.1-10 mg/ml BSA or other non-specific binder. The buffer pH can vary from about 2.3 to about 1.0, but 2.2 is preferred. Temperature conditions range from 2~39~ 56 -about 37C to 4C, room temperature being desirable.
Preferred buffered conditions are O.lN glycine-HCl pH
2.2, l mg/ml BSA at room temperature.
After the pH 2.0 elution, the eluted solution containing phage is neutralized by standard and well-known techniques. The eluted phage are grown in infectable E. coli, e.g. tet+ phage are grown in tet E.coli on media containing tetracycline.
Thus concludes one cycle of selection, lo either at high stringency or low stringency.
Repetition of the cycle is often found advantageous, as it lowers the complexity of eluted phage to manageable quantities (less than about 105).
Repeating the cycle 2-lO times, preferably 3-5 times, is found most practical. It will be apparent to those skilled in the art that indicated variations are readily performed and evaluated, such as switching from high stringency to low stringency on the second cycle of selection, or changing the buffer or its pH.
B. Identification With Antibody Lifts After selection of epitopes bound to phage, it is advantageous to identify with antibody lifts those clones with desired epitopes. The principle is to overlay culture plates of cells infected with selected phage epitopes, remove the overlay, block the overlay, incubate the blocked overlay with desired antibody, label the bound antibody, and locate on the original culture plate those colonies that bind the antibody. Versions of this overlay technique that differ from the present method exist W094/02626 2 1 3 9 ~ 1 7 PCT/US93/06751 in the literature. Methods known in the art are typically adopted for use with plaque formers, unlike the present invention. See, e.g., Young, R.A. et al., Proc Natl. Acad Sci 80, 1194 (1983); Ausubel, F.M. et al. (eds.), "Screening Recombinant DNA
Libraries," in Current Protocols in Molecular Biology, Chapter 6, Greene 1989; and Davis, L.G. et al., Basic Methods in Molecular Biology, pp. 214-215, Elsevier 1986.
Plates having epitope phage-infected lo colonies are grown to the extent that the colonies are sufficiently large, i.e., between about lmm and about 4mm in diameter, yielding mature plates.
Mature plates are overlaid with a disk that binds proteins. The disc is typically nitrocellulose, but it may also be IMMOBILON P, cellulose acetate and the like. The disk is immediately removed and subjected to further treatment.
Blocking the overlay or disk is first performed to eliminate or substantially reduce the background of non-specific interactions. Useful blocking agents include BSA, milk solids and similar proteinaceous preparations. The disks are soaked for at least 2 hours in buffer, containing between about 0.1% (v/v) and about 1.0% (v/v) neutral detergent and at least 1% blocking agent. One preferred embodiment for this blocking step is soaking for 4 hours each disk in TTBS, 10% evaporated milk, at room temperature. A preferred range is incubation for at least 2 hours, in a buffer near neutrality (5.0-8.0) containing 0.1% (v/v) - 1.0% (v/v) neutral detergent, 21~ 7 in about 1% to about 20% blocking agent, within a temperature range of about 4C to about 80C.
Washing the blocked disks to remove excess blocking agent follows, and is carried out in a buffer lacking the blocking agent. One preferred embodiment for this washing step is soaking each disk two or three times in TTBS, pH 7.3-7.5, at room temperature. A preferred range of conditions is soaking for at least 10 minutes, in a buffer with a pH that does not destroy antibody (5.0-8.0), containing 0.1% (v/v) to 1.0% (v/v) neutral detergent, within a temperature range of about 4C to about 80C.
Contacting the disk with screening antibody follows. One preferred embodiment is incubating the washed disks overnight at 4C with gentle rocking, in TTBS, 1% evaporated milk, 0.5 to 1.0 ~g/ml antibody. A preferred range of conditions is incubating the disks for at least 4 hours, within a temperature range of between about 4C and about 65C, in buffer near neutrality containing about 0.1%
(v/v) to about 1.0~/o (v/v) neutral detergent, in 0.1%
to 5% blocking agent, and 0.1 to 5 ~g/ul antibody.
A second series of washes are performed, here to remove excess or unbound antibody. One preferred embodiment is soaking each disk four times in TTBS for 20 minutes at room temperature.
Preferred ranges of conditions are at least 2 soaks in buffer without blocking agents at a pH near neutrality (6.0-8.0), for 5 minutes to 1 hour, between about 10C and 45C.
_ W094/02626 ; PCT/US93/06751 The resulting washed disks having bound antibody are treated with a labeled second-stage ~ reagent to determine the location of the bound antibody and the corresponding epitope clone. Any labeled or tagged second-stage reagent useful for binding the bound antibody can in principle be incorporated into the procedure for the purposes of identifying the clones having epitopes bound by antibody. One preferred embodiment is soaking the washed disks having bound antibody in TTBS, 1% milk, l25I-protein A (0.5 to l~ curie/ml) for l.5 to 3 hours. Preferred ranges of conditions are incubating the disks for at least l hour, within a temperature range of between about 4C to about 65C, in buffer near neutrality containing about 0.1% (v/v) to about l.O% (v/v) neutral detergent, in about 0.1% to about 5% blocking agent and detectable quantities of labeled protein A. Another preferred second-stage reagent is labeled protein G, e.g., l25I-protein G. Other appropriate second-stage reagents include, but are not limited to, double antibody, such as l25I-labeled mouse anti-human IgG, or mouse anti-human IgG tagged with beta-galactosidase or peroxidase. Substantial purity of labeled second-stage reagent is desirable.
The disks having bound labeled antibody are now soaked or washed to remove unbound label. One preferred embodiment is soaking 20 minutes four times in TTBS. The location of the labeled, bound antibody on the disks is determined by conventional procedures appropriate for the labeled second-stage reagent.
W094/02626 2~395-1~ PCT/US93/0675,~
X-ray film is used for 125I. Chromogenic substrates are useful in a variety of enzyme-antibody detection kits.
Once the location of the bound antibody is determined, e.g., a pattern of dark spots on developed X-ray film, one identifies the appropriate colonies on the original mature plate, since regrown as needed. Subsequent replating, growth, and sequencing gives a particular selected principal neutralizing epitope (SPNE).
COMBINATION THERAPY
The vaccines of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immuno-modulators, anti-infectives, or vaccines of the following Table.
_ ~094/02626 21 3951 7 PCT/US93/067~1 TABLE I
ANTI-VIRALS
Drl-g Name Manufacturer Indication AL-721 Ethigen ARC, PGL
(Los Angeles, CA) HIV positive, AIDS
Recombinant Human Triton Biosciences AIDS, Kaposi's Interferon Beta (Almeda, CA) sarcoma, ARC
Acem~nn~n Carrington Labs ARC
(Irving, TX) (See also immuno-modulators) Cytovene Syntex sight Ganciclovir threateining CMV
(Palo Alto, CA) peripheral CMV
retinitis d4T Bristol-Myers AIDS, ARC
Didehydrodeoxy- (New York, NY) 15 thymidine ddI Bristol-Myers AIDS, ARC
Dideoxyinosine (New York, NY) EL10 Elan Corp, PLC HIV infection (Gainesville, GA) (See also immuno-modulators) Foscarnet Astra Pharm. CMV retinitis, HIV
Trisodium Products, Inc. infection, other Phosphonoformate (Westborough, MA) CMV infections W O 94/02626 PC~r/US93/06751 . _ 2~39~ 62 -Drug Name Manufacturer Indication L-697,661 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV RT
L-696,229 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV RT
L-735,524 Merck AIDS, ARC, HIV
(Rahway, NJ) positive asymptomatic, or in combination with AZT, ddC or ddI. Inhibitor of HIV Protease, not HIV RT
Dideoxycytidine; Hoffman-La Roche AIDS, ARC
ddC (Nutley, NJ) 20 Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Diapren, Inc.
(Roseville, MN, marketer) W094/02626 2 1 ~ 9 5 1 7 PCT/US93/06751 Drug Name Manufacturer Indication Peptide T Peninsula Labs AIDS
- Octapeptide (Belmont, CA) Sequence Retrovir Burroughs Wellcome AIDS, adv, ARC
Zidovudine; AZT (Rsch. Triangle Park, pediatric AIDS, NC) Kaposi's sarcoma, asymptomatic EIV
infection, less severe EIV
disease, neu~ological involvement, in combination w/
other therapies, post-exposure pro-phylaxis in health care workers Rifabutin Adria Laboratories ARC
Ansamycin LM 427 (Dublin, OH) Erbamont (Stamford, CT) Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV
Ind. Ltd. positive asymptomatic (Osaka, Japan) Viratek/ICN
Virazole (Costa Mesa, CA) asymptomatic HIV
Ribavirin positive, LAS, ARC
Alpha Interferon Burroughs Wellcome Kaposi's sarcoma, (Rsch. Triangle HIV in combination Park, NC) w/Retrovir 2139~
- 64 _ Immuno-modulators Dru~ Name Manufacturer Indication Antibody which Advanced Biotherapy AIDS, ARC
neutralizes pH Concepts labile alpha aber- (Rockville, MD) rant Interferon in an immuno-adsorption column AS-101 Wyeth-Ayerst Labs. AIDS
(Philadelphia, PA) . Bropirimine Upjohn advanced AIDS
(Kalamazoo, MI) Acemannan Carrington Labs, Inc. AIDS, ARC
(Irving, TX) (See also anti-virals) CL246,738 American Cyanamid AIDS, Kaposi's (Pearl River, NY) sarcoma Lederle Labs (Wayne, NJ) EL10 Elan Corp, PLC HIV infection (Gainesville, GA) (See also anti-virals) 20 Gamma Interferon Genentech ARC, in combination (S. San Francisco, w/TNF (tumor necrosis CA) factor) _ W094/02626 2 1 3 9 5 ~ 7 PCT/US93/06751 Dru~ Name Manufacturer Indication Granulocyte Genetics Institute AIDS
- Macrophage Colony (Cambridge, MA) Stimulating Sandoz Factor (East Hanover, NJ) Granulocyte Hoeschst-Roussel AIDS
5 Macrophage Colony (Somerville, NJ) Stimulating Immunex Factor (Seattle, WA) Granulocyte Schering-Plough AIDS
Macrophage Colony (Madison, NJ) Stimulating Factor AIDS, in combination w/Retrovir HIV Core Particle Rorer seropositive HIV
Immunostimulant (Ft. Washington, PA) IL-2 Cetus AIDS, in combaintion Interleukin-2 (Emerycille, CA) w/Retrovir l5 IL-2 Hoffman-La Roche AIDS, ARC, HIV, in Interleukin-2 (Nutley, NJ) combination w/Retrovir Immune Globulin Cutter Biological pediatric AIDS, in Intravenous (Berkeley, CA) combination (human) w/Retrovir W094/02626 ` ` PCT/US93/06751 2139~17 Drug Name Manufacturer Indication IMREG-l Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL
IMREG-2 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL
Imuthiol Diethyl Merieux Institute AIDS, ARC
Dithio Carbamate (Miami, FL) INTRON A Schering Plough Kaposi's sarcoma Alpha-2 (Madison, NJ) w/Retrovir: AIDS
Interferon Methionine- TNI Pharmaceutical AIDS, ARC
Enkephalin (Chicago, IL) MTP-PE Ciba-Geigy Corp. Kaposi's sarcoma Muramyl- (Summit, NJ) Tripeptide Granulocyte Amgen AIDS, in combination Colony (Thousand Oaks, CA) w/Retrovir 15 Stimulating Factor rCD4 Genentech AIDS, ARC
Recombinant (S. San Francisco, Soluble Human CD4 CA) 20 Recombinant Biogen AIDS, ARC
Soluble Human CD4 (Cambridge, MA) _ W094/02626 2 1 ~`9 5 1 7 PCT/US93/06751 Drug Name Manufacturer Indication Roferon-A Hoffman-La Roche Kaposi's sarcoma Interferon (Nutley, NJ) AIDS, ARC, in Alfa 2a combination wlRetrovir SK&Fl06528 Smith, Kline & French HIV infection Soluble T4 Laboratories (Philadelphia, PA) Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ) Tumor Necrosis Genentech ARC, in combina-l~ Factor; TNF (S. San Francisco, tion w/gamma CA) Interferon Anti-Infectives Clindamycin with Upjohn PCP
Primaquine (Kalamazoo, MI) Diflucan Pfizer cryptococcal Fluconazole (New York, NY) meningitis, candidiasis Pastille Squibb Corp. prevention of Nystatin Pastille (Princeton, NJ) oral candidiasis 20 Ornidyl Merrell Dow PCP
Eflornithine (Cincinnati, OH) W094/02626 2 1 3 ~ 5 1 7 PCT/US93/06751 Dru~ Name Manufacturer Indication Pentamidine LyphoMed PCP treatment Isethionate (IM (Rosemont, IL) & IV) Piritrexim Burroughs Wellcome PCP treatment (Rsch. Triangle Park, NC) Pentamidine Fisons Corporation PCP prophylaxis isethionate for (Bedford, MA) inhalation Spiramycin Phone-Poulenc cryptosporidial Pharmaceuticals diarrhea (Princeton, NJ) Intraconazole- Janssen Pharm. histoplasmosis;
R51211 (Piscataway, NJ) cryptococcal meningitis Trimetrexate Warner-Lambert PCP
Other Recombinant ~uman Ortho Pharm. Corp. severe anemia Erythropoietin (Raritan, NJ) assoc. and Retrovir therapy 20 Megestrol Acetate Bristol-Myers treatment of (New York, NY) anorexia assoc.
w/AIDS
It will be understood that the scope of combinations of the antigenic conjugates of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS. The antigenic conjugates as AIDS or HIV vaccines of this invention include vaccines to be used pre- or post-exposure to prevent or treat HIV infection or disease, and are I0 capable of producing an immune response specific for the immunogen.
The compound L-697,661 is 3-([4,7-dichloro-1,3-benzoxazol-2-yl)methyl]amino)-5-ethyl-6-methyl-pyridin-2(1H)-one or pharmaceutically acceptable salt thereof. The compound L-696,229 is 3-t2-(1,3-benz-oxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one or pharmaceutically acceptable salt thereof. The compound L-735,524 is N-(2(R)-hydroxy-l(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide, or pharmaceutically acceptable salt thereof.
Biolo~ical Deposits The cell line producing "447 antibody", also known as 447-52D, is a Human x Human x Mouse Heterohybridoma cell line, which was deposited on or before 12 April 1991 at the American Type Culture Collection, Rockville, Maryland, under the requirement of a U.S. Patent Deposit.
W 0 94/02626 2~9517 PC~r/US93/06751 Library Construction A. Random Library A phage library containing random 15 amino acid epitopes was constructed by the methods of Scott, J.K. et al. Science 249, 386 (1990). In this protocol, synthetic 110 bp BglI fragments were prepared containing the degenerate coding æequence (NNK)15, wherein N stands for an equal mixture of lo G, A, T and C, and K stands for an equal mixture of G
and T. The library was constructed by ligating the synthetic 110 bp BglI fragments in phage fUSE5 and transfecting E. coli cells with the ligation product by electroporation.
The resulting phage oligopeptide epitope library (also known as Library ALPHA) had a complexity of approximately 40 x 106 different epitopes.
B. Semi Random Libraries In order to determine the influence of sequence which flanks GPXR (SEQ. ID N0: 123) on binding and ultimately on the induction of a 447 like antibody response, and to determine the influence of potential loop formation, the following libraries were constructed in the same manner as Example lA:
__W094/02626 2 ~ 3 9 S 1 7 PCT/US93/06751 LIBRARY Peptide Sequence Complexity SEQ. ID.
BETA xxxxxxxxxGPXRXX 92X106 124 GAMMA T.T.xxxxxGP~Rxxxxxl.T. 66X10 125 DELTA ~xxxxxGPXR~C 45X106 126 EPSILON ~xxxxxxxxxxxxxxC 200X106 127 X is any amino acid Library BETA consists of random polypeptide sequences around GP~R (SEQ. ID NO: 123); library GAMMA adds terminal leucines for potential loop formation;
library DELTA instead adds a terminal cysteine on each end for potential loop formation; library EPSILON is a control of any sequence with a cysteine loop.
Bead Coatin~ Procedure Polystyrene beads (d = 0.25 inch) were coated with between 1 and 10 ~g of 447 antibody per ml in 50 mM Na2 C03, pH 9.6, 0.02% sodium azide.
(Note that any solid phase adsorbent should work).
Beads were incubated in the antibody solution at 4C
overnight. The next day the coated beads were washed 3x with phosphate buffered saline and lx with water.
After washing, the antibody-coated beads were air dried and stored frozen at -20OC until needed.
Before use, the antibody-coated beads were coated with 10 mg/ml BSA (to block free sites on the plastic) in TTBS (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% (v/v) Tween 20) for 4 or more hours. Each batch of beads was checked for antibody activity by its ability to bind l25I protein A, before being used in a phage selection screen.
Stringent PhaPe Selection with Antibody-Coated Beads A. First Method-Low Strin~ency The random epitope phage library ALPHA was incubated at 4C overnight with gentle rocking, with antibody-coated beads in TTBS, l mg/ml BSA.
Typically, a total volume of lcc containing about lOll total phage was used. The next day the bead, containing bound phage, was washed lO to 12 times in TTBS, in a volume of lOcc per wash, at room temperature, with a gentle rocking motion, for lO
minutes per wash. The liquid was carefully drained off the bead between each wash. After the last wash the bound phage were eluted off the bead by incubating for 5 minutes at room temperature in a minimal volume (typically 200 ~l) of O.lN HCl, adjusted to pH 2.2 with glycine, lmg/ml BSA. The solution with the eluted phage was neutralized by adding 12 ~l of 2M Tris, pH unadjusted, per 200 ~l phage solution. The eluted phage were then used to infect E. coli K9lK cells. Infected cells were plated onto LB agar plates containing 40 ~g/ml tetracycline. Since the phage carry a tetracycline resistance marker, only infected cells grow on the plates. Typically, one bead selected between 5000 and lO0,000 independent phage.
_ ~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 B. Second Method-HiEh Strin~ency The random epitope library or semi-random library was incubated at 4C overnight with gentle rocking, with antibody-coated beads in TTBS, l mg/ml BSA. Typicallyi a total volume of lcc containing on 5 the order of lO total phage was used, corresponding to the complexity of the library 2 lO00. The next day the bead containing the bound phage was washed lO times in TTBS, in a volume of lOcc per wash, at 65C, with gentle rocking, for lO
minutes per wash. Note that 65C in TTBS does not destroy phage. There followed one wash at room temperature in TTBS pH 4Ø The liquid was carefully drained off the bead between each wash. Next, the bound phage were eluted off the bead by incubating for 5 minutes at room temperature in 200 ~l of O.lN
HCl, adjusted to pH 2.2 with glycine, l mg/ml BSA.
The phage solution was neutralized by adding 12 ~l of 2M Tris, pH unadjusted. The eluted phage were then used to infect E. coli K9lK cells. Infected cells were grown in l x Luria broth containing 40 ~g/ml tetracycline (250 cc) and incubated with shaking for 48 hours at 37C. Phage were harvested and precipitated twice with PEG (polyethylene glycol). The precipitated phage were then titered 2s and approximately lOlO of the first round selected phage were again incubated with a 447-antibody coated bead, washed as described above, regrown and harvested. Three cycles of selection and growth were performed. E. coli infected with phage were plated as clonal isolates.
2139517 ` ~ 74 Screening of Selected Phage with Antibody Lifts After l or more rounds of selection according to Example 3, the infected E.coli colonies were screened for the ability to bind 447 antibody (using the same antibody as used to select the phage). This was done by growing the plates until the colonies reached a diameter of one to four mm, placing nitrocellulose disks onto the plates, lifting the disks and placing them in a solution of 10%
evaporated milk, TTBS for 4 or more hours. After lifting, the plate containing the infected colonies were regrown for several hours at 37C and placed at 4C until needed. The nitrocellulose disks, at the end of 4 or more hours in the solution of 10%
evaporated milk and TTBS, were washed 2-3x in TTBS
and placed in TTBS and 1% milk and 0.5 to l ~glml antibody solution. They were then incubated at 4C
overnight with gentle rocking. After incubation in the antibody solution, the disks were washed 4x in lOOcc TTBS for 20 minutes with gentle rocking. They were then incubated in TTBS and 1% milk and Il25 protein A (.5 to l ~ curie/ml) for l-l/2 to 3 hours. The disks were again washed 4x in lO0 cc TTBS
for 20 minutes. They were placed on X-ray film for 12 to 72 hours. The film was developed and colonies corresponding to dark spots were picked. If the plates were too dense to pick isolated colonies, the picked colony(ies) was replated at a lower density and the screen repeated to get clonal isolates.
_ W094/02626 2 1 3 9 5 1 7 PCT/US93/06751 PCR Sequencin~
Phage infected E. coli K9lK cells were grown overnight at 37C in lx Luria broth, 40 ~g/ml tetra-cycline on a rollerdrum. The cells were pelleted and 1 ~1 of æupernatant was used as the template in PCR
reactions. The template was amplified using a 100-fold excess of one primer over the other.
Template and oligonucleotide primers (Primer 1008:
5'-TCG AAA GCA AGC TGA TAA ACC G-3' SEQ ID N0:129, located 106 nucleotides upstream of random insert and Primer 1009: 5'-ACA GAC AGC CCT CAT AGT TAG CG-3' SEQ
ID N0 130, located 87 nucleotides downstream from random insert) were reacted in a volume of 100 ~1 containing 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM
MgC12, O.01% (w/v) gelatin, 200 ~M each dNTP, and 2.5 units Taq polymerase. Reactions were overlaid with mineral oil and amplified in a thermal cycler for an initial 8 minute 94C incubation, then 30 cycles of 30 seconds at 94C, 1 minute at 55C and 2 minutes at 72C followed by a 5 minute incubation at 72C. The mineral oil was removed, 2 ml of water added to the reactions, and the sample centrifuged in a microconcentrator for 30 minutes at 1000 x g. The retentate volume was brought to 2 ml with water and centrifuged as above. The retentate was then collected by centrifugation for 2 minutes at 500 x g. Retentate concentrations were determined by electrophoresis on a 1% agarose gel containing 0.5 ~g/ml Ethidium bromide and visualization under W094/02626 2 1 3g 5 17 PCT/US93/067~1 _ ultraviolet light. The retentate was dried along with enough limiting primer from PCR reaction (or internal primer 1059-5'GTA AAT GAA TTT TCT GTA TGA GG
3' SEQ. ID N0:128 located 27 nucleotides downstream from insert) to give a 5:1 primer:template molar ratio. The DNA/primer mixture was resuspended in 8~1 water and 2~1 Tris-Buffer (200 mM Tris HCl, pH 7.5, 100 mM MgC12, 250 mM NaCl) Kit). The primer and template were annealed, and chain-termination sequencing reactions were set up. A 6% sequencing gel was run at 60 watts for approximately 1 hour and 30 minutes. The gel was dried and exposed to X-ray film overnight, and the sequence determined.
SPNE-pIII-(His~6Fusions The HIV/pIII fusion was expressed in E. Coli using the T7 polymerase system from Rosenberg, A.H.
et. al., Gene 56, 125 (1987). The plasmid pET-3a (commercially available from Novagen, Madison, WI) was digested with Xba I and BamHI and the 5 kb vector fragment isolated. The isolated vector fragment was ligated with the Xba I,BgI II-digested HIV/pIII
fusion prepared by polymerase chain reaction (PCR) of the candidate HIV fuse phage clones.
Two synthetic DNA oligomers were used to amplify a portion of the phage pIII gene (including the HIV sequences) and append sequences which permit _~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 efficient expression and purification of the pIII
product. The first synthetic DNA oligomers, 5' CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCCGACG
GGGCT 3' (Seq ID No: 131), has homology with the fuse phage pIII gene with sequences encoding the mature amino terminus of Ala-Asp-Gly-Ala. PCR amplification from this site incorporates sequences encoding the mature pIII protein, and rebuilds the pET-3a vector from the Xba I site to the initiating methionine.
The second synthetic DNA oligomer, sequence 5' CTCAGATCTATTAATGGTGATGGTGATGATGTATTTTGTCACAATCAA-TAGAAAATTC 3' (Seq ID No.: 132) encodes the reverse strand of the carboxyl-terminal portion of pIII
ending with residues Cys-Asp-Lys-Ile (Seq ID No:
133). PCR with this oligo rebuilds the fuse phage lS pIII gene up to the transmembrane domain and appends six histidine residues to the carboxyl-terminal isoleucine. The presence of the histidine residues facilitates purification of the pIII fusion protein by metal chelation chromotography tHochuli, E. et al., J. Chromat. 411, 177 (1987)] using nitrilotriacetic acid (NTA) resin (available from Qiagen, Chatsworth, CA).
Expression of the pIII fusion is obtained by transforming the expression plasmid into E. coli strain ~L21 (DE3) [Rosenberg, A.H. et al., supra;
U.S. Patent 4,952,496; Steen, et al., EMB0 J 5, 1099 (1986).] This strain contains the T7 phage RNA
polymerase gene under control of the lac operator/promoter. Addition of isopropylthiogalactoside (IPTG) at culture OD6oo=0.6-0.8 induces T7 RNA polymerase expression 2`3q~\~
W 094/02626- ` PC~r/US93/067~1 _ which transcribes pIII mRNA to high levels. This RNA
is translated yielding pIII fusion protein which is harvested 3-4 hours post-induction and chromatographed on NTA resin.
E} ~ LE 7 Synthesis of Selected Oli~opeptide The oligopeptide LLRTIMIGPGRLLHS (SEQUENCE
lo ID. NO. 23, hereinafter 473) was selected for immunological characterization. It was synthesized by the solid-phase method.
Extraction and Purification of OMPC
A. First Method All materials, reagents and equipment were sterilized by filtration, steam autoclave or ethylene oxide, as appropriate; asceptic technique was used throughout.
A 300 gm (wet weight) aliquot of 0.5% phenol inactivated cell paste of Meningococcal group Bll was suspended in 1200 mls of distilled water then suspended by stirring magnetically for 20 minutes at room temperature. The suspended cells were pelleted at 20,000 xg for 45 minutes at 5C.
For extraction, the washed cells were suspended in 1500 mls 0.1 M Tris, 0.01 M EDTA Buffer pH 8.5 with 0.5V/o sodium deoxycholate (TED Buffer) and homogenized with a 500 ml Sorvall omnimixer at _ W094/02626 2 ~ 3 9 517 PCT/US93/06751 setting 3 for 60 seconds. The resulting suspension was transferred to ten Erlenmeyer flasks (500 ml) for extraction in a shaking water bath for 15 minutes at 56C. The extract was centrifuged at 20,000 x g for 90 minutes at 5C and the viscous supernatant fluid was decanted (volume = 1500 mls). The decanted fluid was very turbid and was recentrifuged to clarify further at 20,000 x g for 90 minutes at 5C. The twice spun supernatant fluid was stored at 5C. The extracted cell pellets were resuspended in 1500 mls TED Buffer. The suspension was extracted for 15 minutes at 56C and recentrifuged at 20,000 x g for 90 minutes. The supernatant fluids which contained purified OMPC were decanted (volume = 1500 mls) and stored at 5C.
B. Second Method All material, reagents, equipment and filters were sterilized by heat, filtration or ethylene oxide. One e~ception was the K-2 ultracentrifuge which was sanitized with a 0.5%
formalin solution. Laminar flow canopies provided sterility protection during equipment connections.
Aseptic techniques were followed throughout the entire operations. Overnight storage of the protein was at 2-8C between steps. A 0.2 micron sterile filtration was conducted just before the final diafiltration to ensure product sterility.
Two 600-liter batches of Neisseria meningitidis were fermented and killed with 0.5%
phenol, then concentrated to roughly 25 liters using two 10 ft2 0.2 micron polypropylene cross-flow W094/02626 PCT/US93/06751 _ 2~395~
filtration membranes. The concentrated broth then was diafiltered with 125 liters of cell wash buffer (0.11 M Sodium Chloride, 17.6 mM Sodium Phosphate Diabasic, 23.3 mM Ammonium Chloride, 1.34 mM
Potassium Chloride, adjusted to pH 7 with 85%
Phosphoric Acid followed by 2.03 mM Magnesium Sulfate Heptahydrate).
For extraction, an equal volume of 2X-TED
buffer (0.2M Tris, 0.02M EDTA adjusted to pH 8.5 with concentrated HCl followed by the addition of 1.0%
sodium deoxycholate) was added to the cell slurry.
The resulting slurry was heated to 56% 3C and maintained at this temperature for 30 minutes to complete the extraction of OMPC from the cells.
For further purification, the extracted cell slurry was centrifuged at 30,000 x g (18,000 rpm) in a "one-pass" flow mode in a K-ultracentrifuge, and the supernatant stream was collected. The low-speed supernatant was concentrated to 10 liters on two 0.1-micron polysulfone autoclavable hollow-fiber membranes and collected in an 18 liter sterile bottle. The filtration equipment was given two 4-liter rinses with TED buffer (O.lM Tris, 0.01M
EDTA, adjusted to pH 8.5 with concentrated HCl, followed by the addition of sodium deoxycholate to 0.5%) which was combined with the retentate. The retentate was subdivided into two or three equal parts. Each part was centrifuged at 80,000 x g (35,000 rpm) for 30 minutes. The OMPC protein was pelleted, and the majority of soluble proteins, nucleic acids and endotoxins remained in the supernatant. The supernatant was discarded. The _ W094/02626 2~ 3 95 1 7 PCT/US93/06751 pelleted protein was resuspended by recirculating 55% 5C TED buffer through the rotor. The first high-speed resuspensions were combined and subjected to a second low-speed spin. The second low-speed spin ensured that residual cell debris was removed from the product stream. The second low speed supernatant was subdivided into two or three equal parts. Each fraction was given two consecutive high-speed spins. All high-speed spins were operated under the same conditions and each further purified io the OMPC protein.
For sterile filtration and final diafiltration, the third high-speed resuspensions were diluted with an equal volume of TED buffer and filtered through a 0.2 micron cellulose acetate filter. When all fractions were permeated, an 8 L
TED buffer rinse was used to flush the filtration system. The permeate and rinse were combined and concentrated to 3 liters on a 0.1 micron polysulfone autoclavable hollow fiber membrane. The material then was diafiltered with 15 liters of sterile pyrogen free water. The retentate was collected in a 4-liter bottle along with a l-L rinse to give the final product. The final aqueous suæpension was stored at 2-8C, as purified OMPC.
C. Third Method OMPC is purified from 0.2 M LiCl-O.lM Na Acetate, pH 5.8, extracts by ultracentrifugation, by the method of C.E. Frasch et al. J. Exp. Med. 140, 87-104 (1974).
wog4~o2626 ~395~ PCT/US93/06751_ Oligopeptide 473 was conjugated to OMPC by the co-conjugation method of EPO467700 of Leanza, W.J. et al., to give 473-OMPC conjugate, as follows:
A. Thiolation of OMPC:
OMPC (43.4 mg, 10 mL) was pelleted by ultracentrifugation (43K rpm, 2h, 4C). The pellet was resuspended in a sterile filtered (0.22~m) solution which consisted of: pH 11, 0.1 M borate buffer (4 mL), N-Acetyl homocysteine thiolactone (45 mg), DTT (15 mg), and EDTA (85 mg). The resulting solution was degassed and purged with nitrogen (process repeated 3x) and stored under N2 overnight at room temperature (17 h). The thiolation mixture was transferred to a centrifuge tube and topped with pH 8.0, 0.1 M phosphate buffer (approximately 4.5 mL). The protein was pelleted via ultracentrifugation, resuspended (after homogeniz-ation) in pH 8.0, 0.1 M phosphate buffer, and repelleted by ultracentrifugation. This pellet was resuspended in lX TED buffer, wtih a total resuspension volume of 7.0 mL. An Ellman's analysis on this solution (100 ~L) revealed that it contained 0.961 ~mol SH/mL solution (6.72 ~mol SH total, 0.15S ~mol SH/mg OMPC used).
B. Conjugation:
The beta-maleimidopropionyl peptide (5.8 ~mol) was dissolved in acetonitrile (1.0 mL) giving Solution P. A solution of beta-maleimidopropionic _ ~094/02626 2 1 3 9 5 1 7 PCT/US93/06751 acid (5.5 ~mol) in water (l.o mL) was prepared, which is Solution M.
Thiolated OMPC (6.0 mL, 5.77 ~mol), which was prepared in step A, was transferred to a sterile 15 mL centrifuge tube. This solution was vortexed and solution M (420 ~L, 2.31 ~mol) added. The mixture was stirred briefly and allowed to age at room temperature (10 min). Negt, the reaction mixture was vortexed and solution P (596 ~L, 3.46 ~mol) added. The reaction migture was vortexed briefly and allowed to age at room temperature for 2 h.
The conjugate was spun in a clinical centrifuge to remove any precipitated material. The supernatant was removed and the conjugate was pelleted by ultracentrifugation (43K rpm, 2 h, 4C).
The pellet was resuspended in TED buffer (total volume 6.5 mL), affording 473-OMPC conjugate.
Lowry Protein Assay: 3.04 mg/mL
Amino Acid Analysis:
Lys: 835 nmol/mL
Beta-Ala: 157 nmol/mL
Nle: 175 nmol/mL
Loading (Based on Nle): 58 nmol peptide/mg OMPC
Loading % (w/w%; Based on Nle): 11%
~l395l7 W O 94/02626 - . P(~r/US93/06751 Immunization Protocol for 473-OMPC conjugate Four New Zealand white rabbits (2 to 2.5 kg) were immunized with the peptide 473-OMPC conjugate vaccine (the vaccine) in the following manner: For time zero inoculations the vaccine was formulated into complete Freund's adjuvant (CFA) tl:l(v/v) of CFA and 600~g/ml of conjugate in saline]. Each dose (1.0 ml) consisted of a total of 300 ~g of vaccine.
Each rabbit was inoculated with the vaccine preparation at two sites, by intra-muscular (im) injection, in the upper hind leg. Two booster inoculations were given to each rabbit at week 4 and week 8 post initial injection. The vaccine for these booster injections was formulated into incomplete Freund's adjuvant. Each dose also consisted of a total of 300 ~g of vaccine.
Each rabbit was bled and sera was prepared by standard methods for anti-peptide ELISA tests (Example 10) and anti-HIV neutralization tests (Example 11). Sera collected represent time zero and biweekly intervals through week 14.
Measurement of Antibody Responses in Rabbits Immunized with 473-OMPC Conjugate Vaccine (ELISA).
Elicited anti-peptide antibody responses in vaccinated rabbits were determined by the use of an _ ~094/02626 2 1 ~ 9 5 1 ~ PCT/US93/06751 enzyme-linked immunoadæorbent assay (ELISA). In this assay, microtiter plates were coated with about 0.5 ~g peptide 473 per well using an overnight incubation of peptide solution at 36C in a humidified atmosphere.
Elicited anti-HIV isolate MN specific antibody responses were measured by the use of an anti-peptide 402 ELISA assay. In this assay the 402 peptide (primary sequence = NleCYNKRKRIHIGPGRA~YllKNlIGC, SEQ. ID. NO. 122, with disulfide bonding between the two C residues) was the coating peptide. Peptide 402 is a cyclic representation of the ~IV isolate MN
gpl20 V3 loop sequence.
For 473 ELISA tests, titers were determined with 0 time and weeks 2, 4, 6, 8, 10, 12 and 14 sera.
See Table I. For 402 ELISA tests, titers were determined for weeks 10, 12 and 14 sera. See Table II, in which the ELISA antigen is 402 instead of 473.
Test sera were diluted 5-fold serially, were reacted for 1 hr with the peptide adsorbed wells, and were washed extensively. Positive results were identified after reactions of phosphatase-conjugated goat anti-rabbit sera with each well for 1 hr at 36C, washing and the addition of a solution of 1.0 mg/mL
p-nitrophenyl phosphate (pNPP) in 10% diethanolamine, 0.5 mM MgC12 (pH 9.8) to each well. This last 2S reaction proceeded for 30 minutes at room temperature and was stopped by addition of 3.0 _ NaOH. Absorbance at 405 nm was determined by using a plate reader.
-W 0 94/02626 ~ 13~ 5 17 PC~r/US93/06751 Measurement of Virus Neutralizin~ Antibody Responses Elicited in Rabbits Immunized with 473-OMPC ConjuPates.
Neutralization of Infectivity in MT-4 Cells in vitro: For neutralization tests 2-fold serial dilutions of sera were made and 100 ~L volumes were used in each test well in 96 well culture plates.
All sera were heat inactivated before use. Generally 1:10 was the starting dilution of sera. An aliquot of 100 ~L virus stock dilution was added to each test well. The HIV isolates used to determine virus neutralization by anti-473 rabbit sera were IIIB, MN, SF-2, AL-l and WMW-2. The virus-antisera mixtures were incubated at 37C for 1 hr after which 1 x 104 MT-4 cells in 50 ~L of culture medium were added to each well and the cultures were incubated for 7 days. The level of neutralization was determined by using the MTT dye reduction readout. MTT was added to each well to 500 ~g/mL, incubated at 37C for 2 hr, and solubilized after addition of acid-isopro-panol (0.04N HCl in isopropanol) to approximately 50%
of the volume of each well. A clearly distinguishable bluish-purple color develops in wells containing viable cells that are protected from infection due to virus neutralization by anti-473 antibody whereas wells containing MT-4 cells killed by the infection remain yellow. The neutralization endpoints were determined as the last dilution of antisera preparation that prevents cell killing. Uninfected _ NO94/02626 21~ g ~1 7 PCT/US93/06751 MT-4 cells were cultured with each test and a virus retitration was performed with each analysis.
For results, see Tables IIIA and IIIB.
Table IIIA contains the neutralization data obtained in experiments using isolates MN, AL-l (Alabama) and SF-2. Table IIIB contains that for WMJ-2 and lO week only for isolate IIIB. Values given represent the reciprocal of the endpoint dilution.
1'0
6 2, ¦ 3 g 5 PCI`/US93/06751 TABLE I
Anti-473 peptide ELISA titers after vaccination with 473-OMPC.
Anti-Deptide ELISA titers ~ * Weeks 0 2 _ - 8 10 12 14 1 <ZO <20500 Z,500 2,50062,50062,50062,500 Rabbits 2 <20<20 2,500 12,5002,50012,500 62,500 12,501 3 <20 1002,50062,50062,50062,50062,500312,500 4 <20 5002,50012,50012,50012,50012,50012,500 15NOTE: Asterisks indicate the times of inoculation. All values are given as the reciprocal of the endpoint dilution.
TAOLE II
Anti-402 peptide ELISA titers after vaccination with 473-OMPC.
25Anti-402 ELISA titers ~ ~ Weeks 0 2 4 ~ 8 10 12 14 Rabbits 2 500 50 100 3 <100 <20 <20 4 12,500 12,500 12,500 ~VO 94lO2626 2 1 3 9 5 1 7 PCI`/US93/06751 TABLE IIIA
In Vitro Neutralization by Anti 473-OMPC Sera.
MN Neutralization ~ ~ Weeks P 2 _ 6 8 10 12 <10 <10 <10 Rabbits Z <10 <10 <10 3 <10 <10 <10 4 <10 <10 <10 Alabama Neutralization l 5 ~ ~ Weeks 0 2 - 6 _ 10 12 <10 <10 <10 Rabbits 2 <10 <10 <10 3 <10 <10 <10 4 <lO <lO 20 SF-Z Neutralization ~ ~ Weeks 2 5 o 2 _ 6 8 l 0 12 1<10 <10 80 Rabbits Z <10 160 160 3<10 <10 <10 4<lO <lO 80 W094/02626 213~17 PCr/US93/06751_ TABLE IIIB
In Vitro Neutralization by Anti 473-OMPC Sera.
WMJ-Z Neutralization ~ ~ Weeks p 2 _ 6 8 10 12 <lû <10 <lû
Rabbits Z <10 <10 <10 3 <10 <10 <10 4 <10 <10 <10 IIIB Neutralization ~ ~ ~eeks û 2 _ 6 8 10 12 <10 <10 Rabbits 2 <10 <10 3 <10 <10 4 <10 <10 ~hile the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptions, and modifications, as come within the scope of the claims and its equivalents.
~.VO94/02626 2 1 39 ~1~ PCI/US93/06751 SEQUENCE LISTING
(l) GENERAL INFORMATION:
(i) APPLICANT: P. Keller, A.J. Conley, A.R. Shaw, B.A. Arnold (ii) TITLE OF INVENTION: Immunological Conjugates of OMPC and HIV-Specific Selected Principal Neutralization Epitopes (iii) NUMBER OF SEQUENCES: 146 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Merck & Co., Inc.
(B) STREET: P.O. Box 2000 (C) CITY: Rahway (D) STATE: NJ
(E) COUNTRY: USA
(F) ZIP: û7065 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFT~ARE: PatentIn Release #l.0, Version #l.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(c) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Meredith, Roy D.
(B) REGISTRATION NUMBER: 30,777 (C) REFERENCE/DOCKET NUMBER: l86l4 (ix) TELECOMMUNICATION INFORMATION:
2 5 (A) TELEPHONE: (908) 594-4678 (B) TELEFAX: (908) 594-4720 (C) TELEX: l38825 W O 94/02626 2 ~ PC~r/US93/06751 _ ~2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Pro Arg Leu Glu Thr His Phe Gly Pro Lys Arg Ser His Val Gly 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (5) TYPE: amino acid (C) STP.AI;JEu.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Trp Arg Leu Gly Pro Gly Arg Gly Ser Met Pro Cys Arg Leu Gly 213~517 _ ~0 94/02626 PC~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Gln Gly Leu Leu Arg Val Leu Tyr Ala Phe Gly Pro Gly Arg Val (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Val Leu Val Trp Gln Arg Lys Val Phe Phe Gly Pro His Arg Ser 1 5 lû 15 WO 94/02626 2 1 39 5 17 PCI`/US93/06751 _ -- 94 _ (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Arg Ser Ser Ser Trp Ala Trp Arg His Leu Tyr Gly Pro Ala Arg ~5 (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:6:
His Ser Gln Ala Val Lys Phe Gly Pro Gly Arg Thr Leu Val Pro 1 5 1~ 15 . JVO 94/02626 213 9~17 PCI /US93/06751 (2) INFORMATION FOR SEQ ID NO:7:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Trp Asp Arg Gly Asn Ser Ser Gly Arg His Leu Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:8:
lS
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii~ MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Asp Leu Gln Ala Arg Ser Lys Thr Tyr Phe Tyr Gly Pro Gly Arg WO 94/02626 ~ 1'3 9 5 ~ ~ PCr/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:9:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:JEL.ICSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Thr Trp His Leu Arg Val Arg Gly Ala His Phe Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Trp Leu Arg Val Leu Leu Gly Pro Ala Arg Pro Ile Tyr Trp Arg _-'VO 94/02626 ~13 9 ~17 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:ll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANJE~.:[SS: single (D) TOPOLOGY: linear (i;) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll:
Leu Leu Leu Gly Pro Ala Arg Ala Pro Val Arg Val Asn Leu Ala (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (P) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Cys Lys Pro Arg Ala Pro Met Leu Phe Gly Pro Ala Arg Gly Leu ~3~ PCI/US93/06751_ (Z) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
lD (vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Leu Leu Leu Ile Gly Pro Gly Arg Glu Leu Arg Pro Ile Asn Leu (2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~uN~SS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Val Phe Lys Val Ile Asn Arg Ile Leu His Tyr Gly Pro Asn Arg ~-VO 94/02626 2 1 39 ~ 1 7 PCr/US93/06751 (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi~ IMMEDIATE SOURCE: Random Epitope Library Alpha (xi~ SEQUENCE DESCRIPTION: SEQ ID NO:15:
Phe Phe Tyr Gly Pro Gly Arg Tyr Pro Pro Arg Phe Lys Leu Gly (2) INFORMATION FOR SEQ ID NO:16:
(i~ SEQUENCE CHARACTERISTICS:
(A~ LENGTH: 15 amino acids (B~ TYPE: amino acid (C~ STRANJEu.;_SS: single (D~ TOPOLOGY: linear (ii~ MOLECULE TYPE: peptide (iii~ HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi~ IMMEDIATE SOURCE: Random Epitope Library Alpha (xi~ SEQUENCE DESCRIPTION: SEQ ID NO:16:
Asp Val Gly Trp Val Thr Gly Thr Gln His Tyr Gly Pro Arg Arg W094/02626 al3~5~ PCI/US93/06751_ _ 100 --(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Gly Leu Tyr Thr Cys Met Tyr Gly Pro Ser Arg His Ile Cys Val (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Cys Ala Thr Ser Ile Gly Gly Val Leu Phe Gly Pro Gly Arg Gly _~0 94/02626 ~1 3~ 1 7 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:l9:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
Trp Arg Met Met Leu Gly Pro Gly Arg Asp Tyr Ala Gly Pro Ala (Z) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Thr Glu Leu Gly Arg Gly Tyr Ile Ser His Gly Pro Ala Arg Gly WO94/02626 ~139S11 PCI/US93/06751_ , (2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: s;ngle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Arg Ile Arg Leu Pro Arg Gly Pro Gly Arg Pro Gln Thr Thr Met 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:22:
His Leu Gly Pro Ser Arg Gly Ala Asn Leu Gly Lys Ile Gly Ala _NO 94/02626 2 ~ 3 9 5 1 7 PCr/US93/06751 ~2) INFORMATION FOR SEQ ID NO:Z3:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Leu Leu Arg Thr Ile Met Ile Gly Pro Gly Arg Leu Leu His Ser (2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Leu His Val Gly Pro Asn Arg Gly Lys Ser Glu Asp Asn Tyr Arg WO 94/02626 2 1 39 5 17 PCI/US93/06751 ~
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Gly Gln Ile Ile Phe Ile Gly Pro Gly Arg Leu Gly Asn Gly Glu 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (F) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
Leu Gln Leu Leu Ile Gly Pro Gly Arg Thr Val Gly Lys Ile Arg _,WO94/02626 213g~1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIA7E SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:Z7:
Phe Tyr Thr Ser Gly Lys Thr Ile Phe Tyr Tyr Gly Pro Arg Arg (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2~:
Thr Lys Ile Gly Pro Gly Arg Val Phe Asp Gly Arg Trp Arg Phe W0 94/02626 ~ 1395~ PCI/US93/06751 . _ _ 106 -(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:J~u.lESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
Ala Cys Trp Ser Arg Glu Tyr Gly Pro Ala Arg Met Ser Cys Thr (2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEuNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:30:
Ile Leu Phe Gly Pro Gly Arg Cys Ser Val Asp Ala Val Ser Gly _~0 94/02626 ~1 3951 7 PCI/US93/06751 _ 107 --(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino ac;d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
Tyr Leu Ala Met Arg Gly Ala Gly Tyr Met Ile Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEuN_SS: single 2 0 ( D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Asn Cys Ser Val His Val Gly Ala Gly Arg Asn Ser Ala Trp Cys WO 94/02626 2 1~ 9 S ~ ~ PCI/US93/06751` _ _ 108 -(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Asn Arg Tyr Gly Pro Gly Arg Val Gly Phe Val Arg Ser Gln Pro (2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i J MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:34:
Ala Arg Gly Trp Gly Gly Val Phe Tyr Gly Pro Gly Arg Gly Glu _ ~VO 94/02626 2 1 ~ 9 5 1 7 PC~r/US93/067~1 (2) INFORMATION FOR SEQ ID NO:35:
~ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAl:J~u.lCSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Tyr Gly Arg Phe Ser Phe Gly Pro Gly Arg Gly Tyr Met Val Ile (2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Tyr Tyr Tyr Arg Asn Val Leu Val Gly Pro Gly Arg Trp Trp Leu WO 94/02626 PCI/US93/06751 `~
213~3517 _ 110 --(2) INFORMATION FOR SEQ ID NO:37:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
Trp Ser Trp Val Arg Leu Lys Ala Val Leu Leu Gly Pro Ser Arg (2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STpAllJ~uN~ss: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:38:
Arg Phe Gln Glu Gly Gln Lys Val Leu Val Gly Pro Gly Arg Arg _ WO 94/02626 2 1 3~ ~1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
Ser Cys Met Thr Ser Val Leu Val Gly Pro 61y Arg Gln Asp Asn (2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:40:
Gly Ile Leu Arg Gln Pro Leu Leu Ile Gly Pro Gly Arg Ala Pro W094/02626 dl3 9~1 ~;L PCI/US93/06751._ 2) lNFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
Trp Asp Thr Leu Gly Trp Val Val Ser Asn Phe Gly Pro Gly Arg (2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~u.:ESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:42:
Val Leu Arg Cys Phe Gly Pro Leu Arg Asp Ala Arg Cys Ser Val _WO94/02626 ~1 39~jI~ PCI/US93/06751 -- 113 _ 35(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
Gln Ile Trp Tyr Phe 61y Pro Gly Arg Ser Gln Ser Gly Ser Met (2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~u.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
Leu Met Val Val Gln Val Gly Pro Ala Arg Thr Phe Leu Gln Gly lû 15 ~1 3951 ~
(Z) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:JEu.lCSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
Gly Pro Ser Leu Phe Asn Ser Gly Val Arg Tyr Gly Pro Lys Arg 1 5 1~ 15 (2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;l_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
Val His Phe Ile Gly Pro Gln Arg Gly Gly Asn Ser Ser His Leu 2 1 3 q~5 1 ~
~'V0 94/02626 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS: -(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:Jtu.;_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: 'EQ ID NO:47:
Pro Tyr Ser Asp Leu Leu Leu Ser Lys Tyr Phe Gly Pro Gly Arg (z) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANu~u.;_~S: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:48:
Leu Asp Gln Tyr Arg Val Leu Leu Trp Gly Pro Gly Arg Thr Thr WO94/02626 ~ 1 3q5 1~L PCI`/US93/067SI_-(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
Val Leu Lys Ile Leu Arg His Ala Tyr Phe Gly Pro Gly Arg Trp (Z) INFORMATION FOR SEQ ID NO:5û:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:50:
Val Arg His Met Gly Pro Gly Arg Gly Met Val Leu Gly Ile Thr _ ~V0 94/02626 2,1 3 g 5 ~ 7 P(~r/US93/0675 (2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
Asn Tyr Phe 61y Pro Gly Arg Gly Gly Val Val Val Thr Gly His (2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (O) TYPE: amino acid (C) STRAI;JE~ SS: single (D) TOPOLOGY: linear 2 0 (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:52:
Gln Val Phe Gly Pro Gly Arg Thr Asn Pro Arg Ser Asn Leu Leu W O 94/02626 PC~r/US93/06751 _ 213gS17 (2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
Met Glu Arg Asp Leu Val Arg Phe Gly Pro Asn Arg Asp Trp Arg (2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STPAI:JEu.. sS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
Asn Gly Leu Lys Leu Cys Arg Val Gly Pro Ser Arg Glu Gly Cys _~VO 94/02626 21 395 1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:55:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANJE~.:CSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:SS:
Phe Asp Gly Gl n Ser Lys Val Val Leu Arg Gl y Pro Gly Arg Gl y (2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1 i near 2 0 ( i i ) MOLECULE TYPE: peptide ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:56:
Pro Val Lys Phe Gly Pro Gln Arg Ser Gly Gly Ala Thr Arg Pro WO 94/02626 al39$ 17 PCr/US93/06751`
2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
Ile Thr Pro Arg Leu Tyr Gly Pro Ser Arg Met Arg Tyr Asn Gln (2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: consensus peptide for seq. Id Nos. 1-57.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
Trp Asp Gly Leu Gly Trp Gln Ile Val His Phe Gly Pro Gly Arg Gly Gly Asn Gly Ile Asn Leu Gly Ala _~VO 94/02626 21 3 9 5 1 7 PCI/US93/06751 (Z) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
Asn Lys Arg Glu Phe Gly Pro Ala Arg Ala Ala Arg Asn Arg (Z) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:60:
His Arg Arg Asp Ile Gly Pro Ala Arg Thr Arg Glu Ile Gly WO 94/02626 2139517 PCI`/US93/06751`_ (2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
Gly Ala Gly His Val Gly Pro Gly Arg Tyr Gly Ala Leu Ser (2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
Ser Ala Val His Leu Gly Pro Gln Arg Gln Arg Ala Thr Asp _~VO 94/02626 æ~ 39 5 I7 PCI/US93/06751 2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI:J~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
Ser Thr Arg His Leu Gly Pro Gly Arg Val Glu Gly Val Leu 1 5 lû
(2) INFORMATION FOR SEQ ID NO:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LEN6TH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
Gly Val His Arg Phe Gly Pro Gly Arg Gly Glu Gly Met Val W094/02626 al39si7 PCI/US93/067Sl~
_ lZ4 --(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: am;no acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
Gly Gly Tyr His Trp Gly Pro Gly Arg Gly Ser Val Glu Ala lS (2) INFORMATION FOR SEQ ID NO:66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJE~ S: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:
Gln Ala Trp His Phe Gly Pro Gly Arg Asp His Gly Glu _~094/02626 21395t 7 PCr/US93/06751 (2) INFORMATION FOR SEQ ID NO:67:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:
Lys Ala Asn His Tyr Gly Pro Ser Arg Gly Pro Gly Ser Arg (2) INFORMATION FOR SEQ ID NO:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
Leu Leu Gly Pro Gly Arg Gly Ser Ser Ser Val Arg Gly Glu Leu lû 15 W O 94/02626 213951~ P(~r/US93/06751`_-(2) INFORMATION FOR SEQ ID NO:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAl:JEuN~SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
Ser Gly Trp Trp Gly Gly Val His Val Gly Pro Gly Arg Gly Thr (2) INFORMATION FOR SEQ ID NO:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:
Trp Ser Lys Arg Glu Ser Val Met Phe Gly Pro Gly Arg Gly Thr _ WO 94/02626 2 t 3 9 5~1 7 - i PCI`/US93/06751 _ lZ7 -(2) INFORMATION FOR SEQ ID NO:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
1~ (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:
Trp Asp Ser Arg Ala Thr Leu Arg Leu Gly Pro Gly Arg Ser Ser (2) INFORMATION FOR SEQ ID NO:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJEu.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:
Gly Lys Val Phe Tyr Gly Pro Gly Arg Glu Trp His Ala WO 94/02626 2 1 3 9 5 1 7 PCI`/US93/06751 _ 128 --(Z) INFORMATION FOR SEQ ID NO:73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:
Ala Arg Val Phe Leu Gly Pro Gly Arg Gly Val Val Tyr Asp lS (2) INFORMATION FOR SEQ ID NO:74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STP.ANJ~u.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:
Arg Val Gln Lys Leu Gly Pro Gly Arg Gln Thr Ala Ser Gly _ ~VO 94/02626 2 1 3 9 5 ~ 7 P(~r/US93/06751 2) INFORMATION FOR SEQ ID NO:75:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:
Lys Leu Gly Pro Gly Arg Gly Gly Tyr Phe Gly Ala Gln Val 1 5 lû
(2) INFORMATION FOR SEQ ID NO:76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI:JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:
Arg Lys Val Asn Ile Gly Pro Gly Arg Val His Gly Asn Ser WO94/02626 2139517 PCI/US93/067~1 (2) INFORMATION FOR SEQ ID NO:77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRal:JEu.;_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:
Arg Gly Val Lys Ile Gly Pro Gly Arg Ile Ala Ser Gly Tyr (2) INFORMATION FOR SEQ ID NO:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:
Lys Asp Leu His Ile Gly Pro Gly Arg Met Asp Gly Leu Arg _WO 94/02626 21 3q 5 1 ~ PCI'/US93/06751 -- 131 _ (Z) INFORMATION FOR SEQ ID NO:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:
Ala Gln Arg Ser His Leu Ile Gly Pro Gly Arg Ala Glu Thr Gly (2) INFORMATION FOR SEQ ID NO:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:
Lys Gln Val Arg Leu Gly Pro Ala Arg Gly Asp Ile Ile Gly (2) INFORMATION FOR SEQ ID NO:81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:
Arg Gln Val Met Leu Gly Pro Gly Arg Gly Asp Arg Leu Glu (2) INFORMATION FOR SEQ ID NO:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (x;) SEQUENCE DESCRIPTION: SEQ ID NO:82:
Arg Ser Val Leu Met Gly Pro Ala Arg Ser Thr Arg Val Val _.1VO 94/02626 2 1 3 9 5 1 7 ~ PCI/US93/06751 (Z) INFORMATION FOR SEQ ID NO:83:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: l;near (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:
Lys Phe Val Glu Leu Gly Pro Gly Arg Lys Gly Gln Gly (2) INFORMATION FOR SEQ ID NO:84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~L.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:B4:
Asp Arg Gly Ser Arg Phe Val Leu Leu Gly Pro Gly Arg Met Gly WO 94/02626 2 1 3 9 5`i 7 - PCI/US93/06751 _ _ 134 --(2) INFORMATION FOR SEQ ID NO:85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:
Glu Gln Leu His Arg Leu Val Ala Phe Gly Pro Gly Arg Ala Ala 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:
Leu Pro Ser Val Asn Leu Gly Pro Gly Arg Asn Ala Arg Lys Gly _ WO 94/02626 2 1 39S 1 ~7 - PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: am:no acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:
Gln His Arg Ala Ala Ser Val His Leu 61y Pro Ser Arg Ala Gly 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
Leu Met Phe Val Arg Val Val Lys Leu Gly Pro Ala Arg Val Pro W 0 94/02626 ~ 1 3 g S 1 7 . . PC~r/US93/067~1 _ (Z) INFORMATION FOR SEQ ID NO:89:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:
Tyr Gly Leu Val Ile Arg Cys Glu Val Gly Pro Ser Arg Ser Cys (2) INFORMATION FOR SEQ ID NO:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:
Arg Glu Leu His Met Gly Pro Gly Arg Ala Arg Pro Gly Phe _ WO 94/02626 2 13~ 17 PCI'/US93/06751 _ 137 --(2) INFORMATION FOR SEQ ID NO:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI;JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:
Cys Arg Val Asp Phe Gly Pro Gly Arg Leu Gly Ser Arg Thr (2) INFORMATION FOR SEQ ID NO:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:92:
Asn Val Val Ala Ile Gly Pro Gly Arg Ser Asn Val Val Thr W O 94/02626 21 3951 7 P(~r/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 am;no acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:
Lys Glu Val His Phe Gly Pro Gly Arg Gly Gly Gln Arg Ser (2) INFORMATION FOR SEQ ID NO:94:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (8) TYPE: amino acid (C) STRAI:J~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:
Xaa Xaa Tyr Leu Ile Gly Pro Gly Arg Gly Trp Glu Arg Glu _ WO 94/02626 2 1 395 l ~ PCr/US93/067~1 _ 139 -(2) INFORMATION FOR SEQ ID NO:9S:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:
Ala Gly Cys Gln Val Gly Pro Gly Arg Pro Xaa Cys Gly Lys ( 2) INFORMATION FOR SEQ ID NO:96:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:96:
Arg Glu Val His Phe Gly Pro Arg Arg Asp Glu Pro Gly Arg WO 94/02626 2 1 3 9 5 1 7 PCI/US93/06751 ._ _ 140 --(2) INFORMATION FOR SEQ ID NO:97:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: lineir (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:
Ile Gly Arg Asn Leu Gly Pro Gly Arg Val Val Ser Asn Val l 5 l0 (2) INFORMATION FOR SEQ ID NO:98:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:
Lys Asn Val His Val Gly Pro Gly Arg Gly Gln Arg Thr Val l 5 l0 _WO 94/02626 2 t 3 9 ~ 1 7 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:99:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i;) MOLECULE TYPE: peptide (iii? HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:
Arg Leu His Leu Val Gly Pro Ala Arg Val Ser Pro Leu Ser 15(2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
Ser Lys Val Glu Ile Gly Pro Gly Arg Gly Pro Leu Met Arg WO 94/02626 - ~ C PCI`/US93/06751 _ ~1395 1~
(2) INFORMATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
Ala Val Ile His Val Gly Pro Ser Arg Leu Lys Ser Gln Tyr 15(2) INFORMATION FOR SEQ ID NO:102:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJE~ SS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:
Gly Arg Ile Asn Tyr Gly Pro Gly Ala Pro Gly Leu Met _ WO 94/02626 2139~1 ~ PCI`/US93/06751 _ 143 -(2) INFORMATION FOR SEQ ID NO:103:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 a0ino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:
Glu Val His Tyr Tyr Gly Pro Gly Arg Arg Ala Pro Ala Ser ~2) INFORMATION FOR SEQ ID NO:lû4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:
Val Glu Arg His Leu Gly Pro Gly Arg Gly Leu Gln Met Gly WO 94/02626 21~9517 PCI/US93/06751 _ _ 144 --(2) INFORMATION FOR SEQ ID NO:105:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:
Asn Ser Phe His Leu Gly Pro Gly Arg Ser Arg Thr Tyr Ser (2) INFORMATION FOR SEQ ID NO:106:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:106:
Gly Val Val Lys Leu Gly Pro Gly Arg Thr Ala Gly Lys Leu _ W0 94/02626 1 39 5 1 7 / PCI /US93/067~1 _ 145 --(2) INFORMATION FOR SEQ ID NO:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:
Leu Ile Gly Pro Gly Arg Ser Ser Val Ala Met Thr Ile Arg Glu lo 15 lS(2) INFORMATION FOR SEQ ID NO:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon 2S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:
Leu Val Arg Met Leu Gly Pro Gly Arg Gly Asn Asp Arg Thr His lo 15 WO 94/02626 2 1 395 1 ~ PCI'/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:109:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:J~.I[SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:
Gln Arg Gly Lys Thr Phe Tyr Gly Pro Gly Arg Gly Ser Gly Gln 15(2) INFORMATION FOR SEQ ID NO:llO:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:
Asp Arg Gly Lys Ile Val Tyr Gly Pro Gly Arg Thr Gln Ser _ ~VO 94/02626 PC~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:lll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:lll:
Asp Trp Arg Ser Val His Ile Gly Pro Ala Arg Arg Glu Val Leu 1 5 lû 15 15(2) INFORMATION FOR SEQ ID NO:112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:
Gly Phe Ser Ser Ser Arg Val Leu Val Gly Pro Gly Arg Gly Val W O 94/02626 2~ ~95 ~ P(~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:113:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:
Val Lys Arg Arg Asp Ala Val His Ala Gly Pro Gly lS(2) INFORMATION FOR SEQ ID NO:114:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Se~i Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:
Asp Ser Glu Arg Val Gly Val Leu Leu Gly Pro Gly Arg Gly Val _WO 94/02626 2 1 3g 51 7 PCI/US93/06751 _ 149 -(2) INFORMATION FOR SEQ ID NO:llS:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRA!lJEJ;:-ss: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:
Asp Leu Gly Arg Pro Ala Val Arg Phe Gly Pro Gly Arg Ile Ile (2) INFORMATION FOR SEQ ID NO:116:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:116:
Leu Ser Arg Phe Arg Glu Trp His Val Gly Pro Gly Arg Val Pro 1 5 10 . 15 (2) INFORMATION FOR SEQ ID NO:117:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear W094/02626 213957; - PCr/US93/067~1_ (;i) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:
Ala Ala Leu Arg Lys Val Arg Xaa Tyr Gly Pro Ala Arg Gln Ser lo 15 (2) INFORMATION FOR SEQ ID N0:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID N0:118:
Ile Gly Val Thr Arg Ala Leu Phe Phe Gly Pro Gly Arg Gly Thr 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:ll9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 _ WO 94/02626 2 1 3 9 S 1 7 --- ` PCI/US93/06751 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll9:
Ser Leu Ser Arg Ala His Val His Arg Gly Pro Gly Arg Val Ser (2) INFORMATION FOR SEQ ID NO:lZO:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:
Leu Val Tyr Arg Ala Ala His Tyr Gly Pro Gly Arg Gly Val lû
(2) INFORMATION FOR SEQ ID NO:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:-E~.ICSS: single 2 5 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
W 0 94/02626 ~3g511 PC~r/US93/067~1 _ (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (x;) SEQUENCE DESCRIPTION: SEQ ID NO:121:
Arg Gly Trp Arg Pro Val Leu Ala Val Gly Pro Gly Arg Trp Glu (2) INFORMATION FOR SEQ ID NO:122:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 am;no acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:
Nle Cys Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Ile Gly Cys 2 0 (2) INFORMATION FOR SEQ ID NO:123:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANJ~u.:_SS: single (D) TOPOLOGY: linear -(1l) MOLECULE TYPE: pept1de (;;;) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(v;) IMMEDIATE SOURCE: Internal Consensus Pept;de.
Compare w;th SEQ ID. NO. 146.
(x;) SEQUENCE DESCRIPTION: SEQ ID NO:123:
Gly Pro Xaa Arg _ WO 94/02626 2 1 3 9 5 1 7 ` ` PCI`/US93/067~1 _ 153 -(2) INFORMATION FOR SEQ ID NO:124:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library BETA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:125:
(i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library GAMMA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:
Leu Leu Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Leu Leu WO 94/02626 PCr/US93/06751 ~
2139~7~
_ 154 -(2) INFORMATION FOR SEQ ID NO:126:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRAI:JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library DELTA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:
Cys Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Cys (2) INFORMATION FOR SEQ ID NO:127:
(i) SEQUENCE CHARACTERISTICS:
15(A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 20(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library EPSILON formula (x;) SEQUENCE DESCRIPTION: SEQ ID NO:127:
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys _ W O 94/02626 PC~r/US93/06751 213951 7`
_ 155 -(2) INFORMATION FOR SEQ ID NO:128:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRAI:J~u;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:
(2) INFORMATION FOR SEQ ID NO:129:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRAI:JEu.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:
(2) INFORMATION FOR SEQ ID NO:130:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (c) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:
W 0 94/02626 2 1`3 9 5 1 ? P(~r/US93/06751 _ 156 -(2) INFORMATION FOR SEQ ID NO:131:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:
(2) INFORMATION FOR SEQ ID NO:132:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:
(2) INFORMATION FOR SEQ ID NO:133:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid 2 5 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: carboxy terminal fragment of pIII
internal to fusion peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
_ W O 94/02626 2 1 3 9 S 1 7 PC~r/US93,0675l _ 157 -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:
Cys Asp Lys Ile (2) INFORMATION FOR SEQ ID NO:134:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ Id Nos. 59-89 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:
Cys Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly Cys 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:135:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID Nos. 59-89 without Cys constraints.
W094/02626 ~13951 7 PCI/US93/06751 __ (x;) SEQUENCE DESCRIPTION: SEQ ID NO:135:
Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly (Z) INFORMATION FOR SEQ ID NO:136:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library BETA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:
Asp Gly Ser Arg Arg Ala Val His Leu Gly Pro Gly Arg Gly Val 1 5 10 lS
(2) INFORMATION FOR SEQ ID NO:137:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of liorary GAMMA
_ WO 94/02626 21 3951 7 s PCr/US93/06751 _ 159 -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:
Leu Leu Lys Glu Val His Phe Gly Pro Gly Arg Gly Arg Gly Gly Arg 1 5 lû 15 Leu Leu (2) INFORMATION FOR SEQ ID NO:138:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library DELTA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:
Cys Arg Gly Val His Leu Gly Pro Gly Arg Gly Ala Arg Met Ser Cys 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:139:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lC amino acids (B) TYPE: amino acid 2 5 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library EPSILON
W O 94/02626 ` PC~r/US93/06751 _ 213g5l760 (x;) SEQUENCE DESCRIPTION: SEQ ID NO:139:
Cys Asp Arg Gly Ser Val Leu Ile Gly Pro Gly Arg Gly Ser Ser Xaa 1 5 10 lS
Gly Cys (2) INFORMATION FOR SEQ ID NO:140:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID Nos: 90-121 without Cys constraints.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser (2) INFORMATION FOR SEQ ID NO:141:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANJ~JN[ss: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
_ WO 94/02626 2 1 3 9 5 1 7 PCI'/US93/06751 (;v) ANIT-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID NOS:
90-121 with Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:
Cys Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser Cys ZO
10(2) INFORMATION FOR SEQ ID NO:142:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear lS(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Con5ensus peptide of SEQ ID NOS:
59-121 without Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu Gly Leu Ser WO 94/02626 ~ PCI/US93/06751 ~
(2) INFORMATION FOR SEQ ID NO:143:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID NOS:
59-121 with Cys constraints.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:
Cys Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu lS Gly Leu Ser Cys (2) INFORMATION FOR SEQ ID NO:144:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(VI) IMMEDIATE SOURCE: Modified consensus peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:144:
Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser _NO 94/02626 21 3 9 5 I 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:145:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRA'.J~u.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Modified consensus peptide with Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:
Cys Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser Cys (2) INFORMATION FOR SEQ ID NO:146:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(v;) IMMEDIATE SOURCE: Selected internal consensus peptide, wherein Xaa is any amino acid except Gly. Compare with Seq. ID No. 123.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:
Gly Pro Xaa Arg
Anti-473 peptide ELISA titers after vaccination with 473-OMPC.
Anti-Deptide ELISA titers ~ * Weeks 0 2 _ - 8 10 12 14 1 <ZO <20500 Z,500 2,50062,50062,50062,500 Rabbits 2 <20<20 2,500 12,5002,50012,500 62,500 12,501 3 <20 1002,50062,50062,50062,50062,500312,500 4 <20 5002,50012,50012,50012,50012,50012,500 15NOTE: Asterisks indicate the times of inoculation. All values are given as the reciprocal of the endpoint dilution.
TAOLE II
Anti-402 peptide ELISA titers after vaccination with 473-OMPC.
25Anti-402 ELISA titers ~ ~ Weeks 0 2 4 ~ 8 10 12 14 Rabbits 2 500 50 100 3 <100 <20 <20 4 12,500 12,500 12,500 ~VO 94lO2626 2 1 3 9 5 1 7 PCI`/US93/06751 TABLE IIIA
In Vitro Neutralization by Anti 473-OMPC Sera.
MN Neutralization ~ ~ Weeks P 2 _ 6 8 10 12 <10 <10 <10 Rabbits Z <10 <10 <10 3 <10 <10 <10 4 <10 <10 <10 Alabama Neutralization l 5 ~ ~ Weeks 0 2 - 6 _ 10 12 <10 <10 <10 Rabbits 2 <10 <10 <10 3 <10 <10 <10 4 <lO <lO 20 SF-Z Neutralization ~ ~ Weeks 2 5 o 2 _ 6 8 l 0 12 1<10 <10 80 Rabbits Z <10 160 160 3<10 <10 <10 4<lO <lO 80 W094/02626 213~17 PCr/US93/06751_ TABLE IIIB
In Vitro Neutralization by Anti 473-OMPC Sera.
WMJ-Z Neutralization ~ ~ Weeks p 2 _ 6 8 10 12 <lû <10 <lû
Rabbits Z <10 <10 <10 3 <10 <10 <10 4 <10 <10 <10 IIIB Neutralization ~ ~ ~eeks û 2 _ 6 8 10 12 <10 <10 Rabbits 2 <10 <10 3 <10 <10 4 <10 <10 ~hile the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptions, and modifications, as come within the scope of the claims and its equivalents.
~.VO94/02626 2 1 39 ~1~ PCI/US93/06751 SEQUENCE LISTING
(l) GENERAL INFORMATION:
(i) APPLICANT: P. Keller, A.J. Conley, A.R. Shaw, B.A. Arnold (ii) TITLE OF INVENTION: Immunological Conjugates of OMPC and HIV-Specific Selected Principal Neutralization Epitopes (iii) NUMBER OF SEQUENCES: 146 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Merck & Co., Inc.
(B) STREET: P.O. Box 2000 (C) CITY: Rahway (D) STATE: NJ
(E) COUNTRY: USA
(F) ZIP: û7065 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFT~ARE: PatentIn Release #l.0, Version #l.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(c) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Meredith, Roy D.
(B) REGISTRATION NUMBER: 30,777 (C) REFERENCE/DOCKET NUMBER: l86l4 (ix) TELECOMMUNICATION INFORMATION:
2 5 (A) TELEPHONE: (908) 594-4678 (B) TELEFAX: (908) 594-4720 (C) TELEX: l38825 W O 94/02626 2 ~ PC~r/US93/06751 _ ~2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Pro Arg Leu Glu Thr His Phe Gly Pro Lys Arg Ser His Val Gly 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (5) TYPE: amino acid (C) STP.AI;JEu.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Trp Arg Leu Gly Pro Gly Arg Gly Ser Met Pro Cys Arg Leu Gly 213~517 _ ~0 94/02626 PC~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Gln Gly Leu Leu Arg Val Leu Tyr Ala Phe Gly Pro Gly Arg Val (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Val Leu Val Trp Gln Arg Lys Val Phe Phe Gly Pro His Arg Ser 1 5 lû 15 WO 94/02626 2 1 39 5 17 PCI`/US93/06751 _ -- 94 _ (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Arg Ser Ser Ser Trp Ala Trp Arg His Leu Tyr Gly Pro Ala Arg ~5 (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:6:
His Ser Gln Ala Val Lys Phe Gly Pro Gly Arg Thr Leu Val Pro 1 5 1~ 15 . JVO 94/02626 213 9~17 PCI /US93/06751 (2) INFORMATION FOR SEQ ID NO:7:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Trp Asp Arg Gly Asn Ser Ser Gly Arg His Leu Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:8:
lS
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii~ MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Asp Leu Gln Ala Arg Ser Lys Thr Tyr Phe Tyr Gly Pro Gly Arg WO 94/02626 ~ 1'3 9 5 ~ ~ PCr/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:9:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:JEL.ICSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Thr Trp His Leu Arg Val Arg Gly Ala His Phe Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Trp Leu Arg Val Leu Leu Gly Pro Ala Arg Pro Ile Tyr Trp Arg _-'VO 94/02626 ~13 9 ~17 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:ll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANJE~.:[SS: single (D) TOPOLOGY: linear (i;) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll:
Leu Leu Leu Gly Pro Ala Arg Ala Pro Val Arg Val Asn Leu Ala (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (P) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Cys Lys Pro Arg Ala Pro Met Leu Phe Gly Pro Ala Arg Gly Leu ~3~ PCI/US93/06751_ (Z) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
lD (vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Leu Leu Leu Ile Gly Pro Gly Arg Glu Leu Arg Pro Ile Asn Leu (2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~uN~SS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Val Phe Lys Val Ile Asn Arg Ile Leu His Tyr Gly Pro Asn Arg ~-VO 94/02626 2 1 39 ~ 1 7 PCr/US93/06751 (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi~ IMMEDIATE SOURCE: Random Epitope Library Alpha (xi~ SEQUENCE DESCRIPTION: SEQ ID NO:15:
Phe Phe Tyr Gly Pro Gly Arg Tyr Pro Pro Arg Phe Lys Leu Gly (2) INFORMATION FOR SEQ ID NO:16:
(i~ SEQUENCE CHARACTERISTICS:
(A~ LENGTH: 15 amino acids (B~ TYPE: amino acid (C~ STRANJEu.;_SS: single (D~ TOPOLOGY: linear (ii~ MOLECULE TYPE: peptide (iii~ HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi~ IMMEDIATE SOURCE: Random Epitope Library Alpha (xi~ SEQUENCE DESCRIPTION: SEQ ID NO:16:
Asp Val Gly Trp Val Thr Gly Thr Gln His Tyr Gly Pro Arg Arg W094/02626 al3~5~ PCI/US93/06751_ _ 100 --(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Gly Leu Tyr Thr Cys Met Tyr Gly Pro Ser Arg His Ile Cys Val (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Cys Ala Thr Ser Ile Gly Gly Val Leu Phe Gly Pro Gly Arg Gly _~0 94/02626 ~1 3~ 1 7 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:l9:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
Trp Arg Met Met Leu Gly Pro Gly Arg Asp Tyr Ala Gly Pro Ala (Z) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Thr Glu Leu Gly Arg Gly Tyr Ile Ser His Gly Pro Ala Arg Gly WO94/02626 ~139S11 PCI/US93/06751_ , (2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: s;ngle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Arg Ile Arg Leu Pro Arg Gly Pro Gly Arg Pro Gln Thr Thr Met 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:22:
His Leu Gly Pro Ser Arg Gly Ala Asn Leu Gly Lys Ile Gly Ala _NO 94/02626 2 ~ 3 9 5 1 7 PCr/US93/06751 ~2) INFORMATION FOR SEQ ID NO:Z3:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Leu Leu Arg Thr Ile Met Ile Gly Pro Gly Arg Leu Leu His Ser (2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Leu His Val Gly Pro Asn Arg Gly Lys Ser Glu Asp Asn Tyr Arg WO 94/02626 2 1 39 5 17 PCI/US93/06751 ~
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Gly Gln Ile Ile Phe Ile Gly Pro Gly Arg Leu Gly Asn Gly Glu 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (F) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
Leu Gln Leu Leu Ile Gly Pro Gly Arg Thr Val Gly Lys Ile Arg _,WO94/02626 213g~1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIA7E SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:Z7:
Phe Tyr Thr Ser Gly Lys Thr Ile Phe Tyr Tyr Gly Pro Arg Arg (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2~:
Thr Lys Ile Gly Pro Gly Arg Val Phe Asp Gly Arg Trp Arg Phe W0 94/02626 ~ 1395~ PCI/US93/06751 . _ _ 106 -(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:J~u.lESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
Ala Cys Trp Ser Arg Glu Tyr Gly Pro Ala Arg Met Ser Cys Thr (2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEuNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:30:
Ile Leu Phe Gly Pro Gly Arg Cys Ser Val Asp Ala Val Ser Gly _~0 94/02626 ~1 3951 7 PCI/US93/06751 _ 107 --(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino ac;d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
Tyr Leu Ala Met Arg Gly Ala Gly Tyr Met Ile Gly Pro Ala Arg (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEuN_SS: single 2 0 ( D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Asn Cys Ser Val His Val Gly Ala Gly Arg Asn Ser Ala Trp Cys WO 94/02626 2 1~ 9 S ~ ~ PCI/US93/06751` _ _ 108 -(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Asn Arg Tyr Gly Pro Gly Arg Val Gly Phe Val Arg Ser Gln Pro (2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i J MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:34:
Ala Arg Gly Trp Gly Gly Val Phe Tyr Gly Pro Gly Arg Gly Glu _ ~VO 94/02626 2 1 ~ 9 5 1 7 PC~r/US93/067~1 (2) INFORMATION FOR SEQ ID NO:35:
~ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAl:J~u.lCSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Tyr Gly Arg Phe Ser Phe Gly Pro Gly Arg Gly Tyr Met Val Ile (2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Tyr Tyr Tyr Arg Asn Val Leu Val Gly Pro Gly Arg Trp Trp Leu WO 94/02626 PCI/US93/06751 `~
213~3517 _ 110 --(2) INFORMATION FOR SEQ ID NO:37:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
Trp Ser Trp Val Arg Leu Lys Ala Val Leu Leu Gly Pro Ser Arg (2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STpAllJ~uN~ss: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:38:
Arg Phe Gln Glu Gly Gln Lys Val Leu Val Gly Pro Gly Arg Arg _ WO 94/02626 2 1 3~ ~1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
Ser Cys Met Thr Ser Val Leu Val Gly Pro 61y Arg Gln Asp Asn (2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:40:
Gly Ile Leu Arg Gln Pro Leu Leu Ile Gly Pro Gly Arg Ala Pro W094/02626 dl3 9~1 ~;L PCI/US93/06751._ 2) lNFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
Trp Asp Thr Leu Gly Trp Val Val Ser Asn Phe Gly Pro Gly Arg (2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~u.:ESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:42:
Val Leu Arg Cys Phe Gly Pro Leu Arg Asp Ala Arg Cys Ser Val _WO94/02626 ~1 39~jI~ PCI/US93/06751 -- 113 _ 35(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
Gln Ile Trp Tyr Phe 61y Pro Gly Arg Ser Gln Ser Gly Ser Met (2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~u.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
Leu Met Val Val Gln Val Gly Pro Ala Arg Thr Phe Leu Gln Gly lû 15 ~1 3951 ~
(Z) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:JEu.lCSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
Gly Pro Ser Leu Phe Asn Ser Gly Val Arg Tyr Gly Pro Lys Arg 1 5 1~ 15 (2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;l_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
Val His Phe Ile Gly Pro Gln Arg Gly Gly Asn Ser Ser His Leu 2 1 3 q~5 1 ~
~'V0 94/02626 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS: -(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:Jtu.;_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: 'EQ ID NO:47:
Pro Tyr Ser Asp Leu Leu Leu Ser Lys Tyr Phe Gly Pro Gly Arg (z) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANu~u.;_~S: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:48:
Leu Asp Gln Tyr Arg Val Leu Leu Trp Gly Pro Gly Arg Thr Thr WO94/02626 ~ 1 3q5 1~L PCI`/US93/067SI_-(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
Val Leu Lys Ile Leu Arg His Ala Tyr Phe Gly Pro Gly Arg Trp (Z) INFORMATION FOR SEQ ID NO:5û:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:50:
Val Arg His Met Gly Pro Gly Arg Gly Met Val Leu Gly Ile Thr _ ~V0 94/02626 2,1 3 g 5 ~ 7 P(~r/US93/0675 (2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
Asn Tyr Phe 61y Pro Gly Arg Gly Gly Val Val Val Thr Gly His (2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (O) TYPE: amino acid (C) STRAI;JE~ SS: single (D) TOPOLOGY: linear 2 0 (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:52:
Gln Val Phe Gly Pro Gly Arg Thr Asn Pro Arg Ser Asn Leu Leu W O 94/02626 PC~r/US93/06751 _ 213gS17 (2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
Met Glu Arg Asp Leu Val Arg Phe Gly Pro Asn Arg Asp Trp Arg (2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STPAI:JEu.. sS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
Asn Gly Leu Lys Leu Cys Arg Val Gly Pro Ser Arg Glu Gly Cys _~VO 94/02626 21 395 1 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:55:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANJE~.:CSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:SS:
Phe Asp Gly Gl n Ser Lys Val Val Leu Arg Gl y Pro Gly Arg Gl y (2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1 i near 2 0 ( i i ) MOLECULE TYPE: peptide ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:56:
Pro Val Lys Phe Gly Pro Gln Arg Ser Gly Gly Ala Thr Arg Pro WO 94/02626 al39$ 17 PCr/US93/06751`
2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Random Epitope Library Alpha (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
Ile Thr Pro Arg Leu Tyr Gly Pro Ser Arg Met Arg Tyr Asn Gln (2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: consensus peptide for seq. Id Nos. 1-57.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
Trp Asp Gly Leu Gly Trp Gln Ile Val His Phe Gly Pro Gly Arg Gly Gly Asn Gly Ile Asn Leu Gly Ala _~VO 94/02626 21 3 9 5 1 7 PCI/US93/06751 (Z) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
Asn Lys Arg Glu Phe Gly Pro Ala Arg Ala Ala Arg Asn Arg (Z) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:60:
His Arg Arg Asp Ile Gly Pro Ala Arg Thr Arg Glu Ile Gly WO 94/02626 2139517 PCI`/US93/06751`_ (2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
Gly Ala Gly His Val Gly Pro Gly Arg Tyr Gly Ala Leu Ser (2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
Ser Ala Val His Leu Gly Pro Gln Arg Gln Arg Ala Thr Asp _~VO 94/02626 æ~ 39 5 I7 PCI/US93/06751 2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI:J~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
Ser Thr Arg His Leu Gly Pro Gly Arg Val Glu Gly Val Leu 1 5 lû
(2) INFORMATION FOR SEQ ID NO:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LEN6TH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
Gly Val His Arg Phe Gly Pro Gly Arg Gly Glu Gly Met Val W094/02626 al39si7 PCI/US93/067Sl~
_ lZ4 --(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: am;no acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
Gly Gly Tyr His Trp Gly Pro Gly Arg Gly Ser Val Glu Ala lS (2) INFORMATION FOR SEQ ID NO:66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJE~ S: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:
Gln Ala Trp His Phe Gly Pro Gly Arg Asp His Gly Glu _~094/02626 21395t 7 PCr/US93/06751 (2) INFORMATION FOR SEQ ID NO:67:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:
Lys Ala Asn His Tyr Gly Pro Ser Arg Gly Pro Gly Ser Arg (2) INFORMATION FOR SEQ ID NO:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
Leu Leu Gly Pro Gly Arg Gly Ser Ser Ser Val Arg Gly Glu Leu lû 15 W O 94/02626 213951~ P(~r/US93/06751`_-(2) INFORMATION FOR SEQ ID NO:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAl:JEuN~SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
Ser Gly Trp Trp Gly Gly Val His Val Gly Pro Gly Arg Gly Thr (2) INFORMATION FOR SEQ ID NO:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:
Trp Ser Lys Arg Glu Ser Val Met Phe Gly Pro Gly Arg Gly Thr _ WO 94/02626 2 t 3 9 5~1 7 - i PCI`/US93/06751 _ lZ7 -(2) INFORMATION FOR SEQ ID NO:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
1~ (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:
Trp Asp Ser Arg Ala Thr Leu Arg Leu Gly Pro Gly Arg Ser Ser (2) INFORMATION FOR SEQ ID NO:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJEu.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:
Gly Lys Val Phe Tyr Gly Pro Gly Arg Glu Trp His Ala WO 94/02626 2 1 3 9 5 1 7 PCI`/US93/06751 _ 128 --(Z) INFORMATION FOR SEQ ID NO:73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:
Ala Arg Val Phe Leu Gly Pro Gly Arg Gly Val Val Tyr Asp lS (2) INFORMATION FOR SEQ ID NO:74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STP.ANJ~u.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:
Arg Val Gln Lys Leu Gly Pro Gly Arg Gln Thr Ala Ser Gly _ ~VO 94/02626 2 1 3 9 5 ~ 7 P(~r/US93/06751 2) INFORMATION FOR SEQ ID NO:75:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:
Lys Leu Gly Pro Gly Arg Gly Gly Tyr Phe Gly Ala Gln Val 1 5 lû
(2) INFORMATION FOR SEQ ID NO:76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI:JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:
Arg Lys Val Asn Ile Gly Pro Gly Arg Val His Gly Asn Ser WO94/02626 2139517 PCI/US93/067~1 (2) INFORMATION FOR SEQ ID NO:77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRal:JEu.;_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:
Arg Gly Val Lys Ile Gly Pro Gly Arg Ile Ala Ser Gly Tyr (2) INFORMATION FOR SEQ ID NO:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:
Lys Asp Leu His Ile Gly Pro Gly Arg Met Asp Gly Leu Arg _WO 94/02626 21 3q 5 1 ~ PCI'/US93/06751 -- 131 _ (Z) INFORMATION FOR SEQ ID NO:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJEu;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:
Ala Gln Arg Ser His Leu Ile Gly Pro Gly Arg Ala Glu Thr Gly (2) INFORMATION FOR SEQ ID NO:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi ) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:
Lys Gln Val Arg Leu Gly Pro Ala Arg Gly Asp Ile Ile Gly (2) INFORMATION FOR SEQ ID NO:81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:
Arg Gln Val Met Leu Gly Pro Gly Arg Gly Asp Arg Leu Glu (2) INFORMATION FOR SEQ ID NO:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (x;) SEQUENCE DESCRIPTION: SEQ ID NO:82:
Arg Ser Val Leu Met Gly Pro Ala Arg Ser Thr Arg Val Val _.1VO 94/02626 2 1 3 9 5 1 7 ~ PCI/US93/06751 (Z) INFORMATION FOR SEQ ID NO:83:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: l;near (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:
Lys Phe Val Glu Leu Gly Pro Gly Arg Lys Gly Gln Gly (2) INFORMATION FOR SEQ ID NO:84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANJ~L.._SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:B4:
Asp Arg Gly Ser Arg Phe Val Leu Leu Gly Pro Gly Arg Met Gly WO 94/02626 2 1 3 9 5`i 7 - PCI/US93/06751 _ _ 134 --(2) INFORMATION FOR SEQ ID NO:85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:
Glu Gln Leu His Arg Leu Val Ala Phe Gly Pro Gly Arg Ala Ala 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:
Leu Pro Ser Val Asn Leu Gly Pro Gly Arg Asn Ala Arg Lys Gly _ WO 94/02626 2 1 39S 1 ~7 - PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: am:no acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:
Gln His Arg Ala Ala Ser Val His Leu 61y Pro Ser Arg Ala Gly 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
Leu Met Phe Val Arg Val Val Lys Leu Gly Pro Ala Arg Val Pro W 0 94/02626 ~ 1 3 g S 1 7 . . PC~r/US93/067~1 _ (Z) INFORMATION FOR SEQ ID NO:89:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:
Tyr Gly Leu Val Ile Arg Cys Glu Val Gly Pro Ser Arg Ser Cys (2) INFORMATION FOR SEQ ID NO:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:
Arg Glu Leu His Met Gly Pro Gly Arg Ala Arg Pro Gly Phe _ WO 94/02626 2 13~ 17 PCI'/US93/06751 _ 137 --(2) INFORMATION FOR SEQ ID NO:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRAI;JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:
Cys Arg Val Asp Phe Gly Pro Gly Arg Leu Gly Ser Arg Thr (2) INFORMATION FOR SEQ ID NO:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:92:
Asn Val Val Ala Ile Gly Pro Gly Arg Ser Asn Val Val Thr W O 94/02626 21 3951 7 P(~r/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 am;no acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:
Lys Glu Val His Phe Gly Pro Gly Arg Gly Gly Gln Arg Ser (2) INFORMATION FOR SEQ ID NO:94:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (8) TYPE: amino acid (C) STRAI:J~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:
Xaa Xaa Tyr Leu Ile Gly Pro Gly Arg Gly Trp Glu Arg Glu _ WO 94/02626 2 1 395 l ~ PCr/US93/067~1 _ 139 -(2) INFORMATION FOR SEQ ID NO:9S:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:
Ala Gly Cys Gln Val Gly Pro Gly Arg Pro Xaa Cys Gly Lys ( 2) INFORMATION FOR SEQ ID NO:96:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Gamma (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:96:
Arg Glu Val His Phe Gly Pro Arg Arg Asp Glu Pro Gly Arg WO 94/02626 2 1 3 9 5 1 7 PCI/US93/06751 ._ _ 140 --(2) INFORMATION FOR SEQ ID NO:97:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: lineir (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:
Ile Gly Arg Asn Leu Gly Pro Gly Arg Val Val Ser Asn Val l 5 l0 (2) INFORMATION FOR SEQ ID NO:98:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:
Lys Asn Val His Val Gly Pro Gly Arg Gly Gln Arg Thr Val l 5 l0 _WO 94/02626 2 t 3 9 ~ 1 7 PCI`/US93/06751 (2) INFORMATION FOR SEQ ID NO:99:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i;) MOLECULE TYPE: peptide (iii? HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:
Arg Leu His Leu Val Gly Pro Ala Arg Val Ser Pro Leu Ser 15(2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
Ser Lys Val Glu Ile Gly Pro Gly Arg Gly Pro Leu Met Arg WO 94/02626 - ~ C PCI`/US93/06751 _ ~1395 1~
(2) INFORMATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
Ala Val Ile His Val Gly Pro Ser Arg Leu Lys Ser Gln Tyr 15(2) INFORMATION FOR SEQ ID NO:102:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANJE~ SS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:
Gly Arg Ile Asn Tyr Gly Pro Gly Ala Pro Gly Leu Met _ WO 94/02626 2139~1 ~ PCI`/US93/06751 _ 143 -(2) INFORMATION FOR SEQ ID NO:103:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 a0ino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:
Glu Val His Tyr Tyr Gly Pro Gly Arg Arg Ala Pro Ala Ser ~2) INFORMATION FOR SEQ ID NO:lû4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:
Val Glu Arg His Leu Gly Pro Gly Arg Gly Leu Gln Met Gly WO 94/02626 21~9517 PCI/US93/06751 _ _ 144 --(2) INFORMATION FOR SEQ ID NO:105:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:
Asn Ser Phe His Leu Gly Pro Gly Arg Ser Arg Thr Tyr Ser (2) INFORMATION FOR SEQ ID NO:106:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0 ( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Delta (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:106:
Gly Val Val Lys Leu Gly Pro Gly Arg Thr Ala Gly Lys Leu _ W0 94/02626 1 39 5 1 7 / PCI /US93/067~1 _ 145 --(2) INFORMATION FOR SEQ ID NO:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:
Leu Ile Gly Pro Gly Arg Ser Ser Val Ala Met Thr Ile Arg Glu lo 15 lS(2) INFORMATION FOR SEQ ID NO:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon 2S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:
Leu Val Arg Met Leu Gly Pro Gly Arg Gly Asn Asp Arg Thr His lo 15 WO 94/02626 2 1 395 1 ~ PCI'/US93/06751 _ (2) INFORMATION FOR SEQ ID NO:109:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:J~.I[SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:
Gln Arg Gly Lys Thr Phe Tyr Gly Pro Gly Arg Gly Ser Gly Gln 15(2) INFORMATION FOR SEQ ID NO:llO:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 2 0( i i ) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:
Asp Arg Gly Lys Ile Val Tyr Gly Pro Gly Arg Thr Gln Ser _ ~VO 94/02626 PC~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:lll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Epsilon (xi) SEQUENCE DESCRIPTION: SEQ ID NO:lll:
Asp Trp Arg Ser Val His Ile Gly Pro Ala Arg Arg Glu Val Leu 1 5 lû 15 15(2) INFORMATION FOR SEQ ID NO:112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lS amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:
Gly Phe Ser Ser Ser Arg Val Leu Val Gly Pro Gly Arg Gly Val W O 94/02626 2~ ~95 ~ P(~r/US93/06751 (2) INFORMATION FOR SEQ ID NO:113:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:
Val Lys Arg Arg Asp Ala Val His Ala Gly Pro Gly lS(2) INFORMATION FOR SEQ ID NO:114:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20(ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Se~i Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:
Asp Ser Glu Arg Val Gly Val Leu Leu Gly Pro Gly Arg Gly Val _WO 94/02626 2 1 3g 51 7 PCI/US93/06751 _ 149 -(2) INFORMATION FOR SEQ ID NO:llS:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRA!lJEJ;:-ss: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:
Asp Leu Gly Arg Pro Ala Val Arg Phe Gly Pro Gly Arg Ile Ile (2) INFORMATION FOR SEQ ID NO:116:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:116:
Leu Ser Arg Phe Arg Glu Trp His Val Gly Pro Gly Arg Val Pro 1 5 10 . 15 (2) INFORMATION FOR SEQ ID NO:117:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear W094/02626 213957; - PCr/US93/067~1_ (;i) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:
Ala Ala Leu Arg Lys Val Arg Xaa Tyr Gly Pro Ala Arg Gln Ser lo 15 (2) INFORMATION FOR SEQ ID N0:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 (iv) ANTI-SENSE: N0 (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID N0:118:
Ile Gly Val Thr Arg Ala Leu Phe Phe Gly Pro Gly Arg Gly Thr 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:ll9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: N0 _ WO 94/02626 2 1 3 9 S 1 7 --- ` PCI/US93/06751 (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll9:
Ser Leu Ser Arg Ala His Val His Arg Gly Pro Gly Arg Val Ser (2) INFORMATION FOR SEQ ID NO:lZO:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:
Leu Val Tyr Arg Ala Ala His Tyr Gly Pro Gly Arg Gly Val lû
(2) INFORMATION FOR SEQ ID NO:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRAI:-E~.ICSS: single 2 5 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (i;i) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
W 0 94/02626 ~3g511 PC~r/US93/067~1 _ (vi) IMMEDIATE SOURCE: Semi Random Epitope Library Beta (x;) SEQUENCE DESCRIPTION: SEQ ID NO:121:
Arg Gly Trp Arg Pro Val Leu Ala Val Gly Pro Gly Arg Trp Glu (2) INFORMATION FOR SEQ ID NO:122:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 am;no acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:
Nle Cys Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Ile Gly Cys 2 0 (2) INFORMATION FOR SEQ ID NO:123:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANJ~u.:_SS: single (D) TOPOLOGY: linear -(1l) MOLECULE TYPE: pept1de (;;;) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(v;) IMMEDIATE SOURCE: Internal Consensus Pept;de.
Compare w;th SEQ ID. NO. 146.
(x;) SEQUENCE DESCRIPTION: SEQ ID NO:123:
Gly Pro Xaa Arg _ WO 94/02626 2 1 3 9 5 1 7 ` ` PCI`/US93/067~1 _ 153 -(2) INFORMATION FOR SEQ ID NO:124:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library BETA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:125:
(i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library GAMMA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:
Leu Leu Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Leu Leu WO 94/02626 PCr/US93/06751 ~
2139~7~
_ 154 -(2) INFORMATION FOR SEQ ID NO:126:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRAI:JE~ SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library DELTA formula (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:
Cys Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Cys (2) INFORMATION FOR SEQ ID NO:127:
(i) SEQUENCE CHARACTERISTICS:
15(A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 20(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Library EPSILON formula (x;) SEQUENCE DESCRIPTION: SEQ ID NO:127:
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys _ W O 94/02626 PC~r/US93/06751 213951 7`
_ 155 -(2) INFORMATION FOR SEQ ID NO:128:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRAI:J~u;:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:
(2) INFORMATION FOR SEQ ID NO:129:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRAI:JEu.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:
(2) INFORMATION FOR SEQ ID NO:130:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (c) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:
W 0 94/02626 2 1`3 9 5 1 ? P(~r/US93/06751 _ 156 -(2) INFORMATION FOR SEQ ID NO:131:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:
(2) INFORMATION FOR SEQ ID NO:132:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer (iii) HYPOTHETICAL: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:
(2) INFORMATION FOR SEQ ID NO:133:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid 2 5 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: carboxy terminal fragment of pIII
internal to fusion peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
_ W O 94/02626 2 1 3 9 S 1 7 PC~r/US93,0675l _ 157 -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:
Cys Asp Lys Ile (2) INFORMATION FOR SEQ ID NO:134:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ Id Nos. 59-89 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:
Cys Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly Cys 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:135:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID Nos. 59-89 without Cys constraints.
W094/02626 ~13951 7 PCI/US93/06751 __ (x;) SEQUENCE DESCRIPTION: SEQ ID NO:135:
Arg Ser Val His Leu Gly Pro Gly Arg Gly Asp Gly Leu Gly (Z) INFORMATION FOR SEQ ID NO:136:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library BETA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:
Asp Gly Ser Arg Arg Ala Val His Leu Gly Pro Gly Arg Gly Val 1 5 10 lS
(2) INFORMATION FOR SEQ ID NO:137:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of liorary GAMMA
_ WO 94/02626 21 3951 7 s PCr/US93/06751 _ 159 -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:
Leu Leu Lys Glu Val His Phe Gly Pro Gly Arg Gly Arg Gly Gly Arg 1 5 lû 15 Leu Leu (2) INFORMATION FOR SEQ ID NO:138:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library DELTA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:
Cys Arg Gly Val His Leu Gly Pro Gly Arg Gly Ala Arg Met Ser Cys 1 5 lû 15 (2) INFORMATION FOR SEQ ID NO:139:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: lC amino acids (B) TYPE: amino acid 2 5 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of library EPSILON
W O 94/02626 ` PC~r/US93/06751 _ 213g5l760 (x;) SEQUENCE DESCRIPTION: SEQ ID NO:139:
Cys Asp Arg Gly Ser Val Leu Ile Gly Pro Gly Arg Gly Ser Ser Xaa 1 5 10 lS
Gly Cys (2) INFORMATION FOR SEQ ID NO:140:
(;) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID Nos: 90-121 without Cys constraints.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser (2) INFORMATION FOR SEQ ID NO:141:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANJ~JN[ss: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
_ WO 94/02626 2 1 3 9 5 1 7 PCI'/US93/06751 (;v) ANIT-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID NOS:
90-121 with Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:
Cys Asp Leu Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Ser Pro Arg Ser Cys ZO
10(2) INFORMATION FOR SEQ ID NO:142:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear lS(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Con5ensus peptide of SEQ ID NOS:
59-121 without Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu Gly Leu Ser WO 94/02626 ~ PCI/US93/06751 ~
(2) INFORMATION FOR SEQ ID NO:143:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Consensus peptide of SEQ ID NOS:
59-121 with Cys constraints.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:
Cys Asp Ser Ser Arg Arg Val Val His Leu Gly Pro Gly Arg Gly Glu lS Gly Leu Ser Cys (2) INFORMATION FOR SEQ ID NO:144:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(VI) IMMEDIATE SOURCE: Modified consensus peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:144:
Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser _NO 94/02626 21 3 9 5 I 7 PCI/US93/06751 (2) INFORMATION FOR SEQ ID NO:145:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRA'.J~u.:_SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(vi) IMMEDIATE SOURCE: Modified consensus peptide with Cys constraints (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:
Cys Trp Arg Ser Val His Leu Gly Pro Gly Arg Gly Ser Gly Ser Cys (2) INFORMATION FOR SEQ ID NO:146:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES
(iv) ANTI-SENSE: NO
(v;) IMMEDIATE SOURCE: Selected internal consensus peptide, wherein Xaa is any amino acid except Gly. Compare with Seq. ID No. 123.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:
Gly Pro Xaa Arg
Claims (28)
1. An antigenic conjugate of HIV-specific, selected principal neutralization epitopes covalently linked to purified outer membrane proteosome of Neisseria, wherein said conjugate is of the formula (SPNE)n?(OMPC) wherein:
SPNE is the selected principal neutralization epitope of HIV, which is a polypeptide of one or more amino acid sequences of Table A
or fragment thereof, said fragment having at least 5 amino acids in length and including the GPXR loop region or homolog thereof;
n indicates the number of polypeptides of SPNE
covalently linked to OMPC and is 1-50;
- indicates covalent linkage;
OMPC is purified outer membrane proteosome of Neisseria, said conjugate optionally substituted with a , which is an anion or polyanion at physiological pH, said a consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid, or pharmaceutically acceptable salt thereof.
SPNE is the selected principal neutralization epitope of HIV, which is a polypeptide of one or more amino acid sequences of Table A
or fragment thereof, said fragment having at least 5 amino acids in length and including the GPXR loop region or homolog thereof;
n indicates the number of polypeptides of SPNE
covalently linked to OMPC and is 1-50;
- indicates covalent linkage;
OMPC is purified outer membrane proteosome of Neisseria, said conjugate optionally substituted with a , which is an anion or polyanion at physiological pH, said a consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid, or pharmaceutically acceptable salt thereof.
2. The antigenic conjugate of Claim 1 wherein the conjugate is a covalent conjugate of OMPC
of Neisseria and the epitope is any of the consensus peptide sequences 58, 134-145.
of Neisseria and the epitope is any of the consensus peptide sequences 58, 134-145.
3. The antigenic conjugate of Claim 1 wherein the conjugate is a covalent conjugate of OMPC
of Neisseria and a polypeptide epitope of 5 or more amino acids of any of the consensus peptide sequences 58, 134-145.
of Neisseria and a polypeptide epitope of 5 or more amino acids of any of the consensus peptide sequences 58, 134-145.
4. The antigenic conjugate of Claim 1 wherein the covalent linkage between SPNE and OMPC
consists essentially of a bigeneric spacer.
consists essentially of a bigeneric spacer.
5. The antigenic conjugate of Claims 1-4, wherein said OMPC is derived from Neisseria meningitidis.
6. An AIDS vaccine comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more of the sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, carrier or vector, said vaccine to be used pre- and post-exposure to prevent or treat HIV
infection or disease, said vaccine capable of eliciting specific HIV neutralizing antibodies, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a- consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
infection or disease, said vaccine capable of eliciting specific HIV neutralizing antibodies, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a- consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
7. An AIDS vaccine of Claim 6 wherein the conjugate is a covalent conjugate of OMPC of Neisseria and the epitope is any of the consensus peptide sequences 58, 134-145.
8. An AIDS vaccine of Claim 6 wherein the conjugate is a covalent conjugate of OMPC of Neisseria and a polypeptide epitope of 5 or more amino acids of any of the consensus peptide sequences of Table A.
9. An AIDS vaccine of Claim 6 wherein the covalent linkage between SPNE and OMPC consists essentially of a bigeneric spacer.
10. An AIDS vaccine of Claim 6 wherein said OMPC is derived from Neisseria meningitidis.
11. A pharmaceutical composition comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more of the sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, said composition useful as a vaccine capable of producing specific HIV neutralizing antibody in mammals, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a-consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
12. The pharmaceutical composition of Claim 11 wherein the conjugate is a covalent conjugate of OMPC of Neisseria and the epitope is any of the consensus peptide sequences 58, 134-145.
13. The pharmaceutical composition of Claim 11 wherein the conjugate is a covalent conjugate of OMPC of Neisseria and a polypeptide epitope of 5 or more amino acids with any of the consensus peptide sequences 58, 134-145.
14. The pharmaceutical composition of Claim 11 wherein the covalent linkage between SPNE and OMPC
consists essentially of a bigeneric spacer.
consists essentially of a bigeneric spacer.
15. The pharmaceutical composition of Claim 11 wherein said OMPC is derived from Neisseria meningitidis.
16. A method of vaccinating against ARC or AIDS, comprising administering an effective amount of a pharmaceutical composition comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more of the sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a-consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
17. A method of preventing infection by HIV, comprising administering an effective amount of a pharmaceutical composition comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a-consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
18. A method of treating AIDS, comprising administering an effective amount of a pharmaceutical composition comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a- consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, proprionic or phosphonic acid.
19. A method of treating infection by HIV, comprising administering an effective amount of a pharmaceutical composition comprising an antigenic conjugate of HIV-specific selected principal neutralization epitopes having one or more sequences of Table A, said epitopes covalently linked to purified outer membrane proteosome of Neisseria, said conjugate mixed with a suitable immunological adjuvant, said purified outer membrane proteosome optionally substituted with a-, which is an anion or polyanion at physiological pH, said a-consisting of one to five residues of anions selected from the group consisting of carboxylic, sulfonic, or propionic phosphonic acid.
20. HIV-specific selected principal neutralization epitope polypeptides having any of sequences 1-121, 134-145.
21. HIV-specific selected principal neutralization consensus polypeptide having any of the sequences 58, 134-145.
22. A method of screening phage epitope libraries with a screening antibody, comprising the steps of (a) subjecting a phage epitope library to one or more cycles of low or high stringency selection, yielding selected phage, and (b) identifying the selected phage with antibody lifts.
23. A method of screening phage epitope libraries with a screening antibody, comprising the steps of (a) subjecting a phage epitope library to one or more cycles of high stringency selection, yielding selected phage, and (b) identifying the selected phage with antibody lifts.
24. A method of screening phage epitope libraries with a screening antibody, comprising the steps of (a) contacting a solid-phase supported screening antibody with a sample of phage epitope library in excess of library complexity;
(b) washing the product of step(a) to remove unbound and/or low affinity phage within a temperature range of between about room temperature to about 65°C, and retaining the complex of solid-phase supported screening antibody bound to phage;
(c) eluting the bound phage of said complex of step (b) with buffer having pH between about 1.0 and about 2.3;
(d) neutralizing the solution containing eluted phage, yielding selected phage.
(b) washing the product of step(a) to remove unbound and/or low affinity phage within a temperature range of between about room temperature to about 65°C, and retaining the complex of solid-phase supported screening antibody bound to phage;
(c) eluting the bound phage of said complex of step (b) with buffer having pH between about 1.0 and about 2.3;
(d) neutralizing the solution containing eluted phage, yielding selected phage.
25. The method of Claim 24, wherein step (b) is the high stringency procedure, comprising 1. washing the product of step (a) 3 to 20 times in buffer at about neutral pH at about 65°C, to effect removal of unbound phage; and 2. washing the fraction of step 1 containing solid-phase supported screening antibody bound to phage, by about a 2-5 minute contact in a buffer having a pH between about 3.0 and about 5.0 at a temperature between about 4°C and about 37°C, to effect removal of low affinity phage epitopes, to give the complex of solid-phase supported screening antibody bound to phage.
26. The method of Claim 24, wherein step (b) is the low stringency wash procedure.
27. A method of selecting phage epitope libraries with a screening antibody by high stringency selection procedure, comprising the steps of (a) contacting a solid-phase supported screening antibody with a sample of phage epitope library in excess of library complexity;
(b1) washing the product of step (a) 3 to 20 times in buffer at about neutral pH at about 65°C, to effect removal of unbound phage;
(b2) washing the fraction of step (b1) containing solid-phase supported screening antibody bound to phage, by about a 2-5 minute contact in a buffer having a pH between about 3.0 and about 5.0 at a temperature between about 4°C and about 37°C, to effect removal of low affinity phage epitopes from the complex of solid-phase supported screening antibody bound to phage;
(c) eluting the bound phage off said complex by incubating between about 1 to about 15 minutes in a buffer of pH between about 1.0 and about 2.3, containing between about 0.1 to 10 µg/ml of a blocking agent, without detergent, at a temperature between about 37°C and about 40°C; and (d) neutralizing the solution containing the eluted phage, yielding phage selected by the high stringency procedure.
(b1) washing the product of step (a) 3 to 20 times in buffer at about neutral pH at about 65°C, to effect removal of unbound phage;
(b2) washing the fraction of step (b1) containing solid-phase supported screening antibody bound to phage, by about a 2-5 minute contact in a buffer having a pH between about 3.0 and about 5.0 at a temperature between about 4°C and about 37°C, to effect removal of low affinity phage epitopes from the complex of solid-phase supported screening antibody bound to phage;
(c) eluting the bound phage off said complex by incubating between about 1 to about 15 minutes in a buffer of pH between about 1.0 and about 2.3, containing between about 0.1 to 10 µg/ml of a blocking agent, without detergent, at a temperature between about 37°C and about 40°C; and (d) neutralizing the solution containing the eluted phage, yielding phage selected by the high stringency procedure.
28. The method of Claim 27, comprising the high stringency selection procedure and identification with antibody lifts, comprising the additional steps of (e) plating out cells infected with phage selected by the high stringency procedure of step (d) and growing up the resulting colonies, yielding mature plates;
(f) overlaying the mature plates with a disk or other surface that binds protein, and immediately removing said overlaid disk;
(g) blocking the overlaid disk by incubating the disk for at least 2 hours, in a buffer of a pH between about 5.0 and about 8.0, containing about 0.1% (v/v) to about 1% (v/v) neutral detergent, in about 1% to about 20% blocking agent, within a temperature range of about 4°C to about 80°C, yielding blocked disks;
(h) washing the blocked disks to remove excess blocking agent by incubating the disk for at least 10 minutes in a buffer of a pH between about 5.0 and about 8.0, containing about 0.1%(v/v) to about 1% (v/v) neutral detergent, within the temperature range of about 4°C to about 80°C, yielding washed blocked disks;
(i) contacting the resulting disk with screening antibody by incubating the disks for at least 4 hours, in a buffer containing between about 0.1 to about 5 µg/ml screening antibody, in a temperature range between about 4°C and about 65°C;
(j) washing the disk to effect removal of unbound antibody;
(k) labeling the bound antibody with a labeled second-stage reagent; and (l) identifying colonies corresponding to bound antibody.
(f) overlaying the mature plates with a disk or other surface that binds protein, and immediately removing said overlaid disk;
(g) blocking the overlaid disk by incubating the disk for at least 2 hours, in a buffer of a pH between about 5.0 and about 8.0, containing about 0.1% (v/v) to about 1% (v/v) neutral detergent, in about 1% to about 20% blocking agent, within a temperature range of about 4°C to about 80°C, yielding blocked disks;
(h) washing the blocked disks to remove excess blocking agent by incubating the disk for at least 10 minutes in a buffer of a pH between about 5.0 and about 8.0, containing about 0.1%(v/v) to about 1% (v/v) neutral detergent, within the temperature range of about 4°C to about 80°C, yielding washed blocked disks;
(i) contacting the resulting disk with screening antibody by incubating the disks for at least 4 hours, in a buffer containing between about 0.1 to about 5 µg/ml screening antibody, in a temperature range between about 4°C and about 65°C;
(j) washing the disk to effect removal of unbound antibody;
(k) labeling the bound antibody with a labeled second-stage reagent; and (l) identifying colonies corresponding to bound antibody.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91721492A | 1992-07-20 | 1992-07-20 | |
US91721592A | 1992-07-20 | 1992-07-20 | |
US91721792A | 1992-07-20 | 1992-07-20 | |
US91721292A | 1992-07-20 | 1992-07-20 | |
US917,214 | 1992-07-20 | ||
US917,215 | 1992-07-20 | ||
US917,212 | 1992-07-20 | ||
US917,217 | 1992-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2139517A1 true CA2139517A1 (en) | 1994-02-03 |
Family
ID=27505999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002139517A Abandoned CA2139517A1 (en) | 1992-07-20 | 1993-07-19 | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4683093A (en) |
CA (1) | CA2139517A1 (en) |
WO (1) | WO1994002626A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2282378A (en) * | 1993-09-30 | 1995-04-05 | Merck & Co Inc | Conjugates of epitopes of HIV with a protein complex from Neisseria |
GB2294047A (en) * | 1994-10-14 | 1996-04-17 | Merck & Co Inc | Synthetic peptides for use as epitopes specific for HIV |
PL325604A1 (en) * | 1995-09-18 | 1998-08-03 | Us Army Med Res Mat Command | Improved methods of obtaining non-covalently complexed and multvalent proteosomal subunitary vaccines |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US7001600B1 (en) | 1996-02-09 | 2006-02-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
US6911527B1 (en) | 1999-01-11 | 2005-06-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | HIV related peptides |
EP1159297A2 (en) * | 1999-01-11 | 2001-12-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Hiv related peptides |
ATE538806T1 (en) * | 2004-09-07 | 2012-01-15 | Burnham Inst | PEPTIDES SPECIFICALLY SITE IN CARDIAC VESSELS AND RELATED CONJUGATES AND METHODS |
US7501486B2 (en) | 2004-09-07 | 2009-03-10 | Burnham Institute For Medical Research | Peptides that selectively home to heart vasculature and related conjugates and methods |
AU2013322258B2 (en) * | 2012-09-27 | 2019-06-13 | Idexx Laboratories, Inc. | Method of detection of Schmallenberg virus (SBV) and kit |
-
1993
- 1993-07-19 AU AU46830/93A patent/AU4683093A/en not_active Abandoned
- 1993-07-19 CA CA002139517A patent/CA2139517A1/en not_active Abandoned
- 1993-07-19 WO PCT/US1993/006751 patent/WO1994002626A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU4683093A (en) | 1994-02-14 |
WO1994002626A1 (en) | 1994-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2143823C (en) | Retro-, inverso - and retro-inverso synthetic peptide analogues | |
CA2164818C (en) | Tandem synthetic hiv-1 peptides | |
US6331404B1 (en) | HIV envelope polypeptides | |
DK174910B1 (en) | Antigen, method of preparation of antigen, method of diagnosis and immunogenic preparations | |
AU640619B2 (en) | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
US5763574A (en) | HIV-specific synthetic antigens and their use | |
US5470720A (en) | HIV antibody assays comprising p24-gp41 chimeric antigens | |
US5166050A (en) | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections | |
JP2003529319A (en) | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 | |
JPH05262667A (en) | Vaccine using viral antigen | |
JPH02238884A (en) | Plasmid containing gene coding feline leukemia virus antigen and host containing said plasmid | |
JP2001510039A (en) | Respiratory syncytial virus epitopes useful for diagnosis and therapy and antibodies comprising them | |
GB2196634A (en) | Monoclonal antibodies to HIV and related peptides | |
JPH06501260A (en) | Peptides used for inducing neutralizing antibodies and vaccination against human immunodeficiency virus | |
CA2139517A1 (en) | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes | |
IE912846A1 (en) | New embodiments of the hiv principal neutralizing¹determinant | |
JPH03128399A (en) | Aids immune complex | |
GB2282379A (en) | Conjugates of epitopes of HIV with a protein complex from Neisseria | |
US5851535A (en) | Mimotopic polypeptides of Toxoplasma gondii and applications | |
US20060094017A1 (en) | Immunogens for hiv vaccine | |
GB2282378A (en) | Conjugates of epitopes of HIV with a protein complex from Neisseria | |
GB2282380A (en) | Conjugate of epitopes of HIV with a protein complex from Neisseria | |
GB2282381A (en) | Conjugates of epitopes of HIV with a protein complex from Neisseria | |
JPH03503639A (en) | Peptides PF10 to PF19 of retrovirus HIV, methods for the synthesis of said peptides, especially their use for diagnostic purposes | |
EP0343132B1 (en) | Methods and systems for producing HIV antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |